Document:

Prepared by MERRILL CORPORATION

QuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

EMPLOYMENT AGREEMENT    
  

    THIS EMPLOYMENT AGREEMENT (hereinafter referred to as the Agreement is made effective as of the
October 15, 2001, by and between Western Gas Resources, Inc., a Delaware corporation, (hereinafter referred to as the "Corporation" or
"Company"), and Peter A. Dea, (hereinafter referred to as the "Employee"). 

WITNESSETH:  

    A.  The
Corporation, its subsidiaries and affiliates (the "Western Companies") acquire, design, construct and operate
natural gas gathering and processing facilities, market, store and transport natural gas, natural gas liquids and sulfur, market electrical power and explore for, develop, and produce oil and gas. 

    B.  The
Corporation desires to employ Employee as its Chief Executive Officer and President and Employee has agreed to accept such position upon the terms and
conditions set forth herein. 

    NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, the parties hereto agree as follows: 

    1.  Employment. Corporation hereby employs the Employee and the Employee hereby accepts such employment with the
Corporation upon the terms and conditions hereinafter set forth. The Employee's employment shall commence on November 1, 2001, and continue until May 31, 2005 unless it is earlier
terminated in accordance with the provisions of paragraph 12 hereof. Employee's employment may be extended, from time to time, by a written agreement signed by both parties. 

    2.  Powers, Duties and Responsibilities.

    a.  Employee
shall devote his full time, attention and effort to the business of the Western Companies during the Corporation's normal business hours and during such
other times as are reasonably necessary for the proper performance of his responsibilities hereunder, provided that Employee may serve as an outside director for Echo Star, and as a committee member,
director, or trustee of selected nonprofit organizations, as long as such activities don't interfere with the performance of his duties under this Agreement. 

    b.  Employee's
primary duties shall be to act as Chief Executive Officer and President and shall perform the duties customarily associated with such position. 

    c.  The
Employee shall perform his duties at the Corporation's headquarters in Denver, Colorado. 

    3.  Compensation and Bonus.

    a.  For
all of the services rendered by Employee pursuant to this Agreement, the Corporation shall pay the Employee an annual base salary of not less than $475,000
(hereinafter referred to as ("Compensation"), payable in accordance with the Corporation's normal pay practices during the term of Employee's employment. In no event shall Employee's current annual
base salary be decreased, but it may, from time to time be increased at the discretion of Corporation during the term of this Agreement. The Compensation shall be paid on a calendar-year
basis, and shall be pro rated for any partial year. 

    b.  In
addition to the Employee's Compensation, the Corporation shall pay to the Employee a bonus (the "Incentive Bonus") for each calendar year during the term of his
employment, of between fifty-five percent (55%) and one hundred ten percent (110%) of Employee's Compensation paid for such calendar year. The payment of any bonus will be dependent upon
whether the actual financial performance of the Corporation meets the budget projections adopted 

  
by the Board of Directors for such calendar year. If the Corporation fails to meet its minimum budget expectations, Employee will not receive any Incentive Bonus for that calendar year. Except in the
case of death or disability, Employee must be employed by the Corporation at the end of the calendar year (or May 31, 2005, in the case of the last year of this Agreement) in order to receive
an Incentive Bonus for that year. The Incentive Bonus for calendar year 2001 shall be based on the Compensation paid to Employee in such year. The criteria for determining the amount of the Incentive
Bonus shall be determined by mutual agreement between the Employee and the Board of Directors within 60 days of the effective date of this Agreement. The bonus shall be paid within
60 days following the end of the calendar year. 

    4.  Officer Insurance Coverage—Costs of Defense. During the term of Employee's employment and for two
(2) years thereafter, the Corporation shall provide to Employee officer liability insurance coverage to cover any claims that may be made arising from his past, present, or future activities on
behalf of the Western Companies, in the same manner as such insurance is provided to the other officers of the Corporation, provided that such insurance coverage is available to the Corporation at a
reasonable cost. Thereafter, if the Employee wants continuing officer liability insurance coverage, he shall be responsible for the cost thereof. 

    5.  Cooperation With Respect to Investigations, Claims or Litigation. During the term of Employee's employment and at
all times thereafter, should a Western Company become involved in any investigation, claim, or litigation relating to or arising out of Employee's past, present, or future duties with a Western
Company or with respect to any matters which the Employee has knowledge, Employee agrees to fully, and in good faith, cooperate with the Corporation with respect to such investigation, claim, or
litigation. The Corporation shall reimburse Employee for his reasonable out-of-pocket expenses incurred to provide such cooperation. 

    6.  Indemnification Agreement. Exhibit "A", attached hereto and incorporated herein by reference is an
Indemnification Agreement by and between the Corporation and the Employee. The Corporation and the Employee each agree to execute and deliver such Indemnification Agreement concurrently with the
execution and delivery of this Agreement. To the extent any provision set forth in the Indemnification Agreement is in conflict with any provision set forth in this Agreement, the provision set forth
in the Indemnification Agreement shall govern. 

    7.  Employee Benefits.

    a.  During
the term of employment, Employee shall be eligible to participate in the employee benefit plans maintained by the Corporation, in accordance with the
provisions of such plans, as such plans may be changed from time to time. Employee shall receive five (5) weeks of paid vacation per year, to be taken at such time and manner as to not
unreasonably interfere with the performance of his duties. Employee shall have all other benefits provided to or received by other executives of the Company. 

    b.  Pursuant
to, and as more fully explained in, the stock option agreement attached hereto as Exhibit B and executed herewith, Corporation will provide Employee
with 300,000 stock options to purchase common stock of the Corporation, at an exercise price equal to five dollars ($5.00) below the closing price for the Company's stock on the effective date of this
Employment 

  
Agreement (November 1, 2001), with vesting of the stock options to occur over a four year period, in accordance with the following schedule: 

	Year of Service

Completed
	 	Percentage of

Options Vested
	 
	1	 	25	%
	2	 	25	%
	3	 	25	%
	4	 	25	%

For
these purposes, a Year of Service shall be 12 months of full-time employment with the Company during a period beginning September 1, and ending August 31. Employee
must be employed on the last day of any such 12-month period in order to have completed a year of service. The Employee hereby agrees and acknowledges that nothing in this Agreement
guarantees him the right to any additional grant of stock options. However, the Board of Directors, in its sole discretion, may grant additional stock options to Employee. Employee shall receive
registered stock upon the exercise of his options. 

    8.  Confidential Information. Employee acknowledges that pursuant to the employment hereunder, Employee occupies a
position of trust and confidence. Accordingly, in order to facilitate the performance of this Agreement and the activities contemplated by this Agreement, the Western Companies may disclose to
Employee or Employee may develop or obtain certain proprietary or confidential information of the Western Companies. During Employee's employment hereunder and for a period of one (1) year
therefrom, Employee hereby agrees not to use or to disclose to any person, other than in the discharge of his duties under this Agreement, any "proprietary or confidential" information of the Western
Companies, including, but not limited to, any information concerning the business operations, business strategies, or internal structure of the Western Companies, the customers or clients of the
Western Companies, any acquisition strategies of the Western Companies, the gas and other products, marketing or transportation strategies of the Western Companies, its subsidiaries or affiliates, the
terms of any gas gathering, processing, marketing, or transportation contracts entered into by the Western Companies, past, present or future research done by the Western Companies respecting the
business or operations of the Western Companies, or customers or clients or potential customers or clients of the Western Companies, personnel data of the Western Companies, product or process
knowledge, the Employee's work performed for, or relating to or for, any customer or client of any Western Company or the gas or other product pricing for any customer or client of any Western
Company, any method or procedure relating or pertaining to projects developed by any Western Company or contemplated by any Western Company to be developed, or any gas gathering, processing, drilling,
marketing, transportation project which any Western Company is developing, or any plans or strategy related to the foregoing Information shall not be deemed to be Confidential Information for purposes
of this Agreement which: (i) is or hereafter becomes publicly known through no act or
omission of the Employee; (ii) is received by Employee without restriction on disclosure from a third party who disclosed the information without violating any restriction on confidentiality or
disclosure; (iii) is independently developed by Employee without reference to the Confidential Information and without violation of any confidentiality restriction; or (iv) is divulged
by Employee pursuant to statute, regulation, or the order of a court of competent jurisdiction, provided that Employee previously notifies the Corporation so as to allow the Corporation to take
appropriate protective measures. 

    If
the Employee violates this agreement of confidentiality, the Corporation shall, in addition to any other remedy provided by law, be permitted to pursue an action for injunctive
relief, monetary damages, or both. The Employee acknowledges that all such information constitutes confidential and/or proprietary information of the Western Companies and agrees that such information
shall be kept confidential, such information shall be used solely for the purpose of performing the obligations 

  
hereunder or activities contemplated by this Agreement, and that he shall not otherwise disclose or make use of such information, except in response to a court order. 

    9.  Non-Solicitation. During Employee's employment hereunder and for a period of six (6) months
thereafter, Employee shall not engage in any of the following: (a) hire, offer to hire (or participate in the hiring or offer to hire of) any officer or employee of any Western Company; or
(b) directly solicit any current customer of the Corporation at any time during Employee's term of employment with the Corporation. Provided, however, these restrictions shall not apply after a
Change of Control, as defined in paragraph 15(a)(2) or as provided in paragraph 17(a). This provision, however, shall not be construed to require the Employee to violate any law
forbidding anti-competitive practices or any law regarding anti-trust. 

    In
addition, nothing contained herein shall prevent Employee from hiring any officer or employee of any Western Company as a result of a general solicitation in a publicly-available
publication, including the internet. In the event Employee violates this non-solicitation provision, the Western Company shall, in addition to any other remedy provided by law, be
permitted to pursue an action for injunctive relief, monetary damages, or both. 

    10. Ownership of Documents. All information, drawings, documents and materials whether in writing, on computer disks,
computer hard drive, on magnetic tape or otherwise prepared by the Employee in connection with his employment, or which Employee obtains in the course of or as result of his employment by the
Corporation shall be the sole and exclusive property of the Corporation and will be delivered to the Corporation by the Employee on the earlier of a demand by the Corporation or promptly after
termination of his employment hereunder, together with all written, computer, magnetic tape or other evidence of the information, drawings, document and materials, if any, furnished by any Western
Company to the Employee in connection with the Employee's employment. 

    11. Agreement Not To Compete. The parties hereto recognize that the Employee is retained by the Corporation as part of a
professional, management and executive staff of the Corporation whose duties include the formulation and execution of management policy. Therefore, the Employee hereby agrees that during the term of
his employment hereunder and for a period of six (6) months after the termination of employment, he shall not act or engage in material competition with the activities of or plans of any
Western Company as they exist up to the time of the Employee's termination of employment; provided, however, that this agreement not to compete shall terminate in the event of a Change of Control of
the Corporation or as provided in paragraph 17. Material competition by the Employee shall mean that the Employee is involved in any business or investment activity, in any capacity including
but not limited to an employee, consultant, advisor, agent, shareholder, independent contractor, investor, partner, member, owner or otherwise, which activity directly competes with or has a material
adverse economic effect on any of the material business activities or business plans of any Western Company. Material competition shall not include any activity involving the gathering and processing
business that is not within 25 miles of one of the Western Companies' existing or planned gathering, processing or generation facilities; an activity involving the storage or hub business for natural
gas or natural gas liquids that is not within 100 miles of an existing or planned storage facility of any Western Company; and/or an activity involving the purchase of oil or gas leases, the farming
in of such leases or any similar arrangement, that is not within five (5) miles of the boundaries of an existing oil or gas lease of any Western Company. In the event the Employee violates this
agreement not to compete, the Corporation shall, in addition to any other remedies provided by law, be permitted to pursue an action for injunctive relief (preliminary or permanent), monetary damages,
or both. Provided, however, these restrictions shall not apply after a Change of Control, as defined in paragraph 15(a)(2) or as set forth in paragraph 17. 

  
    12. Termination of Employment. Employee's employment pursuant to this Agreement shall terminate upon the first to occur
of the following events: 

    a.  The
Employee's death. 

    b.  The
Employee's disability, as that term is defined pursuant to the Corporation's disability insurance plan covering its officers. 

    c.  The
Employee's written election to terminate employment, to be effective ninety (90) days thereafter unless an earlier effective date is specified by the
Corporation, with or without Good Reason. 

    d.  The
Corporation's written election to terminate Employee's employment without "cause." 

    e.  The
Corporation's written election to terminate the Employee's employment "for cause." 

    Cause.  For purposes of this Agreement, a termination of employment is for "Cause" if the Employee has been convicted of
a felony involving moral turpitude or the termination is evidenced by a resolution adopted in good faith by two-thirds of the Board that the Employee (a) intentionally and
continually failed substantially to perform his reasonably assigned duties with the Company (other than a failure resulting from the Employee's incapacity due to physical or mental illness or from the
Employee's assignment of duties that would constitute "Good reason" as hereinafter defined) which failure continued for a period of at least thirty days after a written notice of demand for
substantial performance has been delivered to the Employee specifying the manner in which the Employee has failed substantially to perform, or (b) intentionally engaged in conduct which is
demonstrably and materially injurious to the Company; provided, however, that no termination of the Employee's employment shall be for Cause until
(x) there shall have been delivered to the Employee a copy of a written notice setting forth that the Employee was guilty of the conduct set forth in this section and specifying the
particulars thereof in detail, and (y) the Employee shall have been provided an opportunity to be heard in person by the Board (with the assistance of the Employee's counsel if the Employee so
desires). Neither an act nor a failure to act, on the Employee's part shall be considered "intentional" unless the Employee has acted or failed to act with a lack of good faith and with a lack of
reasonable belief that the Employee's action or failure to act was in the best interest of the Company. Notwithstanding anything contained in this Agreement to the contrary, no failure to perform by
the Employee if Employee has terminated for good reason shall constitute Cause for purposes of this Agreement. 

    13. [Section Intentionally Omitted]. 

    14. Employee's Rights and Obligations Upon Death or Disability. If the Employee's employment is terminated as a result
of death or disability, then the Employee shall be entitled to the following in full satisfaction of all of his rights under this Agreement or at law: 

    a.  Employee's Right to Compensation and Benefits. Employee shall be entitled to the pro-rata share of
Compensation and employee benefits, if any, which have been earned but not paid through the date of Employee's death or disability. Employee shall only be entitled to such additional bonus, if any,
which has been previously authorized by the Board of Directors, but has not been paid as of the date of Employee's death or disability. For purposes of this Agreement, a bonus shall be deemed to be
authorized on the date that the Board of Directors fixes the criteria to be met in order for the Employee to earn his bonus. 

    b.  Employee's Obligations. Notwithstanding such termination of employment, if the Employee is terminated as a result of
disability, Employee shall remain bound by the provisions of paragraphs 5, 8, 9, 10 and 11 hereof. 

 

    15. Employee's Rights and Obligations Upon Termination of Employment By the Corporation Without Cause or By Employee for Good Reason.  If Employee's employment is terminated by the Corporation without cause
pursuant to Section 12(d) herein or by the Employee for Good Reason, then Employee shall
be entitled to the following in full satisfaction of his rights under this Agreement or at law: 

    a.  Severance Pay.

    (1) Employee
shall be entitled to severance pay in an amount equal to his most recent Compensation, plus his Incentive Bonus for the calendar year preceding such
termination of employment. Such severance pay will be payable in accordance with the Corporation's normal pay practices over the 12 months following such termination of employment. 

    (2) Notwithstanding
anything else contained herein, in the event Employee's employment is terminated without cause within one year after a Change of Control of the
Corporation (as hereinafter defined), then the Employee shall be entitled to severance pay equal to the sum of three times his most recent Compensation and three times his Incentive Bonus for the
calendar year preceding such termination of employment, reduced by any Compensation or severance pay paid or earned but not yet paid to the Employee after the date the Change of Control of the
Corporation occurred and before the date of termination of employment. Severance pay pursuant to this paragraph shall be paid to the Employee in a lump sum within 60 days following termination
without cause following Change of Control of the Corporation. 

    (3) Notwithstanding
anything else contained herein, in the event Employee's employment is terminated without cause within one year after a Change of Control of the
Corporation (as hereinafter defined), then Employee shall receive either of the following for unvested stock options previously granted to Employee: 

    (i)  in
the event of a Change of Control in which the Corporation is acquired in a cash purchase, then Employee shall receive a lump sum payment constituting the
positive difference between the exercise price of unvested stock options previously granted to Employee and the transaction price of common stock to be paid at Closing; or 

    (ii) in
the event of a Change of Control in which the Corporation is acquired in a stock purchase, then Employee's stock options which have not vested prior to
termination without cause shall be converted to an amount of unqualified options of the acquiring corporation's stock at the original grant price to Employee based upon the conversion rate of the
acquiring corporation's stock on the acquisition date,
provided such option plan contains the same material terms and conditions as the Stock Option Agreement attached hereto. 

    (4) Notwithstanding
anything else contained herein, in the event Employee's employment is terminated without cause within sixty (60) days prior to the release of
a press release, regarding a Change of Control of the Corporation, then the Employee shall be entitled to severance pay equal to three times his Compensation and Incentive Bonus for the preceding
12-month period, reduced by any Compensation or severance pay paid or payable to the Employee after the date of termination and before the date the Change of Control of the Corporation
occurred. Severance pay pursuant to this paragraph shall be payable to the Employee within 60 days following such termination of employment, but before the date of the Change of Control of the
Corporation). 

    (5) For
purposes of this Agreement, "Change of Control of the Corporation" means the acquisition by any person or persons acting in concert (including corporations,
partnerships, associations or unincorporated organizations), of legal ownership or beneficial ownership (within the meaning of Rule 13d-3, promulgated by the Securities and Exchange
Commission 

  
and now in effect under the Securities Exchange Act of 1934 (as amended), of a number of voting shares of capital stock of the Corporation greater than the number of voting shares of capital stock of
the Corporation which are then owned, both legally and beneficially (as defined above), by Brion G. Wise, Bill M. Sanderson, Walter L. Stonehocker, Dean Phillips, Ward Sauvage, their immediate
families and the companies through which they and their immediate families hold ownership in the Corporation ("the Founders"). None of the Founders
shall be counted among those persons acting in concert to acquire ownership unless such Founder, acting in concert with an acquiring person or group (an "Acquiring Group
Founder"), votes against the other Founders in an election for the Board of Directors or the modification of the Corporation's certificate of incorporation or bylaws or in the
vote to accept or reject a plan of merger, sale of substantially all of the assets of the Corporation or similar proposal. The shares of an Acquiring Group Founder shall be counted in the acquiring
group's shares and shall not be counted in the shares of the Founders who are not Acquiring Group Founders. 

    "Change
of Control" shall also be deemed to have occurred if (i) any "person" (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange
Act of 1934, as amended), other than a trustee or other fiduciary holding securities under an employee benefit plan of the Corporation or a corporation owned directly or indirectly by the stockholders
of the Corporation in substantially the same proportions as their ownership of stock of the Corporation, is or becomes the "beneficial owner" (as defined in Rule 13d3 under said Act), directly
or indirectly, of securities of the Corporation representing 20% or more of the total voting power represented by the Corporation's then outstanding Voting Securities, or (ii) during any period
of two consecutive years, individuals who at the beginning of such period constitute the Board of Directors of the Corporation and any new director whose election by the Board of Directors or
nomination for election by the Corporation's stockholders was approved by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors
at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof, or (iii) the stockholders of the
Corporation approve a
merger or consolidation of the Corporation with any other corporation, other than a merger or consolidation which would result in the Voting Securities of the Corporation outstanding immediately prior
thereto continuing to represent (ether by remaining outstanding or by being converted into Voting Securities of the surviving entity) at least 80% of the total voting power represented by the Voting
Securities of the Corporation or such surviving entity outstanding immediately after such merger or consolidation, or the stockholders of the Corporation approve a plan of complete liquidation of the
Corporation or an agreement for the sale or disposition by the Corporation of (in one transaction or a series of transactions) all or substantially all of the Corporation's assets. 

    For
purposes of this paragraph, the term Voting Securities means any securities of the Corporation which vote generally in the election of directors. 

    (6) In
the event of a Change of Control of the Corporation which is not followed by a termination of the Employee without cause, Employee shall continue to serve the
Corporation by the performance of the job and duties described in paragraph 2 hereof, and the Employee shall be employed in the Corporation's offices in Denver, Colorado. 

    b.  Employee's Right to Compensation and Benefits. Employee shall be entitled to the pro rata share of Compensation and
employee benefits, if any, which have been earned but not paid through the date of termination of employment. Employee shall only be entitled to such additional bonus, if any, which has been
previously authorized by the Board of Directors, but has not been paid as of the date of termination of employment. 

  
    c.  Employee's Obligations. Notwithstanding such termination of employment, Employee shall remain bound by the
provisions of paragraphs 5, 8, 9, 10 and 11 hereof; provided, however, that the Agreement Not to Compete in paragraph 11 shall not apply if there has been a Change of Control. 

    d.  Stock Options. Employee's nonvested stock options shall become one hundred percent (100%) vested upon a termination
of employment by the Corporation without cause or by Employee with Good Reason. Employee shall have in all events three (3) months in which to exercise his options in the event of his
termination unless he is terminated for cause by the Corporation or unless Employee terminates this Agreement without Good Reason. 

    e.  Golden Parachute Payments. In the event that there is a Determination (as defined below) that Employee is subject to
any excise tax pursuant to Section 4999 of the Internal Revenue Code of 1986, or otherwise by reason of (a) any payment or distribution by the Company or its affiliated companies to or
for the benefit of Employee (b) the vesting of any stock options awarded to or for the benefit of
Employee by the Company or any of its affiliated companies, (c) any other fact or circumstance arising in connection with this Agreement or Employee's employment with the Company (such excise
tax, together with any interest or penalties imposed with respect thereto, are hereinafter collectively referred to as the "Excise Tax"), the Company shall make a payment to Employee (the
"Grossed-Up Payment") in an amount such that after payment by Employee of all taxes (including any interest and penalties imposed with respect to such taxes), including without limitation,
any income taxes and excise taxes, imposed upon the Grossed-Up Payment the Employee shall retain an amount of the Grossed-Up Payment equal to the Excise Tax. The Company shall
engage at its expense an outside accounting firm to determine whether Employee is subject to an Excise Tax, the amount of such Excise Tax, and the amount of any Grossed-Up Payment due to
Employee pursuant to this paragraph, as well as the underlying assumptions used to make these determinations (the "Determination"). This Determination shall be made within 10 business days of
the receipt of notice from Employee or the Corporation that there may have been an event giving rise to a liability for Excise Tax, and the Corporation shall pay the Employee the
Grossed-Up Payment within five days of the receipt of the Determination. If any of the assumptions used in making the Determination subsequently proves to be incorrect, inaccurate,
or otherwise in error, and if by reason thereof Employee is obligated to pay more in taxes, interest and penalties, than was assumed in the Determination, Employee shall notify the Corporation of such
fact, and the Corporation shall request the outside accounting firm to recompute the amount of the Grossed-Up Payment due to Employee using the correct facts (the "Revised Determination").
This Revised Determination shall be made within 10 business days of the receipt of the notice from Employee, and the Corporation shall pay the Employee the difference between the
Grossed-Up Payment as computed under the Revised Determination, and the Grossed-Up Payment as computed under the original Determination, within five days of the receipt
of the Revised Determination with the result that Employee is held harmless on an after-tax basis for any excise or income tax (including resulting interest and penalties). 

    e.  "Good Reason" shall mean any of the following events which have not been cured by the Corporation within
30 days of the Corporation's receiving notice thereof from Employee: (i) any material breach by the Corporation of its obligations under this Agreement, including the failure of the
Corporation to pay Employee the salary or bonus, if any, or to provide the benefits, if any, in accordance with this Agreement; (ii) any material diminishment in Employee's status, title,
duties, functions, responsibilities or authority or a change that requires Employee to report to someone other than the Board, or a material reduction of base salary or benefits; or (iii) the
Corporation's requiring Employee to be based anywhere other than within twenty-five (25) miles of Employee's current principal place of employment, except for required travel on the
business of the Corporation, or, in the event Employee consents to such relocation, the failure of the 

  
Corporation to pay or reimburse Employee for the reasonable costs incurred by Employee in connection with such relocation. 

    16. Employee's Rights and Obligations Upon Termination of Employment by the Corporation With Cause. If Employee's
employment is terminated by the Corporation with cause pursuant to paragraph 12(e) herein, then the Employee shall be entitled to the following in full satisfaction of all of his rights
under this Agreement or at law. 

    a.  Severance Pay. Employee shall not be entitled to any severance pay. 

    b.  Employee's Rights to Compensation and Benefits. Employee shall only be entitled to the pro rata share of
Compensation and Employee Benefits, if any, earned but not paid through the date of termination of employment. Employee shall only be entitled to such additional bonus, if any, which has been
previously authorized by the Board of Directors, but has not been paid as of the date of termination of employment. 

    c.  Employee's Obligations. Notwithstanding such termination of employment, Employee shall remain bound by the
provisions of paragraphs 5, 8, 9, 10 and 11 hereof. 

    17. Employee's Rights and Obligations Upon Termination of Employment By Employee. If Employee's employment is terminated
by the Employee pursuant to paragraph 12(c) herein, then the Employee shall be entitled to the following in full satisfaction of all of his rights under this Agreement or at law: 

    a.  Severance Pay. Employee shall be entitled to no severance pay; provided, however, that if the Company gives Employee
written notice of its election to enforce the Agreement Not to Compete in paragraph 11 hereof within thirty (30) days of such termination of employment, then Employee shall be entitled
to severance pay in an amount equal to the sum of his most recent Compensation and fifty percent (50%) of his Incentive Bonus, for the calendar year preceding such termination of employment. Such
severance pay will be payable in accordance with the Corporation's normal pay practices over the 12 months following such termination of employment. 

    b.  Employee's Rights to Compensation and Benefits. Employee shall be entitled to the pro rata share of Compensation and
Employee Benefits, if any, which have been earned but not paid through the effective date of such termination of employment. Employee shall only be entitled to such additional bonus, if any, which has
been previously authorized by the Board of Directors, but has not been paid as of the date of termination of employment. 

    c.  Employee's Obligations. Notwithstanding such termination of employment, Employee shall remain bound by the
provisions of paragraphs 5, 8, 9, and 10 hereof. In addition, the provisions of paragraph 11 shall apply only if the Company has made the election described in paragraph 17(a). 

    18. Directorship. Upon the effective date of this Agreement, Employee shall be elected as a member of the Company's
Board of Directors and shall serve in such capacity during the term of his employment with the Company. Upon Employee's termination of employment, for any reason, Employee agrees to resign immediately
from his position as a Director of Corporation. 

    19. Benefit. This Agreement shall inure to the benefit of and be binding upon the Corporation, its successors and
assigns, including, but not limited to (i) any corporation which may acquire all or substantially all of the Corporation's assets and business, (ii) any corporation with or into which
the Corporation may be consolidated or merged, or (iii) any corporation that is the successor corporation in a share exchange, and the Employee, his heirs, guardians and personal and legal
representatives. 

  
    20. Notices. All notices and communications hereunder shall be in writing and shall be deemed given when sent postage
prepaid by registered or certified mail, return receipt requested, and, if intended for the Corporation, shall be addressed to it, to the attention of its President, at: 

Western
Gas Resources, Inc.

12200 North Pecos Street

Denver, Colorado 80234 

or
at such other address which the Corporation shall have given notice to the Employee in the manner herein provided, and if intended for the Employee, shall be addressed to him at his last known
residence, or at such other address at which the Employee shall have given notice to the Corporation in the manner provided herein: 

Employee:
Peter A. Dea

Address: 

    21. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of
Colorado. 

    22. Severability. In the event one or more of the provisions contained in this Agreement, or any application thereof,
shall be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein or any other application or modification thereof,
shall not in any way be affected or impaired. The parties further agree that any such invalid, illegal or unenforceable provision or restriction shall be deemed modified so that it shall be enforced
to the greatest extent permissible under law, and to the extent that any court of competent jurisdiction determines any provision or restriction herein to be overly broad, or unenforceable, such court
is
hereby empowered and authorized to limit such provisions or restriction so that it is enforceable for the longest duration of time, within the largest geographical area and with the broadest scope. 

    23. Miscellaneous.

    a.  Counterparts. This Agreement may be executed in more than one copy, each copy of which shall serve as an original
for all purposes, but all copies shall constitute but one and the same Agreement. 

    b.  Assignment. This Agreement is personal to each of the parties hereto, and neither party may assign nor delegate any
of such party's rights or obligations hereunder without first obtaining the written consent of the other party. 

    c.  Headings. All headings set forth in this Agreement are intended for convenience only and shall not control or affect
the meaning, construction or effect of this Agreement or of any of the provisions hereof. 

    d.  Gender, Plurals and Pronouns. Throughout this Agreement, the masculine gender shall include the feminine and neuter,
and the singular shall include the plural and vice versa, wherever the context and facts require such construction. 

    e.  Binding Arbitration, Attorney's Fees and Expenses. If any dispute arises between the parties to this Agreement with
respect to any amounts due hereunder to any one of the parties (but not as to whether the Corporation is obligated to provide legal representation to the Employee pursuant to Section 4 hereof),
then both parties shall submit the dispute to binding arbitration. Both parties agree to be bound by the decision of such arbitration. The obligation to submit to binding arbitration shall not prevent
either party from seeking a court order or an injunction enforcing the term of this Agreement. In the event of any binding arbitration between the parties, or any litigation to enforce any provision
of this Agreement or any right of either party, the 

  
unsuccessful party to such arbitration or litigation shall pay the successful party all costs and expenses, including reasonable attorney's fees, incurred. 

    f.   Waiver of Breach. The waiver by any party hereto of any provision of this Agreement shall not operate or be
construed as a waiver of any subsequent breach by any party. 

    g.  Entire Agreement. Except for the Indemnification Agreement, this Agreement contains all agreements, understandings,
and arrangements between the parties hereto and no other exists. Except for the Indemnification Agreement, all previous agreements, understandings, and arrangements between the parties relating to
employment are terminated by this Agreement. This Agreement may be amended, waived, changed, modified, extended or rescinded only by a writing signed by the party against whom such amendment, waiver,
change, modification, extension or rescission is sought. 

    IN WITNESS WHEREOF, the parties have hereunto set their hands as of the date first written above. 

	

 	
 	
CORPORATION:

    WESTERN GAS RESOURCES, INC.
	

 	
 	
By	

/s/ LANNY F. OUTLAW   
 Lanny F. Outlaw

Lanny F. Outlaw, authorized on behalf of the Board of Directors
	

 	
 	
EMPLOYEE:
	

 	
 	

 	

/s/ PETER A. DEA   
 Peter A. Dea

  

 
 

Exhibit A    
  

 
 

INDEMNIFICATION AGREEMENT    
  

    THIS INDEMNIFICATION AGREEMENT (this "Agreement"), effective as of November 1, 2001, between Western Gas
Resources, Inc., a Delaware corporation (the "Company"), and Peter A. Dea (the "lndemnitee"). 

    WHEREAS, it is essential to the Company to retain and attract as officers and directors the most capable persons available; 

    WHEREAS, Indemnitee is the Chief Executive Officer, President and director of the Company; 

    WHEREAS, both the Company and Indemnitee recognize the increased risk of litigation and other claims being asserted against directors
of public companies in today's environment; 

    WHEREAS, the Bylaws of the Company require the Company to indemnify and advance expenses to its officers and directors to the full
extent permitted by law and the Indemnitee has been serving and continues to serve as an officer or director of the Company in part in reliance on such Bylaws; 

    WHEREAS, in recognition of Indemnitee's need for substantial protection against personal liability in order to enhance Indemnitee's
continued service to the Company in an effective manner and Indemnitee's reliance on the aforesaid Bylaws, and in part to provide Indemnitee with specific contractual assurance that the protection
promised by such Bylaws will be available to Indemnitee (regardless of, among other things, any amendment to or revocation of such Bylaws, or any change in the composition of the Company's Board of
Directors or acquisition transaction relating to the Company), the Company wishes to provide in this Agreement for the indemnification of and the advancing of expenses to Indemnitee to the fullest
extent (whether partial or complete) permitted by
law and as set forth in this Agreement, and, to the extent insurance is maintained, for the continued coverage of Indemnitee under the Company's directors' and officers' liability insurance policies; 

    NOW, THEREFORE, in consideration of the premises and of Indemnitee continuing to serve the Company directly or, at its request, another
enterprise, and intending to be legally bound hereby, the parties hereto agree as follows: 

	1.
	Certain Definitions:

	(a)
	Change in Control: shall be deemed to have occurred if (i) any "person" (as such term is used in
Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended), other than a trustee or other fiduciary holding securities under an employee benefit plan of the
Company or a corporation owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company, is or becomes the "beneficial
owner" (as defined in Rule 13d3 under said Act), directly or indirectly, of securities of the Company representing 20% or more of the total voting power represented by the Company's then
outstanding Voting Securities, or (ii) during any period of two consecutive years, individuals who at the beginning of such period constitute the Board of Directors of the Company and
any new director whose election by the Board of Directors or nomination for election by the Company's stockholders was approved by a vote of at least two-thirds (2/3) of the
directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute a
majority thereof, or (iii) the stockholders of the Company approve a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result
in the Voting Securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into Voting Securities of the surviving
entity) at least 80% of the total voting 

 

power
represented by the Voting Securities of the Company or such surviving entity outstanding immediately after such merger or consolidation, or the stockholders of the Company approve a plan of
complete liquidation of the Company or an agreement for the sale or disposition by the Company of (in one transaction or a series of transactions) all or substantially all the Company's assets. 

	(b)
	Claim: any threatened, pending or completed action, suit or proceeding, or any inquiry or investigation, whether instituted by the
Company or any other party, that Indemnitee in good faith, believes might lead to the institution of any such action, suit or proceeding, whether civil, criminal, administrative, investigative or
other.

	(c)
	Expenses: include attorneys' fees and all other costs, expenses and obligations paid or incurred in connection with investigating,
defending, being a witness in or participating in (including on appeal), or preparing to defend, be a witness in or participate in any Claim relating to any Indemnifiable Event.

	(d)
	Indemnifiable Event: any event or occurrence related to the fact that Indemnitee is or was a director, officer, employee, agent or
fiduciary of the Company, or is or was serving at the request of the Company as a director, officer, employee, trustee, agent or fiduciary of another corporation, partnership, joint venture, employee
benefit plan, trust or other enterprise, or by reason of anything done or not done by Indemnitee in any such capacity.

	(e)
	Independent Legal Counsel: an attorney or firm of attorneys, selected in accordance with the provisions of Section 3, who
shall not have otherwise performed services for the Company or Indemnitee within the last five years (other than with respect to matters concerning the rights of Indemnitee under this
Agreement, or of other indemnitees under similar indemnity agreements).

	(f)
	Potential Change in Control: shall be deemed to have occurred if (i) the Company enters into an agreement, the consummation
of which would result in the occurrence of a Change in Control; (ii) any person (including the Company) publicly announces an intention to take or to consider taking actions which if
consummated would constitute a Change in Control; (iii) any person, other than a trustee or other fiduciary holding securities under an employee benefit plan of the Company or a corporation
owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company, who is or becomes the beneficial owner, directly or
indirectly, of securities of the Company representing 9.5% or more of the combined voting power of the Company's then outstanding Voting Securities, increases his beneficial ownership of such
securities by five percentage points (5%) or more over the percentage so owned by such person; or (iv) the Board adopts a resolution to the effect that, for purposes of this Agreement, a
Potential Change in Control has occurred.

	(g)
	Reviewing Party: any appropriate person or body consisting of a member or members of the Company's Board of Directors or any other
person or body appointed by the Board who is not a party to the particular Claim for which Indemnitee is seeking indemnification, or Independent Legal Counsel.

	(h)
	Voting Securities: any securities of the Company which vote generally in the election of directors. 

	2.
	Basic Indemnification Arrangement.

	(a)
	In
the event Indemnitee was, is or becomes a party to or witness or other participant in, or is threatened to be made a party to or witness or other participant in, a Claim by
reason of (or arising in part out of) an Indemnifiable Event, the Company shall indemnify Indemnitee to 

 

the
fullest extent permitted by law as soon as practicable but in any event no later than thirty days after written demand is presented to the Company, against any and all Expenses, judgments,
fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines, penalties or
amounts paid in settlement) of such Claim. If so requested by Indemnitee, the Company shall advance (within two business days of such request) any and all Expenses to Indemnitee (an "Expense
Advance"). 

	(b)
	Notwithstanding
the foregoing, the obligations of the Company under Section 2(a) shall be subject to the condition that the Reviewing Party shall not have determined (in a
written opinion, in any case in which the Independent Legal Counsel referred to in Section 3 hereof is involved) that Indemnitee would not be permitted to be indemnified under applicable law.

	(c)
	Notwithstanding
the foregoing, the obligation of the Company to make an Expense Advance pursuant to Section 2(a) shall be subject to the condition that, if, when and
to the extent that the Reviewing Party determines that Indemnitee would not be permitted to be so indemnified under applicable law, the Company shall be entitled to be reimbursed by Indemnitee (who
hereby agrees to reimburse the Company) for all such amounts theretofore paid; provided, however, that if Indemnitee has commenced or thereafter commences legal proceedings in a court, of competent
jurisdiction to secure a determination that Indemnitee should be indemnified under applicable law, any determination made by the Reviewing Party that Indemnitee would not be permitted to be
indemnified under applicable law shall not be binding and Indemnitee shall not be required to reimburse the Company for any Expense Advance until a final judicial determination is made with respect
thereto (as to which all rights of appeal therefrom have been exhausted or lapsed).

	(d)
	If
there has not been a Change in Control, the Reviewing Party shall be selected by the Board of Directors, and if there has been such a Change in Control (other than a Change in
Control which has been approved by a majority of the Company's Board of Directors who were directors immediately prior to such Change in Control), the Reviewing Party shall be the Independent Legal
Counsel referred to in Section 3 hereof.

	(e)
	If
there has been no determination by the Reviewing Party or if the Reviewing Party determines that Indemnitee. substantively would not be permitted to be indemnified in whole or in
part under applicable law, Indemnitee shall have the right to commence litigation in any court in the States of Colorado or Delaware having subject matter jurisdiction thereof and in which venue is
proper seeking an initial determination by the court or challenging any such determination by the Reviewing Party or any aspect thereof, including the legal or factual bases therefor, and the Company
hereby consents to
service of process and to appear in any such proceeding. Any determination by the Reviewing Party otherwise shall be conclusive and binding on the Company and Indemnitee.

	(f)
	Notwithstanding
anything else contained herein, in no event shall Indemnitee be entitled to indemnification under this Agreement for any Claims that relate to liability:
(i) under Section 16(b) of the Securities Exchange Act of 1934, as amended; (ii) under federal or state securities laws for "insider trading"; (iii) conduct finally
adjudged as constituting active or deliberate dishonesty or willful fraud or illegality; (iv) conduct finally adjudged as producing an unlawful personal benefit to Indemnitee; or
(v) prior to a Change of Control, under any Claim initiated by the Indemnitee unless the Board of Directors of the Company shall have authorized or consented to such Claim. 

	3.
	Change in Control. The Company agrees that if there is a Change in Control of the Company (other than a Change in Control which has
been approved by a majority of the Company's Board 

 

of
Directors who were directors immediately prior to such Change in Control) then with respect to all matters thereafter arising concerning the rights of Indemnitee to indemnity payments and Expense
Advances under this Agreement or any other agreement or Company Bylaw now or hereafter in effect relating to Claims for Indemnifiable Events, the Company shall seek legal advice only from Independent
Legal Counsel selected by Indemnitee and approved by the Company (which approval shall not be unreasonably withheld). Such counsel, among other things, shall render its written opinion to the Company
and Indemnitee as to whether and to what extent the Indemnitee would be permitted to be indemnified under applicable law. The Company agrees to pay the reasonable fees of the Independent Legal Counsel
referred to above and to fully indemnify such counsel against any and all expenses (including attorneys' fees), claims, liabilities and damages arising out of or relating to this Agreement or its
engagement pursuant hereto. 

	4.
	Establishment of Trust.

	(a)
	In
the event of a Potential Change in Control, the Company shall: (i) upon written request by Indemnitee, create a trust for the benefit of Indemnitee, with the trustee
chosen by Indemnitee; (ii) from time to time upon written request of Indemnitee, fund such trust in an amount sufficient to satisfy any and all Expenses reasonably anticipated at the time of
each such request to be incurred in connection with investigating, preparing for and defending any Claim relating to an Indemnifiable Event, and any and all judgments, fines, penalties and settlement
amounts of any and all Claims relating to an Indemnifiable Event from time to time actually paid or claimed, reasonably anticipated or proposed to be paid.

	(b)
	Notwithstanding
anything else contained herein, in no event shall the Company be required to deposit more than Five Hundred Thousand Dollars ($500,000) in any trust created
hereunder in excess of amounts deposited in respect of reasonably anticipated Expenses.

	(c)
	The
amount or amounts to be deposited in the trust pursuant to the foregoing funding obligation shall be determined by the Reviewing Party, in any case in which the Independent
Legal Counsel referred to above is involved.

	(d)
	The
terms of the trust shall provide that upon a Change in Control (i) the trust shall not be revoked or the principal thereof invaded, without the written consent of the
Indemnitee, (ii) the trustee shall advance, within two business days of a request by the Indemnitee, any and all Expenses to the Indemnitee (and the Indemnitee hereby agrees to reimburse
the trust under the circumstances under which the Indemnitee would be required to reimburse the Company under Section 2(b) of this Agreement), (iii) the trust shall continue to be
funded by the Company in accordance with the funding obligation set forth herein, (iv) the trustee shall promptly pay to Indemnitee all amounts for which Indemnitee shall be entitled to
indemnification pursuant to this Agreement or otherwise, and (v) all unexpended funds in such trust shall revert to the Company upon a final determination by the Reviewing Party or a court of
competent jurisdiction, as the case may be, that Indemnitee has been fully indemnified under the terms of this Agreement. 

	5.
	Indemnification for Additional Expenses. The Company shall indemnify Indemnitee against any and all expenses (including attorneys'
fees) and, if requested by Indemnitee, shall (within two business days of such request) advance such expenses to Indemnitee, which are incurred by Indemnitee in connection with any action
brought by Indemnitee for (i) indemnification or advance payment of Expenses by the Company under this Agreement or any other agreement or Company Bylaw now or hereafter in effect relating to
Claims for Indemnifiable Events and/or (ii) recovery under any directors' and officers' liability insurance policies maintained by the Company, regardless of whether Indemnitee ultimately is
determined to be entitled to such indemnification, advance expense payment or insurance recovery, as the case may be. 

 

	6.
	Partial Indemnity. Etc. If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or
a portion of the Expenses, judgments, fines, penalties and amounts paid in settlement of a Claim but not, however, for all of the total amount thereof, the Company shall nevertheless indemnify
Indemnitee for the portion thereof to which Indemnitee is entitled. Moreover, notwithstanding any other provision of this Agreement, to the extent that Indemnitee has been successful on the merits or
otherwise in defense of any or all Claims relating in whole or in part to an Indemnifiable Event or in defense of any issue or matter therein, including dismissal without prejudice, Indemnitee shall
be indemnified against all Expenses incurred in connection therewith.

	7.
	Burden of Proof. In connection with any determination by the Reviewing Party or otherwise as to whether Indemnitee is entitled to be
indemnified hereunder the burden of proof shall be on the Company to establish that Indemnitee is not so entitled.

	8.
	No Presumptions. For purposes of this Agreement, the termination of any claim, action, suit or proceeding, by judgment, order,
settlement (whether with or without court approval) or conviction, or upon a plea of nolo contendere, or its equivalent, shall not create a presumption that Indemnitee did not meet any particular
standard of conduct or have any particular belief or that a court has determined that indemnification is not permitted by applicable law. In addition, neither the failure of the Reviewing Party to
have made a determination as to whether Indemnitee has met any particular standard of conduct or had any particular belief, nor an actual determination by the Reviewing Party that Indemnitee has not
met such standard of conduct or did not have such belief, prior to the commencement of legal proceedings by Indemnitee to secure a judicial determination that Indemnitee should be indemnified under
applicable law shall be a defense to Indemnitee's claim or create a presumption that Indemnitee has not met any particular standard of conduct or did not have any particular belief.

	9.
	Nonexclusivity. Etc. The rights of the Indemnitee hereunder shall be in addition to any other rights Indemnitee may have under the
Company's Bylaws or the Delaware General Corporation Law or otherwise. To the extent that a change in the Delaware General Corporation Law (whether by statute or judicial decision) permits greater
indemnification by agreement than would be afforded currently under the Company's Bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the
greater benefits so afforded by such change.

	10.
	Liability Insurance. To the extent the Company maintains an insurance policy or policies providing directors' and officers' liability
insurance, Indemnitee shall be covered by such policy or policies, in accordance with its or their terms, to the maximum extent of the coverage available for any Company director or officer.

	11.
	Period of Limitations. No legal action shall be brought and no cause of action shall be asserted by or in the right of the Company
against Indemnitee, Indemnitee's spouse, heirs, executors or personal or legal representatives after the expiration of two years from the date of accrual of such cause of action, and any claim
or cause of action of the Company shall be extinguished and deemed released unless asserted by the timely filing of a legal action within such two-year period; provided, however, that if
any shorter period of limitations is otherwise applicable to any such cause of action such shorter period shall govern.

	12.
	Amendments. Etc. No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by both of
the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar) nor shall such waiver
constitute a continuing waiver.

	13.
	Subrogation. In the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of
the rights of recovery of Indemnitee, who shall execute all 

 

papers
required and shall do everything that may be necessary to secure such rights, including the execution of such documents necessary to enable the Company effectively to bring suit to enforce such
rights. 

	14.
	No Duplication of Payments. The Company shall not be liable under this Agreement to make any payment in connection with any Claim
made against Indemnitee to the extent Indemnitee has otherwise actually received payment (under any insurance policy, Bylaw or otherwise) of the amounts otherwise indemnifiable hereunder.

	15.
	Binding Effect. Etc. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and
their respective successors, assigns, including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business and/or assets of the
Company, spouses, heirs, executors and personal and legal representatives. This Agreement shall continue in effect regardless of whether Indemnitee continues to serve as an officer or director of the
Company or of any other enterprise at the Company's request.

	16.
	Severability. The provisions of this Agreement shall be severable in the event that any of the provisions hereof (including any
provision within a single section, paragraph or sentence) is held by a court of competent jurisdiction to be invalid, void or otherwise unenforceable in any respect, and the validity and
enforceability of any such provision in every other respect and of the remaining provisions hereof shall not be in any way impaired and shall remain enforceable to the fullest extent permitted by law.

	17.
	Governing Law. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Delaware
applicable to contracts made and to be performed in such state without giving effect to the principles of conflicts of laws. 

    IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of November 1, 2001. 

	 	 	WESTERN GAS RESOURCES, INC.
	

 	
 	
By:	

/s/ LANNY F. OUTLAW   
 Lanny F. Outlaw, authorized on behalf of the Board of Directors
	

 	
 	
INDEMNITEE:
	

 	
 	
By:	

/s/ PETER A. DEA   
 Peter A. Dea

 

 
 

EXHIBIT B    
  

 
 

WESTERN GAS RESOURCES, INC.
  STOCK OPTION AGREEMENT    
  

    THIS AGREEMENT ("Agreement"), effective as of November 1, 2001, by and between Western Gas Resources, Inc. and its successors and assigns
(hereinafter called the "Corporation"), a Delaware corporation, and Peter A. Dea, Chief Executive Officer and President of the Corporation (hereinafter called the "Optionee"). 

R E C I T A L S:  

    A.  The
Optionee is eligible for stock options pursuant to an employment agreement effective October 15, 2001 ("Employment Agreement") by and between Optionee
and Corporation under the terms and conditions of the Employment Agreement and this Agreement. 

    B.  The
Board of Directors of the Corporation considers it desirable and in the Corporation's best interests that the Optionee be given an opportunity to purchase
shares of its Common Stock in order to provide incentive for the Optionee to remain with the Corporation and to promote the success of the Corporation. 

    NOW,
THEREFORE, in consideration of the promises exchanged herein, it is agreed as follows: 

    1.  Grant of Option. The Corporation hereby grants as of November 1, 2001, (the "Grant Date") to the Optionee the
right, privilege and option to exercise 300,000 shares ("Option") of the Common Stock, par value $0.10 (the "Common Stock") of the Corporation, at an exercise price equal to five dollars ($5.00) below
the closing price per share for the Common Stock on the effective date of the Employment Agreement in the manner and subject to the conditions hereafter provided. 

    2.  Period of Exercise of Option. This Option may be exercised in whole or in part, or in installments, from time to
time, with respect to the shares covered hereby, in the amounts and at the times specified below. The Option or any portion thereof, once it becomes exercisable as specified below, shall remain
exercisable until it shall expire in accordance with the provisions of this Agreement. 

    a.  Notwithstanding
anything to the contrary, no Option or portion thereof granted under this Agreement may be exercised after the earlier of (i) five
(5) years after the date the Optionee has the right to exercise such Option or portion thereof, in accordance with paragraph 2(b), below; or (ii) ten (10) years after the
date the Option is granted. 

    b.  Except
as expressly provided in Section 2(e), below, Optionee shall become entitled to exercise that portion of the Option and to purchase the percentage of
the Common Stock subject to the Option in accordance with the following schedule: 

    (1) Commencing
one (1) year from the Grant Date, the Optionee shall have the right to exercise twenty-five percent (25%) of the Option and to
purchase twenty-five percent (25%) of the Common Stock subject to the Option. 

    (2) Commencing
two (2) years from the Grant Date, the Optionee shall have the right to exercise twenty-five percent (25%) of the Option and to
purchase twenty-five percent (25%) of the Common Stock subject to the Option. 

    (3) Commencing
three (3) years from the Grant Date, the Optionee shall have the right to exercise twenty-five percent (25%) of the Option and to
purchase twenty-five percent (25%) of the Common Stock subject to the Option. 

  
    (4) Commencing four (4) years from the Grant Date, the Optionee shall have the right to exercise twenty-five percent (25%) of the Option and to
purchase twenty-five percent (25%) of the Common Stock subject to the Option. 

    The
Optionee's right to purchase Shares subject to the Option shall be cumulative, so that four (4) years from the Grant Date, the Optionee shall be entitled to exercise one
hundred percent (100%) of the Option and to purchase all of the Common Stock subject to the Option, subject to all of the provisions of this Agreement. 

    c.  Except
as provided in Sections 2(d), 2(e) 2(f) and 2(g), Optionee may exercise an Option only if, at the time such Option is exercised, such
Optionee is Chief Executive Officer and President of, and has continuously been employed since the grant of the Option, as the Chief Executive Officer and President by the Corporation. 

    d.  If
Optionee's employment is terminated without cause or by Optionee for Good Reason (as those terms are defined in the Employment Agreement) and Optionee ceases to
be the Chief Executive Officer and President of the Corporation, all of the Options granted to such Optionee shall become one hundred percent (100%) exercisable, without regard to the provisions of
Section 2(b) above; provided, however, that no such Option may be exercised after three (3) months from the later of such
Optionee's date of termination or the date Optionee ceases to be the Chief Executive Officer and President. Upon expiration of said period, all unexercised Options, or portions thereof, shall
terminate, be forfeited, and shall lapse. 

    e.  If
Optionee dies while he is Chief Executive Officer and President of the Corporation, or ceases to be the Chief Executive Officer and President as a result of
disability, all of the Options granted to such Optionee shall become one hundred percent (100%) exercisable, without regard to the provisions of Section 2(b) above. In such event, the
Options may be exercised by the disabled Optionee, or in the event of death, the person or persons to whom his rights under the Option shall pass by will, or by the applicable laws of descent and
distribution; provided, however, that no such Option may be exercised after one hundred eighty (180) days from the later of such Optionee's date
of death, or the date Optionee ceases to be the Chief Executive Officer and President as a result of disability, whichever is applicable. Upon expiration of said period, all unexercised Options, or
portions thereof, shall terminate, be forfeited, and shall lapse. 

    f.   If
Optionee's employment is terminated by the Corporation for cause or by Optionee without good reason (as defined in the Employment Agreement) Optionee may, within
three (3) months thereafter, subject to provisions of Sections 2 (a), (b) and (c), exercise the Option to the extent that the Option was exercisable as of the date of termination
for cause. All unexercised Options, or portions thereof, shall terminate, be forfeited, and shall lapse. 

    g.  Notwithstanding
the provision of Section 2(b), above, in the event (1) there is a "Change of Control" of the Corporation as defined in the Employment
Agreement; and (2) the Optionee is terminated as the Chief Executive Officer and President of the Corporation without cause or terminated by Optionee with Good Reason (as defined in the
Employment Agreement), then all of the Options granted to such Optionee under this Agreement shall become one hundred percent (100%) exercisable, subject to the other provisions of this
Section 2. All unexercised Options, or portions thereof, shall terminate, be forfeited, and shall lapse upon expiration of a three (3) month period, for any of the reasons set forth
herein. 

    3.  Method of Exercise. To exercise an Option, the Optionee, or his successors, shall give written notice to the
Treasurer of the Corporation at its principal office. Said notice shall be accompanied by full payment of the shares being purchased. If the option is exercised by the successor of the Optionee
following his death, proof shall also be submitted of the right of the successor to exercise the option. The Corporation shall not be required to transfer or deliver any certificate or certificates
for shares 

  
purchased upon any such exercise of said option: (a) until after compliance with all then applicable requirements of law; and (b) prior to admission of such shares to listing on any
stock exchange on which the stock may then be listed. In no event shall the Corporation be required to issue fractional shares to the Optionee. 

    4.  Limitation Upon Exercise. The option is not transferable by the Optionee otherwise than by will or the laws of
descent and distribution and is exercisable, during the lifetime of the Optionee, only by the Optionee. 

    5.  Limitation Upon Transfer. Except as otherwise provided herein, the option and all rights granted hereunder shall not
be transferred by the Optionee, and may not be assigned, pledged, or hypothecated in any way and shall not be subject to execution, attachment or similar process. Upon any attempt to transfer the
option, or to assign, pledge, hypothecate or otherwise dispose of such option or of any rights granted hereunder, contrary to the provisions hereof, or upon the levy of any attachment or similar
process upon such option or such rights, such option and such rights shall immediately become null and void. 

    6.  Stock Adjustment. In the event of any change in Common Stock of the Corporation by reason of a stock split, stock
dividend, recapitalization, exchange of shares, or other transaction, the number of shares remaining subject to the option and the option price per share shall be appropriately adjusted by the Board
of Directors. 

    7.  Corporate Reorganization. If there shall be any capital reorganization or consolidation or merger of the Corporation
with another corporation or corporations, or any sale of all or substantially all of the Corporation's properties and assets to any other corporations, the Corporation shall take such action as may be
necessary to enable the Optionee to receive upon any subsequent exercise of such option, in whole or in part, in lieu of shares of Common Stock, securities or other assets as were issuable or payable
upon such reorganization, consolidation, merger or sale in respect of, or in exchange for such shares of Common Stock. 

    8.  Rights of Stockholder. Neither the Optionee, his legal representative, nor other persons entitled to exercise the
option shall be or have any rights of a stockholder in the Corporation in respect of the shares issuable upon exercise of the option granted hereunder, unless and until certificates representing such
shares shall have been delivered pursuant to the terms hereof. 

    9.  Rights of Optionee. Nothing contained in this Agreement shall confer upon Optionee any right to continue to remain
as the Chief Executive Officer and President of the Corporation. 

    10. Stock Reserved. The Corporation shall at all times during the term of this Agreement reserve and keep available such
number of shares of its Common Stock as will be sufficient to satisfy the terms of this Agreement. 

    11. Binding Effect. This Agreement shall be binding upon and inure to the benefit of any successor or successors of the
Corporation. 

    12. Incorporation of Employment Agreement by Reference. This Stock Option Agreement is subject to all of the terms and
conditions contained in the Employment Agreement, a copy of which has been furnished to the Optionee. 

  
    IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the day and year first above written. 

	 	 	WESTERN GAS RESOURCES, INC.
	

 	
 	
By:	

/s/ LANNY F. OUTLAW   
 Lanny F. Outlaw, authorized on behalf of the Board of Directors
	

 	
 	

 	

/s/ PETER A. DEA   
 Optionee

QuickLinks

EMPLOYMENT AGREEMENT

Exhibit A

INDEMNIFICATION AGREEMENT

EXHIBIT B

WESTERN GAS RESOURCES, INC. STOCK OPTION AGREEMENT<Page>

                                  AGREEMENT AND

                                 PLAN OF MERGER

                                  BY AND AMONG

                       INNOVATIVE CLINICAL SOLUTIONS, LTD

                             CLINICAL STUDIES, LTD.

                        COMPREHENSIVE NEUROSCIENCE, INC.

                                       AND

                              CNS ACQUISITION, INC.

                                      DATED

                                OCTOBER 31, 2001

<Page>
                                TABLE OF CONTENTS
<Table>
<Caption>
SECTION                                                                                               PAGE

<S>                                                                                                     <C>
BACKGROUND  1

ARTICLE 1 - THE MERGER...................................................................................2

     1.1          EXECUTION, FILING AND EFFECTIVE TIME...................................................2

     1.2          CONSTITUENT AND SURVIVING CORPORATION; EFFECT OF MERGER................................2

     1.3          CERTIFICATE OF INCORPORATION AND BY-LAWS...............................................2

     1.4          OFFICERS AND BOARDS OF DIRECTORS.......................................................2

     1.5          CONVERSION OF STOCK AND OTHER SECURITIES OF  THE CONSTITUENT CORPORATIONS..............2

     1.6          EXCHANGE OF SHARES.....................................................................5

ARTICLE 2 - CLOSING......................................................................................5

     2.1          THE CLOSING DATE.......................................................................5

     2.2          THE CLOSING............................................................................5

     2.3          FILING OF AMENDED CERTIFICATE AND CERTIFICATE OF MERGER................................6

     2.4          TAX CONSEQUENCES.......................................................................6

ARTICLE 3 - REPRESENTATIONS AND WARRANTIES OF CNS AND ACQUISITION SUB....................................6

     3.1          ORGANIZATION AND QUALIFICATION.........................................................6

     3.2          THE SUBSIDIARIES OF CNS................................................................6

     3.3          CAPITALIZATION.........................................................................7

     3.4          CORPORATE POWER AND AUTHORITY..........................................................8

     3.5           NO VIOLATION..........................................................................8

     3.6          FINANCIAL STATEMENTS...................................................................8

     3.7          BOOKS AND RECORDS......................................................................9

     3.8          ABSENCE OF UNDISCLOSED LIABILITIES.....................................................9

     3.9          CONDUCT OF THE CNS BUSINESS SINCE THE CNS BALANCE SHEET DATE...........................9

     3.10         TANGIBLE PROPERTIES...................................................................11

     3.11         PREMISES..............................................................................11

     3.12         LICENSES AND PERMITS..................................................................12

     3.13         CNS PROPRIETARY ASSETS................................................................12

     3.14         OUTSTANDING COMMITMENTS...............................................................13

     3.15         LITIGATION............................................................................14

     3.16         COMPLIANCE WITH LAW...................................................................15

     3.17         LABOR AND EMPLOYEE RELATIONS..........................................................16

<Page>

<Caption>
SECTION                                                                                               PAGE
<S>                                                                                                     <C>
     3.18         CERTAIN EMPLOYEES.....................................................................16

     3.19         EMPLOYEE BENEFITS.....................................................................17

     3.20         INSURANCE.............................................................................19

     3.21         TRANSACTIONS WITH AFFILIATES..........................................................20

     3.22         TAXES.................................................................................20

     3.23         BROKERS...............................................................................21

     3.24         ENVIRONMENTAL LAWS....................................................................21

     3.25         ACCOUNTS RECEIVABLE...................................................................22

     3.26         SECURITIES AND EXCHANGE COMMISSION FILINGS............................................22

     3.27         DISCLOSURE............................................................................23

     3.28         APPRAISAL RIGHTS......................................................................23

ARTICLE 4 - REPRESENTATIONS AND WARRANTIES OF CSL AND ICSL..............................................23

     4.1          ORGANIZATION AND QUALIFICATION........................................................23

     4.2          THE SUBSIDIARIES OF CSL...............................................................23

     4.3          CAPITALIZATION........................................................................24

     4.4          CORPORATE POWER AND AUTHORITY.........................................................25

     4.5          NO VIOLATION..........................................................................25

     4.6          FINANCIAL STATEMENTS..................................................................25

     4.7          BOOKS AND RECORDS.....................................................................26

     4.8          ABSENCE OF UNDISCLOSED LIABILITIES....................................................26

     4.9          CONDUCT OF BUSINESS SINCE THE CSL BALANCE SHEET DATE..................................27

     4.10         TANGIBLE PROPERTIES...................................................................28

     4.11         PREMISES..............................................................................28

     4.12         LICENSES AND PERMITS..................................................................29

     4.13         CSL PROPRIETARY ASSETS................................................................29

     4.14         OUTSTANDING COMMITMENTS...............................................................30

     4.15         LITIGATION............................................................................31

     4.16         COMPLIANCE WITH LAW...................................................................32

     4.17         LABOR AND EMPLOYEE RELATIONS..........................................................33

     4.18         CERTAIN EMPLOYEES.....................................................................33

     4.19         EMPLOYEE BENEFITS.....................................................................34

     4.20         INSURANCE.............................................................................36

                                       ii
<Page>

<Caption>
SECTION                                                                                               PAGE
<S>                                                                                                     <C>
     4.21         TRANSACTIONS WITH AFFILIATES..........................................................37

     4.22         TAXES.................................................................................37

     4.23         BROKERS...............................................................................38

     4.24         ENVIRONMENTAL LAWS....................................................................38

     4.25         ACCOUNTS RECEIVABLE...................................................................39

     4.26         SECURITIES AND EXCHANGE COMMISSION FILINGS............................................39

     4.27         DISCLOSURE............................................................................39

     4.28         SEC FILINGS...........................................................................40

ARTICLE 5 - COVENANTS OF CNS............................................................................40

     5.1          EMPLOYEE MATTERS......................................................................40

     5.2          CNS SECURED CONVERTIBLE DEBT..........................................................40

     5.3          CNS OPTIONS AND ICSL REPLACEMENT OPTIONS..............................................41

     5.4          CNS STOCKHOLDER APPROVAL..............................................................41

     5.5          TERMINATION OF STOCKHOLDER AND VOTING AGREEMENTS......................................41

     5.6          ADOPTION OF AMENDMENT TO CNS STOCK OPTION PLAN........................................42

     5.7          PAYMENT OF CNS PREFERRED STOCK DIVIDEND...............................................42

     5.8          TERMINATION OF PSILOS AGREEMENT.......................................................42

ARTICLE 6 - COVENANTS OF CSL AND ICSL...................................................................42

     6.1          ICSL ACTIONS..........................................................................42

     6.2          ICSL REPLACEMENT OPTIONS..............................................................43

ARTICLE 7 - MUTUAL COVENANTS............................................................................43

     7.1          BEST EFFORTS COOPERATION..............................................................43

     7.2          ACCESS................................................................................43

     7.3          INSURANCE.............................................................................43

     7.4          COMPLIANCE WITH LAWS..................................................................43

     7.5          KEEPING OF BOOKS AND RECORDS..........................................................44

     7.6          CONDUCT OF BUSINESS...................................................................44

     7.7          LITIGATION............................................................................45

     7.8          CONTINUED EFFECTIVENESS OF REPRESENTATIONS AND WARRANTIES.............................45

     7.9          NO NEGOTIATIONS.......................................................................45

     7.10         FURTHER ASSURANCES....................................................................46

     7.11         REPLACEMENT FACILITY..................................................................46

                                       iii
<Page>

<Caption>
SECTION                                                                                               PAGE
<S>                                                                                                     <C>
     7.12         GENERAL COVENANTS.....................................................................46

     7.13         PROXY STATEMENT/INFORMATION STATEMENT.................................................47

     7.14         PUBLIC ANNOUNCEMENTS..................................................................47

     7.15         CONFIDENTIALITY.......................................................................48

     7.16         CNS VOTING AGREEMENT..................................................................48

     7.17         CSL VOTING AGREEMENT..................................................................48

     7.18         ESCROW AGREEMENT......................................................................48

ARTICLE 8 - CONDITIONS TO ICSL'S AND CSL'S OBLIGATIONS..................................................49

     8.1          REPRESENTATIONS AND WARRANTIES TRUE...................................................49

     8.2          PERFORMANCE...........................................................................49

     8.3          OFFICERS AND DIRECTORS................................................................49

     8.4          CONSENTS..............................................................................49

     8.5          FINANCIAL DUE DILIGENCE...............................................................50

     8.6          NO ACTIONS, SUITS OR PROCEEDINGS......................................................50

     8.7          OPINION OF COUNSEL....................................................................50

     8.8          ACCOUNTANTS...........................................................................50

     8.9          APPROVAL OF ICSL AND ITS COUNSEL......................................................50

     8.10         CLOSING DOCUMENTS.....................................................................50

     8.11         MINIMUM CASH-ON-HAND..................................................................51

     8.12         CONVERTIBLE DEBT......................................................................51

     8.13         INTENTIONALLY BLANK...................................................................51

     8.14         CNS PREFERRED STOCK DIVIDEND..........................................................51

     8.15         FILING OF AMENDED CERTIFICATE.........................................................51

ARTICLE 9 - CONDITIONS TO CNS'S AND ACQUISITION SUB'S OBLIGATION TO CLOSE...............................51

     9.1          REPRESENTATIONS AND WARRANTIES TRUE...................................................52

     9.2          PERFORMANCE...........................................................................52

     9.3          CONSENTS..............................................................................52

     9.4          FINANCIAL DUE DILIGENCE...............................................................52

     9.5          NO ACTIONS, SUITS OR PROCEEDINGS......................................................52

     9.6          OPINION OF COUNSEL....................................................................53

     9.7          APPROVAL OF CNS AND ITS COUNSEL.......................................................53

     9.8          CLOSING DOCUMENTS.....................................................................53

                                       iv
<Page>

<Caption>
SECTION                                                                                               PAGE
<S>                                                                                                     <C>
     9.9          CONSENT OF CERTIFIED PUBLIC ACCOUNTANTS...............................................53

     9.10         TARGUM NOTE...........................................................................54

ARTICLE 10 - MUTUAL CONDITIONS..........................................................................54

     10.1         NO INJUNCTIONS OR RESTRAINTS; ILLEGALITY..............................................54

     10.2         SHAREHOLDERS AGREEMENT................................................................54

     10.3         LEGENDS...............................................................................54

     10.4         TAX TREATMENT.........................................................................54

     10.5         FAIRNESS OPINION......................................................................55

     10.6         STOCKHOLDER APPROVAL..................................................................55

     10.7         INVESTOR RIGHTS AGREEMENT.............................................................55

     10.8         MODIFICATION OF CSL DEBT..............................................................55

     10.9         EMPLOYMENT AGREEMENT..................................................................55

ARTICLE 11 - SURVIVAL...................................................................................55

ARTICLE 12 - INDEMNIFICATION............................................................................56

     12.1         DEFINITIONS...........................................................................56

     12.2         INDEMNIFICATION GENERALLY; ETC........................................................57

     12.3         LIMITATIONS ON INDEMNIFICATION........................................................58

     12.4         LIMITATIONS ON INDEMNIFICATION........................................................59

     12.5         NOTICE AND DEFENSE OF THIRD PARTY CLAIMS..............................................59

     12.6         REMEDIES EXCLUSIVE....................................................................60

ARTICLE 13 - TERMINATION................................................................................60

     13.1         TERMINATION...........................................................................60

     13.2         EFFECT OF TERMINATION.................................................................61

ARTICLE 14 - MISCELLANEOUS..............................................................................62

     14.1         CERTAIN DEFINITIONS...................................................................62

     14.2         NOTICES...............................................................................70

     14.3         ENTIRE AGREEMENT......................................................................71

     14.4         MODIFICATIONS AND AMENDMENTS..........................................................71

     14.5         WAIVERS AND CONSENTS..................................................................71

     14.6         ASSIGNMENT............................................................................72

     14.7         PARTIES IN INTEREST...................................................................72

     14.8         GOVERNING LAW.........................................................................72

                                       v
<Page>

<Caption>
SECTION                                                                                               PAGE
<S>                                                                                                    <C>
     14.9         JURISDICTION AND SERVICE OF PROCESS...................................................72

     14.10        SEVERABILITY..........................................................................73

     14.11        INTERPRETATION........................................................................73

     14.12        HEADINGS AND CAPTIONS.................................................................73

     14.13        CHOICE OF REMEDIES AND ENFORCEMENT....................................................73

     14.14        EXPENSES..............................................................................73

     14.15        COUNTERPARTS..........................................................................73
</Table>

                                       vi
<Page>

                         TABLE OF SCHEDULES AND EXHIBITS

SCHEDULES

3.1      CNS Qualifications

3.2.1    Subsidiaries of CNS

3.3.1    Rights of CNS Capital Stock

3.3.2    CNS Stockholders

3.6      CNS Financial Statements

3.8      Absence of Undisclosed Liabilities of CNS

3.9      Conduct of CNS Business Since the CNS Balance Sheet Date

3.10     CNS Tangible Personal Property

3.11     Property Owned by CNS

3.12     CNS Licenses and Permits

3.13.1   CNS Material Proprietary Assets

3.13.4   CNS Proprietary Assets Licensed to Third Parties

3.14.1   Outstanding Commitments of CNS

3.14.2   List of the Ten Largest Customers of CNS

3.14.3   List of the Ten Largest Suppliers of CNS

3.15     Pending Actions against CNS

3.16     Compliance with the Law by CNS

3.18.1   CNS Employees

3.18.2   CNS Business Relationships

3.18.3   CNS Patient Referrals

3.19.1   CNS Employee Benefits

3.19.2   CNS Plans Qualified Within the Meaning of Section 401(a)

3.19.4   CNS Severance or Separation Obligations

3.20     CNS Insurance Coverage

3.21     CNS Transactions with Affiliates

3.22     CNS Brokers

3.24     CNS Environmental Reports

3.25     CNS Accounts Receivable

4.1      CSL and ICSL Qualifications

4.2      Subsidiaries of CSL

4.3.2    Rights of ICSL Capital Stock

4.5      No Violations by CSL or ICSL

<Page>

4.8      Absence of Undisclosed Liabilities of CSL

4.9      Conduct of CSL Business Since the CSL Balance Sheet Date

4.10     CSL Tangible Personal Property

4.11     CSL Real Property

4.12     CSL Licenses and Permits

4.13.1   CSL Proprietary Assets

4.13.4   CSL Proprietary Assets Licensed to Third Persons

4.14.1   Outstanding Commitments of CSL

4.14.2   List of the Ten Largest Customers of CSL

4.14.3   List of the Ten Largest Suppliers of CSL

4.15     Pending Actions Against CSL

4.16     Compliance with the Law by CSL

4.17     Pending Charges by Employees of CSL

4.18.1   CSL Employees

4.18.3   CSL Patient Referrals

4.19.1   CSL Employee Benefits

4.19.2   CSL Plans Qualified Within the Meaning of 401(a)

4.19.4   CSL Separation and Severance Obligations

4.20     CSL Insurance Coverage

4.21     CSL Transactions with Affiliates

4.22     CSL Taxes

4.23     CSL Brokers

4.24     CSL Environmental Reports

4.25     CSL Accounts Receivable

5.3.3    ICSL Options Subject to Return of Shares on Termination

12.1.4   Contingent Liability Schedule

                                      viii
<Page>

EXHIBITS

5.2      Note Purchase Term Sheet

7.16     CNS Voting Agreement

7.17     CSL Voting Agreement

7.18     Escrow Agreement

8.7      Matters Upon Which Proskauer Rose LLP Will Opine

8.15     CNS Amended Certificate

9.6      Matters Upon Which Hinckley, Allen & Snyder LLP Will Opine

10.2     Shareholders Agreement

10.7     Investor Rights Agreement

                                       ix
<Page>

                          AGREEMENT AND PLAN OF MERGER

         THIS AGREEMENT AND PLAN OF MERGER (the "AGREEMENT") is made and entered
into effective as of October 31, 2001 by and among Innovative Clinical
Solutions, Ltd., a Delaware corporation ("ICSL"), Clinical Studies, Ltd., a
Delaware corporation and a wholly-owned subsidiary of ICSL ("CSL"),
Comprehensive NeuroScience, Inc., a Delaware corporation ("CNS") and CNS
Acquisition, Inc., a Delaware corporation and a wholly-owned subsidiary of CNS
("ACQUISITION Sub"). Capitalized terms used herein shall have the meaning
ascribed to them in Section 14.1 unless the context clearly requires otherwise.

                                   BACKGROUND

         A.    CSL is a healthcare company that provides site management
organization services and conducts clinical research for pharmaceutical
companies and for clinical research organizations (collectively, with all
activities incidental thereto, the "CSL BUSINESS").

         B.    CNS is a healthcare company that performs clinical research,
disseminates information and develops drug treatments for illnesses related to
memory, mood and behavior (collectively, with all activities incidental thereto,
the "CNS BUSINESS").

         C.    The parties hereto desire to effect the merger of Acquisition Sub
with and into CSL, with CSL as the surviving entity (the "MERGER"), which shall
be wholly owned by CNS.

         D.    Immediately prior to the effectiveness of the Merger, CNS shall
cause to be filed with the Secretary of State of the State of Delaware a Third
Amended and Restated Certificate of Incorporation (the "AMENDED CERTIFICATE")
pursuant to which (i) the powers, preferences and rights, and the
qualifications, limitations and restrictions of the outstanding shares of Series
A Preferred Stock, par value $.001 per share (the "CNS PREFERRED STOCK"), shall
be amended, and (ii) the number of authorized shares of CNS Common Stock shall
be increased to 100,000,000 shares (following the filing of the Amended
Certificate, CNS is sometimes hereinafter referred to as "NEWCO").

         E.    Pursuant to this Agreement, ICSL as the holder all of the
outstanding of shares of common stock, par value $.0001 per share, of CSL (the
"CSL COMMON STOCK"), will receive shares of Newco common stock, par value $.001
per share (the "NEW COMMON STOCK"), in the manner set forth in Article 1 of this
Agreement and upon the terms and conditions otherwise set forth in this
Agreement.

         F.    Concurrently with the effectiveness of the Merger, Newco will
issue certain Newco Secured Convertible Promissory Notes ("CONVERTIBLE NOTES")
to certain investors (the "NEWCO INVESTORS") substantially on the terms set
forth herein and in the Note Purchase Term Sheet.

         G.    The Board of Directors of each of ICSL, CSL, CNS and Acquisition
Sub has determined that the Merger is fair and in the best interests of their
respective stockholders, has approved and adopted this Agreement and each of the
Ancillary Agreements to which it is a party and each of the transactions
contemplated hereby and

<Page>

by the Ancillary Agreements (together with the Merger, the "TRANSACTIONS") and,
in the case of ICSL and CSL, has resolved to declare this Agreement advisable
and to recommend to their respective stockholders that they approve this
Agreement and the Transactions, including the Merger.

         H.    For Federal income tax purposes, it is intended that the Merger
shall qualify as a reorganization within the meaning of Section 368(a) of the
Internal Revenue Code.

               NOW, THEREFORE, in consideration of the foregoing premises and
of the mutual covenants and agreements hereinafter contained, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto agree as
follows:

                             ARTICLE 1 - THE MERGER

         1.1   EXECUTION, FILING AND EFFECTIVE TIME.

         On the Closing Date (as hereinafter defined) and subject to the terms
and conditions hereinafter set forth, the parties hereto agree to cause the
Merger to be consummated by filing with the Secretary of State of the State of
Delaware a Certificate of Merger (the "CERTIFICATE OF MERGER") in the form set
forth in EXHIBIT 1.1 hereto, and to take all such further actions as may be
required by law to make the Merger effective. The Merger shall become effective
when the Certificate of Merger is so filed in accordance with the Delaware
General Corporation Law (the "DGCL"), and the time at which the Merger becomes
effective is referred to herein as the "EFFECTIVE TIME."

         1.2   CONSTITUENT AND SURVIVING CORPORATION; EFFECT OF MERGER.

         CSL and Acquisition Sub shall be the constituent corporations in the
Merger, and CSL shall be the surviving corporation, the name of which shall be
Clinical Studies, Ltd. (in such capacity, CSL is sometimes hereinafter referred
to as the "SURVIVING CORPORATION"). At the Effective Time, the Merger shall have
the effect set forth in Section 251 of the DGCL.

         1.3   CERTIFICATE OF INCORPORATION AND BY-LAWS.

         At the Effective Time, the Certificate of Incorporation and By-laws of
Acquisition Sub as in effect at the Effective Time shall be the Certificate of
Incorporation and By-laws of the Surviving Corporation.

         1.4   OFFICERS AND BOARDS OF DIRECTORS.

         At the Effective Time, each of the members of the Board of Directors
and each of the officers of CSL immediately prior to the Effective Time shall
resign or be removed from office and concurrently therewith such directors and
officers as shall be mutually agreed prior to the Effective Time shall be the
directors and officers of the Surviving Corporation, each to serve in accordance
with the provisions of the By-laws of the Surviving Corporation until his
successor is duly elected and qualified.

         1.5   CONVERSION OF STOCK AND OTHER SECURITIES OF THE CONSTITUENT
               CORPORATIONS.

         At the Effective Time, without any action on the part of the holder
thereof, securities of CSL and Acquisition Sub will be converted and exchanged
as provided below.

                                      -2-
<Page>

         1.5.1 The shares of CSL Common Stock held in treasury immediately prior
to the Effective Time shall be cancelled and extinguished. The shares of CSL
Common Stock issued and outstanding immediately prior to the Effective Time that
are not then held in the treasury of CSL shall be canceled and extinguished and
be converted into the right to receive (or have delivered to the Escrow Agent in
accordance with Article 12 hereof), upon surrender to CNS of the CSL
Certificate(s), that number of shares of New Common Stock (together with the
Replacement Option Reserve, the "CSL MERGER CONSIDERATION") resulting from
application of the following formula:

               CSL NET ENTERPRISE VALUE
               ------------------------   - REPLACEMENT OPTION RESERVE
                 CNS PER SHARE VALUE

     For purposes of this Agreement:

                   (a)  The "CSL NET ENTERPRISE VALUE" shall mean $26.4 Million
               LESS (i) all outstanding CSL Debt on the Closing Date and PLUS
               (ii) any CSL Cash-On-Hand on the Closing Date.

                   (b)  The "CNS COMMON EQUITY VALUE" shall mean the CNS Net
               Enterprise Value LESS (i) $10.4 Million and LESS (ii) the CNS
               Preferred Stock Dividend.

                   (c)  The "CNS NET ENTERPRISE VALUE" shall mean $13.6 Million
               LESS (i) all outstanding CNS Debt on the Closing Date (other than
               the Convertible Notes) and PLUS (ii) any CNS Cash-on-Hand on the
               Closing Date (other than the cash proceeds from the Convertible
               Notes).

                   (d)  The "CNS PREFERRED STOCK DIVIDEND" shall mean the
               aggregate accrued but unpaid cumulative dividend on the CNS
               Preferred Stock calculated as of the Closing Date.

                   (e)  "CNS COMMON STOCK EQUIVALENTS" shall mean all CNS Common
               Stock and any and all shares of CNS Common Stock issuable
               pursuant to any and all rights, options, warrants or convertible
               or exchangeable securities (other than CNS Preferred Stock and
               the Convertible Notes), entitling the holder thereof to subscribe
               for or purchase or otherwise acquire shares of CNS Common Stock
               or shares convertible into or exchangeable for CNS Common Stock
               that are issued and outstanding on the Closing Date immediately
               prior to the issuance of CNS Common Stock in satisfaction of the
               CNS Preferred Stock Dividend as contemplated by Section 5.7 and
               the filing of the Amended Certificate with the Secretary of the
               State of Delaware and immediately prior to the issuance of shares
               of New Common Stock to CSL in the Merger and excluding the ICSL
               Replacement Options.

                   (f)  "CNS PER SHARE VALUE" shall mean the CNS Common Equity
               Value divided by the number of shares of CNS Common Stock
               Equivalents.

                                      -3-
<Page>

                   (g)  "REPLACEMENT OPTION RESERVE" shall mean the
               number of shares of New Common Stock issuable upon exercise of
               the ICSL Replacement Options.

               1.5.2    Each share of CNS Preferred Stock and CNS Common Stock,
if any, held in treasury immediately prior to the Effective Time shall represent
a share of New Preferred Stock and New Common Stock, respectively, held in
treasury immediately following the Effective Time. Each share of CNS Preferred
Stock and CNS Common Stock issued and outstanding immediately prior to the
Effective Time that is not then held in the treasury of CNS shall represent a
share of New Preferred Stock and New Common Stock, respectively, as provided in
the Amended Certificate.

               1.5.3    Each share of the common stock, $0.01 par value, of
Acquisition Sub issued and outstanding immediately prior to the Effective Time
shall be converted in to the right to receive, upon the surrender to the
Surviving Corporation of the certificate representing such share, one (1) fully
paid and nonassessable share of CSL Common Stock, which share of the Surviving
Corporation thereupon shall constitute all of the issued and outstanding shares
of capital stock of the Surviving Corporation.

               1.5.4    As soon as practicable following the date of this
Agreement, but in no event later than the Effective Time, the Board of Directors
of ICSL and CNS (or, if appropriate, any committee administering the ICSL
Options or the CNS Options) shall adopt such resolutions or take other actions
as may be required to provide that, at the Effective Time, each former holder of
a ICSL Option that is outstanding immediately prior to the Effective Time who
has executed a waiver and release of such ICSL Option for the benefit of ICSL
and CNS shall be granted a new option to purchase New Common Stock (the "ICSL
REPLACEMENT OPTIONS") and each ICSL Option for which a ICSL Replacement Option
is to be granted shall be canceled. CNS shall adopt a stock option plan or amend
its existing stock option plan to the extent necessary to permit the issuance of
the ICSL Replacement Options. CNS shall provide to each former holder of a ICSL
Option a stock option agreement for a ICSL Replacement Option substantially in
the form of the stock option agreements provided to CNS's employees generally,
except that each ICSL Replacement Option agreement shall provide for a term and
vesting schedule and shall be exercisable on substantially identical terms as
those provided in of such holder's stock option agreement with respect to such
holder's ICSL Option. The number of shares of New Common Stock subject to such
ICSL Replacement Options shall be equal to the product of (a) the aggregate
number of shares of ICSL Common Stock issuable upon exercise of the ICSL Options
and (b) the ICSL Conversion Ratio. The exercise price per share shall be equal
to the exercise price per share of each ICSL Option immediately prior to the
Effective Time divided by the ICSL Conversion Ratio. In addition,
notwithstanding the foregoing, each ICSL Replacement Option granted to a former
holder of a ICSL Option that was an "incentive stock option" shall be adjusted
as required by section 424 of the Code and the regulations promulgated
thereunder, so as not to constitute a modification, extension or renewal of the
option, within the meaning of section 424(h) of the Code. Each of ICSL and CNS
shall take all necessary steps to effectuate the foregoing, including using its
reasonable efforts to obtain from each holder of a ICSL Option any consent or
agreement that may be deemed necessary or advisable in order to effect the
transactions contemplated by this Section 1.5.

                                      -4-
<Page>

               1.5.5    CNS shall take all corporate action necessary to reserve
for issuance a sufficient number of shares of New Common Stock for delivery upon
exercise of the ICSL Replacement Options.

         1.6   EXCHANGE OF SHARES.

               1.6.1    At the Closing, ICSL shall deliver to CNS certificates
representing all of the outstanding shares of CSL Common Stock (the "CSL
CERTIFICATES") together with the address and taxpayer identification number of
ICSL. The CSL Certificate(s) so surrendered shall forthwith be canceled.

               1.6.2    At the Effective Time, any shares of Acquisition Sub
Stock then held by CNS shall be cancelled and exchanged for shares of the
Surviving Corporation.

               1.6.3    At the Closing,Newco shall deliver to ICSL a certificate
representing that number of whole shares of New Common Stock to which ICSL shall
have become entitled pursuant to the provisions of this Article 1, LESS the
Escrowed Shares, which shall be delivered to the Escrow Agent pursuant to
Article 12 hereof and the Escrow Agreement. In the event that there exists any
fractional share that ICSL would otherwise have the right to receive, Newco
shall not be obligated to issue such fractional share and such fractional share
shall be rounded up or down to the nearest whole share.

               1.6.4    CSL may direct Newco to deliver shares of New Common
Stock otherwise issuable to ICSL pursuant to Section 1.6.3 to Steven D.Targum in
satisfaction of the Convertible Portion of the Targum Debt, PROVIDED that Steven
D. Targum becomes a party to the Shareholders Agreement. In connection
therewith, CSL shall provide Newco with such information and documentation as
Newco may reasonably request.

               1.6.5    After the Effective Time, there shall be no transfers on
the stock transfer books of any of CSL or Acquisition Sub of the shares of CSL
Common Stock or Acquisition Sub Stock, as the case may be, which were issued and
outstanding immediately prior to the Effective Time.

                               ARTICLE 2 - CLOSING

         2.1   THE CLOSING DATE.

         Subject to the satisfaction or waiver of each of the conditions
contained in Articles 8, 9 and 10 of this Agreement, the closing of the
Transactions, including the Merger (the "CLOSING") shall take place at the
offices of Hinckley, Allen & Snyder LLP, 1500 Fleet Center, Providence, Rhode
Island at 10:00 a.m. on a date agreeable to the parties within five (5) business
days after the satisfaction or waiver of all conditions to Closing set forth in
Articles 8, 9 and 10, or on such other date or at such other location or time as
may be agreed upon by the parties (such date and time being called the "CLOSING
DATE"), but in no event later than the Termination Date.

         2.2   THE CLOSING.

         At the Closing, CNS, Acquisition Sub, ICSL and CSL shall each deliver
to each other, as applicable, such certificates, instruments, documents and
opinions as are set forth in Articles 8, 9 and 10, each of which shall be duly
executed and delivered, as appropriate.

                                      -5-
<Page>

         2.3   FILING OF AMENDED CERTIFICATE AND CERTIFICATE OF MERGER.

         Immediately prior to the Closing, the Amended Certificate shall be duly
adopted, executed and filed with the Secretary of State of the State of Delaware
and shall have become effective. Contemporaneously with the Closing, the duly
executed Certificate of Merger shall be duly adopted, executed and filed with
the Secretary of State of the State of Delaware.

         2.4   TAX CONSEQUENCES.

         It is intended by the parties hereto that the Merger shall constitute a
"reorganization" within the meaning of Section 368 of the Code. The parties
hereto adopt this Agreement as a "plan of reorganization" within the meaning of
Sections 1.368-2(g) and 1.368-3(a) of the United States Income Tax Regulations.

     ARTICLE 3 - REPRESENTATIONS AND WARRANTIES OF CNS AND ACQUISITION SUB

         CNS and Acquisition Sub hereby jointly and severally represent and
warrant to ICSL and CSL as set forth in this Article 3. All representations and
warranties made in this Article 3 are made subject to the exceptions that are
noted in the CNS Disclosure Schedule. The information provided in one section of
the CNS Disclosure Schedule shall suffice, without repetition or
cross-reference, as a disclosure of such information in any other relevant
section of the CNS Disclosure Schedule, if the disclosure in respect of such one
section of the CNS Disclosure Schedule is sufficient on its face without further
inquiry reasonably to inform ICSL of the information required to be disclosed in
respect of such other sections of the CNS Disclosure Schedule to avoid a
misrepresentation under the relevant counterpart sections of the Agreement.

         3.1   ORGANIZATION AND QUALIFICATION.

               CNS is a corporation duly organized, validly existing and in
good standing under the laws of the State of Delaware. CNS is qualified to do
business as a foreign corporation in each jurisdiction where it is required to
be so qualified, except where the failure to be so qualified could not
reasonably be expected to result in a CNS Material Adverse Change, and each such
jurisdiction and the status of its qualification is set forth on SCHEDULE 3.1
hereto. CNS has previously furnished to ICSL and CSL true and complete copies of
its Certificate of Incorporation and By-laws, as amended to date.

         3.2   THE SUBSIDIARIES OF CNS.

               3.2.1    Each Subsidiary of CNS (a "CNS SUBSIDIARY") is listed
on SCHEDULE 3.2.1. Each CNS Subsidiary is a corporation or limited liability
company duly organized, validly existing and in good standing under the laws of
the State of its incorporation or formation and is qualified to do business as a
foreign corporation or limited liability company in each jurisdiction where it
is required to be so qualified, except where failure to be so qualified could
not reasonably be expected to result in a CNS Material Adverse Change. All
issued and outstanding capital stock or membership interests of each CNS
Subsidiary are duly authorized, validly issued, fully paid and nonassessable and
CNS is the sole owner of all such issued and outstanding capital stock or
membership interests. There are no preemptive rights, rights of first refusal or
similar rights existing with respect to the shares of capital stock or
membership interests of any CNS Subsidiary and no such rights arise or become
exercisable by virtue of or in

                                      -6-
<Page>

connection with the Transactions contemplated hereby. There are no outstanding
or authorized rights, options, warrants, convertible securities, subscription
rights, conversion rights, exchange rights or other agreements or commitments of
any kind that could require any CNS Subsidiary to issue, sell or otherwise cause
to become outstanding any of its capital stock, membership interests or other
securities. There are no outstanding or authorized stock appreciation, phantom
stock, profit participation or similar rights with respect to any CNS
Subsidiary. Except as set forth on SCHEDULE 3.2.1, there are no stockholder's
agreements, voting trusts, proxies or other agreements or understandings with
respect to the voting or ownership of the capital stock of any CNS Subsidiary.
Except as set forth on SCHEDULE 3.2.1, CNS does not control directly or
indirectly or have any direct or indirect equity participation in any
corporation, partnership, joint venture, trust or other business association
other than the CNS Subsidiaries.

               3.2.2    Acquisition Sub has no Subsidiaries.

         3.3   CAPITALIZATION.

               3.3.1    The authorized capital stock of CNS consists of (i)
50,000,000 shares of CNS Common Stock of which 4,409,662 shares are issued and
outstanding and (ii) 20,000,000 shares of Preferred Stock of which 15,600,000
shares are designated as Series A Preferred, of which 10,400,000 shares are
issued and outstanding. All of the issued and outstanding shares of the capital
stock of CNS are, and all of the shares of New Common Stock to be issued in
exchange for shares of CSL Common Stock upon the consummation of the Merger when
issued in accordance with this Agreement, will be validly issued and fully paid
and nonassessable, issued in compliance with all applicable state and federal
securities laws and not issued in violation of any preemptive rights or rights
of first refusal. Except as set forth on SCHEDULE 3.3.1, no preemptive rights,
rights of first refusal or similar rights exist with respect to the shares of
capital stock of CNS, and no such rights arise or become exercisable by virtue
of or in connection with the Transactions. Except as set forth on SCHEDULE
3.3.1, there are no outstanding or authorized rights, options, warrants,
convertible securities, subscription rights, conversion rights, exchange rights
or other agreements or commitments of any kind that could require CNS to issue
or sell any shares of its capital stock (or securities convertible into or
exchangeable for shares of its capital stock). SCHEDULE 3.3.1 contains a true
and correct summary of the exercise or conversion price, vesting schedule and
amount of underlying securities, with respect to all such rights, options,
warrants, agreements or commitments or securities or obligations convertible
into or exchangeable for shares of CNS capital stock. CNS has previously
furnished to ICSL and CSL copies of all plans and agreements relating thereto.
Except as set forth on SCHEDULE 3.3.1, CNS has no obligation to register any
shares of its capital stock under the Securities Act. Except as set forth on
SCHEDULE 3.3.1, CNS is not obligated directly, indirectly or contingently to
purchase or redeem any shares of its capital stock.

               3.3.2    SCHEDULE 3.3.2 sets forth with respect to CNS (a) the
name and the number of outstanding shares of each class of its capital stock
owned by each stockholder of record as of the close of business on the date of
this Agreement and (b) the name of each holder of CNS Options and the number of
shares of CNS Common Stock into which such CNS Options are exercisable and the
exercise price of such CNS Options.

                                      -7-
<Page>

         3.4      CORPORATE POWER AND AUTHORITY.

         CNS and each CNS Subsidiary have full corporate power and authority to
carry on the CNS Business and any other activities now being conducted and to
own, operate and lease their properties in the places where such CNS Business or
such other activities are now conducted and such properties are now owned,
leased or operated. This Agreement and the Transactions, including the Merger,
have been duly approved by the Board of Directors of CNS and the Board of
Directors and CNS, as the sole stockholder of Acquisition Sub. Each of CNS and
Acquisition Sub has all requisite corporate power and authority to enter into
this Agreement and to consummate the Transactions, including the Merger, and
this Agreement and the Ancillary Agreements to be executed and delivered by each
of CNS and Acquisition Sub in connection herewith constitute the legal, valid
and binding obligations of each of CNS and Acquisition Sub enforceable against
it in accordance with their respective terms.

         3.5      NO VIOLATION.

         Neither the execution and delivery of this Agreement and the other
documents and instruments contemplated hereby and the consummation of the
Transactions, including the Merger, nor the performance of this Agreement and
such other documents and instruments in compliance with the terms and conditions
hereof and thereof will (a) violate, conflict with or result in any breach of
the certificate of incorporation, by-laws, operating agreement or any other
charter or organizational document of CNS or any CNS Subsidiary, (b) require any
consent, approval, authorization or permit of, or filing with or notification
to, any Governmental Authority (other than filing the Amended Certificate and
the Certificate of Merger with the Secretary of State of the State of Delaware),
(c) violate, conflict with or result in a breach, default or termination or give
rise to any right of termination, cancellation or acceleration of the maturity
of any payment date of any obligation of CNS or any CNS Subsidiary or increase
or otherwise affect the obligations of CNS or any CNS Subsidiary under any Law
or CNS Permit or any of the terms, conditions or provisions of any mortgage,
indenture, note, license, agreement or other instrument or obligation related to
CNS or any CNS Subsidiary or to CNS's ability to consummate the Transactions,
including the Merger, or result in the creation of any Claim upon or against the
properties of CNS or any CNS Subsidiary, except (i) for such defaults (or rights
of termination, cancellation or acceleration) as to which requisite waivers or
consents, in form and substance satisfactory to ICSL and CSL, have been or will
be obtained in writing and provided to ICSL or CSL at or prior to the Closing or
(ii) where such violations, conflicts or defaults would not, individually or in
the aggregate, result in a CNS Material Adverse Change.

         3.6      FINANCIAL STATEMENTS.

         CNS has previously furnished to ICSL and CSL the following financial
statements of CNS, copies of which are attached hereto on SCHEDULE 3.6: (a)
financial statements consisting of balance sheets, statements of income,
statements of retained earnings and statements of cash flows audited by Deloitte
& Touche LLP for each of the two most recently completed fiscal years (the
"AUDITED CNS FINANCIALS") and (b) unaudited financial statements consisting of a
balance sheet and income statement as of and for the six months ended June 30,
2001, prepared internally by CNS (the "UNAUDITED

                                      -8-
<Page>

CNS FINANCIALS" and together with the Audited CNS Financials, the "CNS FINANCIAL
STATEMENTS"). The balance sheet of CNS dated June 30, 2001 and included among
the CNS Financial Statements is referred to herein as the "CNS BALANCE SHEET."
All CNS Financial Statements were prepared from the books and records of CNS,
which books and records are complete and correct. The CNS Financial Statements
fairly present in all material respects the financial position of CNS and the
CNS Subsidiaries (on a consolidated basis) as of the dates thereof and the
results of CNS's and the CNS Subsidiaries' operations for the periods presented
therein, as the case may be, all in conformity with GAAP, consistently applied,
subject, in the case of the Unaudited CNS Financials, to normal year-end
adjustments in accordance with GAAP and, except that the Unaudited CNS
Financials do not have notes thereto. There has been no change in CNS's
accounting policies except as described in the notes to the CNS Financial
Statements.

         3.7      BOOKS AND RECORDS.

         The minute books and other records of corporate actions of CNS and each
CNS Subsidiary are correct and complete in all material respects. All corporate
action requiring approval of the Board of Directors or the stockholders or
members of either CNS or any CNS Subsidiary has been so approved and confirmed,
as required by the certificate of incorporation, by-laws, operating agreement,
regulations or other organizational documents of each and by the DGCL or other
applicable law, and such approval and confirmation has been so noted in the
minute books. All accounts, books, ledgers and official and other records of CNS
and each CNS Subsidiary have been fully, properly and accurately kept and are
complete, and there are no material inaccuracies or discrepancies contained
therein. The stock ledgers of CNS and each CNS Subsidiary, as previously
provided to ICSL, contain accurate and complete records of all issuances,
transfers and cancellations of shares of the capital stock of CNS and each CNS
Subsidiary. As of the Closing Date, all of the books and records referenced in
this Section 3.7 will be in the possession of CNS.

         3.8      ABSENCE OF UNDISCLOSED LIABILITIES.

         Except as set forth or reserved against in the Balance Sheet as of June
30, 2001 (the "CNS BALANCE SHEET DATE") included in the CNS Financial Statements
and except as set forth on SCHEDULE 3.8 and except which, individually or in the
aggregate, would not cause a CNS Material Adverse Change, CNS (a) did not have
as of the CNS Balance Sheet Date any Liability of any nature including, without
limitation, Liabilities that may become known or arise after the date hereof and
which relate to transactions entered into or any state of facts existing on or
before the CNS Balance Sheet Date, and (b) has not incurred since the CNS
Balance Sheet Date any Liability except in the Ordinary Course of Business (none
of which relates to breaches of contract, breaches of warranty, tort,
infringement or violation of law or which arose out of any action, suit, claim,
governmental investigation or arbitration proceeding).

         3.9      CONDUCT OF THE CNS BUSINESS SINCE THE CNS BALANCE SHEET DATE.

         Since the CNS Balance Sheet Date, except as set forth on SCHEDULE 3.9,
there has been no CNS Material Adverse Change with respect to CNS, and no such
CNS Material Adverse Change is threatened, contemplated, or anticipated. Since
the CNS Balance

                                      -9-
<Page>

Sheet Date, except as set forth on SCHEDULE 3.9, neither CNS nor any CNS
Subsidiary has taken or agreed to take any action that would obligate CNS or any
CNS Subsidiary to have:

                  3.9.1  taken any action or entered into or agreed to enter
into any transaction, agreement or commitment other than in the Ordinary Course
of Business;

                  3.9.2  entered into or agreed to enter into any transaction,
agreement or commitment, or suffered the occurrence of any event or events (a)
that has interfered or is reasonably likely to interfere with the normal and
usual operations of the CNS Business or any CNS Subsidiary or (b) that, singly
or in the aggregate, has resulted or is reasonably likely to result in a CNS
Material Adverse Change;

                  3.9.3  mortgaged, pledged, or otherwise encumbered, or, other
than in the Ordinary Course of Business, sold, transferred or otherwise disposed
of, any of the properties or assets of CNS or any CNS Subsidiary, including any
cancelled, released, hypothecated or assigned indebtedness owed to CNS or any
CNS Subsidiary, or any Claims held by CNS or any CNS Subsidiary;

                  3.9.4  made any investment of a capital nature or entered into
a commitment for such investment either by purchase of stock or securities,
contributions to capital, property transfer or otherwise, or by the purchase of
any property or assets of any other Person;

                  3.9.5  declared, set aside, or paid any dividend or other
distribution (whether in cash, stock, or property, or any combination thereof)
in respect of the capital stock of CNS, or redeemed or otherwise acquired,
directly or indirectly, any shares of capital stock of CNS;

                  3.9.6  paid any long-term liability, otherwise than in
accordance with its terms;

                  3.9.7  paid any bonus compensation to any officer, director,
stockholder or employee of CNS or any CNS Subsidiary or otherwise increased the
compensation paid or payable to any of the foregoing;

                  3.9.8  sold, assigned or transferred any CNS Proprietary
Assets or other intangible assets;

                  3.9.9  entered into any material agreement, contract, lease,
indenture or commitment (whether written or oral) or any amendment, waiver or
modification to any existing agreement, contract, lease, indenture or commitment
(whether written or oral);

                  3.9.10 contracted with or committed to any third party (a) to
sell any capital stock of CNS or Acquisition Sub, (b) to sell any assets of CNS
or any CNS Subsidiary other than in the Ordinary Course of Business, (c) to
effect any merger, consolidation or other reorganization of CNS or any CNS
Subsidiary, or (d) to enter into any agreement with respect thereto;

                  3.9.11 suffered any material casualty or extraordinary losses
(whether or not covered by insurance);

                  3.9.12 made or adopted any change in its accounting practice
or policies; or

                                      -10-
<Page>

                  3.9.13 agreed to do or authorized any of the foregoing.

         3.10     TANGIBLE PROPERTIES.

         SCHEDULE 3.10 contains a true and complete list of all fixed assets,
fixtures, computer hardware and software, automobiles, and other tangible
personal property owned or leased by CNS or any CNS Subsidiary with a book value
in excess of $10,000 ("CNS TANGIBLE PERSONAL PROPERTY"). Except as listed on
SCHEDULE 3.10 with respect to leased CNS Tangible Personal Property, CNS and
each CNS Subsidiary have good title free and clear of all Claims to CNS Tangible
Personal Property owned by CNS or any CNS Subsidiary. With respect to any CNS
Tangible Personal Property leased by CNS or any CNS Subsidiary, all leases,
conditional sale contracts, franchises or licenses pursuant to which CNS or any
CNS Subsidiary may hold or use (or permit others to hold or use) such CNS
Tangible Personal Property are valid and in full force and effect, and there is
not under any of such instruments any existing default or event of default or
event which with notice or lapse of time or both would constitute such a
default, except for any such defaults or notices that individually or in the
aggregate could not reasonably be expected to result in a CNS Material Adverse
Change; and CNS's or any CNS Subsidiary's possession and use of such property
has not been disturbed and no Claim has been asserted against CNS or any CNS
Subsidiary adverse to their rights in such leasehold interests, except for any
such claims that individually or in the aggregate could not reasonably be
expected to result in a CNS Material Adverse Change. All CNS Tangible Personal
Property is adequate and usable for the purposes for which it is currently used
and each item of CNS Tangible Personal Property, whether owned or leased, is in
good operating condition, reasonable wear and tear excepted, and has been
properly maintained and repaired, except as would not, individually or in the
aggregate, result in a CNS Material Adverse Change. CNS Tangible Personal
Property comprises all the equipment necessary for the continuing operation of
the CNS Business in the manner in which is has been operated to date.

         3.11     PREMISES.

         The real property and the leases described on SCHEDULE 3.11 represent
all the real property owned (the "CNS OWNED PREMISES") or leased or subleased
(the "CNS LEASED PREMISES") and the real property leases and subleases (the "CNS
LEASES") entered into or assumed by CNS or any CNS Subsidiary, and, with respect
to the Leased Properties, SCHEDULE 3.11 sets forth the date of the lease and
each amendment thereto and the aggregate annual rental payments and other fees
payable under such lease. Each of the CNS Leases is in full force and effect,
and there is not under any of the CNS Leases any existing default or event of
default or event which with notice or lapse of time or both would constitute
such a default or event of default, except for any such defaults or notices that
singly or in the aggregate could not reasonably be expected to result in a CNS
Material Adverse Change. CNS and each CNS Subsidiary has good and marketable
title to each of the CNS Owned Premises and each CNS Lease conveys good and
marketable leasehold title to the CNS Leased Premises purported to be conveyed
thereunder, is enforceable by CNS or any CNS Subsidiary which is the lessee
thereunder, provides exclusive possession of the CNS Leased Premises leased
thereunder, and following the

                                      -11-
<Page>

Transactions will continue to be enforceable in accordance with its terms. CNS
or any CNS Subsidiary which is the lessee of each respective CNS Leased Premises
has the right to use its respective CNS Leased Premises in accordance with the
terms of each respective CNS Lease free and clear of all Claims. Each of the CNS
Leased Premises is adequately maintained, fully equipped with all necessary
utilities and is in reasonably satisfactory condition and repair, consistent
with the uses to which it is presently being put or intended to be put. To the
Knowledge of CNS, there is no violation of any material covenant, restriction or
other agreement or understanding, oral or written, affecting or relating to
title or use of any CNS Leased Premises. Neither CNS nor any CNS Subsidiary has
received notice of any pending or threatened condemnation or similar proceedings
or any assessments affecting any of the CNS Leased Premises, nor to the
Knowledge of CNS is any such condemnation or assessment contemplated by any
Governmental Authority. CNS has delivered to ICSL and CSL true and correct
copies of all CNS Leases, as amended to date.

         3.12     LICENSES AND PERMITS.

         SCHEDULE 3.12 lists all material licenses, permits, pending
applications, consents, approvals and authorizations of or from any Governmental
Authority (other those issued (i) pursuant to CLIA, (ii) with respect to the
handling and disposal of Hazardous Substances and (iii) by the United States
Drug Enforcement Administration or any state agency with respect to the storage,
use and dispensing of "controlled substances" (as defined by applicable federal
and state Law)) held by CNS and each CNS Subsidiary or used in or otherwise
necessary for the conduct of the CNS Business (collectively, the "CNS PERMITS").
CNS and each CNS Subsidiary have complied with all conditions and requirements
imposed by the CNS Permits and neither CNS nor any CNS Subsidiary has received
any notice of, or has any reason to believe, that any Governmental Authority
intends to cancel, terminate or suspend any of the CNS Permits or that valid
grounds for such cancellation, termination or suspension exist. Except as set
forth on SCHEDULE 3.12, and, except as would not, individually or in the
aggregate, result in a CNS Material Adverse Change, no other licenses, permits,
consents, approvals or authorizations of or from any Governmental Authority
other than the CNS Permits are necessary to operate the CNS Business. CNS and
any CNS Subsidiary own or have the right to use the CNS Permits in accordance
with the terms thereof without any conflict or alleged conflict or infringement
with the rights of others and subject to no Claim. Each CNS Permit is and
immediately after the Transactions will be valid and in full force and effect
and no CNS Permit will be subject to termination or be terminated or adversely
affected by the Transactions.

         3.13     CNS PROPRIETARY ASSETS.

                  3.13.1 SCHEDULE 3.13.1 identifies all material Proprietary
Assets owned by or licensed to, or otherwise used by, CNS or any CNS Subsidiary
(collectively, the "CNS PROPRIETARY ASSETS"). SCHEDULE 3.13.1 lists each patent,
trademark and service mark owned by or licensed to, or otherwise used by, either
CNS or any CNS Subsidiary and states with respect to each such patent, trademark
or service mark, whether it is registered with the U.S. Patent and Trademark
Office or any state or foreign Governmental Agency. Except as set forth in
SCHEDULE 3.13.1, CNS is not obligated to make any payment to any person or
entity for the use of any CNS Proprietary Asset. Except as set forth in

                                      -12-
<Page>

SCHEDULE 3.13.1, neither CNS nor any CNS Subsidiary has developed jointly with
any other Person any CNS Proprietary Asset with respect to which such other
Person has any rights.

                  3.13.2 CNS has taken reasonably prudent steps to protect and
maintain the confidentiality and secrecy of all CNS Proprietary Assets (except
CNS Proprietary Assets whose value would be unimpaired by public disclosure) and
otherwise to maintain and protect the value of all CNS Proprietary Assets.

                  3.13.3 To the Knowledge of CNS, none of the CNS Proprietary
Assets infringes or conflicts with any Proprietary Asset owned or used by any
other Person. Neither CNS nor any CNS Subsidiary has received any notice or
other communication (in writing or otherwise) of any actual, alleged, possible
or potential infringement, misappropriation or unlawful use of, any Proprietary
Asset owned or used by any other Person. To the Knowledge of CNS, neither CNS
nor any CNS Subsidiary is infringing, misappropriating, or making any unlawful
use of, nor has at any time infringed, misappropriated or made any unlawful use
of, any Proprietary Asset owned or used by any other Person. To the Knowledge of
CNS, no other Person is infringing, misappropriating or making any unlawful use
of, and no Proprietary Asset owned or used by any other Person or entity
infringes or conflicts with, any CNS Proprietary Asset.

                  3.13.4 CNS Proprietary Assets constitute all the Proprietary
Assets necessary to enable CNS and the CNS Subsidiaries to conduct the CNS
Business in the manner in which such CNS Business has been and is being
conducted. Except as set forth in SCHEDULE 3.13.4: (a) neither CNS nor any CNS
Subsidiary has licensed any of the CNS Proprietary Assets to any Person, and (b)
neither CNS nor any CNS Subsidiary has entered into any contract, agreement,
covenant not to compete, or other arrangement limiting its ability to exploit
fully any of its CNS Proprietary Assets or to transact business in any market or
geographical area or with any Person.

         3.14     OUTSTANDING COMMITMENTS.

                  3.14.1 SCHEDULE 3.14.1 sets forth a list of all contracts,
agreements, leases, subleases, commitments, licenses and franchises, whether
written or oral, to which CNS or any CNS Subsidiary is a party or which relate
to the CNS Business and under which CNS has any continuing obligations, each of
which (a) relates to the purchase, sale, lease, pledge or license of property or
services the cost or value of which is $50,000 or greater; or (b) pursuant to
which CNS or any CNS Subsidiary is obligated to, or reasonably expects to,
receive or pay, or has received or paid in any 12 month period, in cash,
services, securities or other property, $50,000 or more (collectively, the "CNS
CONTRACTS"). CNS has delivered or made available to ICSL and CSL true, correct
and complete copies of all written CNS Contracts and SCHEDULE 3.14.1 contains an
accurate and complete description of all CNS Contracts which are not in writing.
All of the CNS Contracts are in full force and effect. CNS and any CNS
Subsidiary which is a party to the CNS Contracts have performed all of their
respective obligations to date, and, to CNS's Knowledge, there is not under any
of the CNS Contracts any existing default or event of default or event which
with notice or lapse of time or both would constitute such a default, except
where failure to perform or such default or event of default could not
reasonably be expected to have a CNS Material Adverse Effect. Neither CNS nor
any

                                      -13-
<Page>

CNS Subsidiary has (i) any present expectation or intention of not fully
performing all its obligations under each of the CNS Contracts to which it is a
party or (ii) any Knowledge of any breach or anticipated breach by any other
party to any of the CNS Contracts, except where such breach or anticipated
breach could not reasonably be expected to have a CNS Material Adverse Effect.
None of the CNS Contracts has been terminated or notice of termination given
with respect thereto, and neither CNS nor any CNS Subsidiary has Knowledge of
any intention or right of any party to any CNS Contract to default another party
to any CNS Contract, except where such termination or default could not
reasonably be expected to have a CNS Material Adverse Effect. There exists no
actual or, to the Knowledge of CNS, threatened termination, cancellation or
limitation of the business relationship of CNS or any CNS Subsidiary with any
party to any CNS Contract, except where such termination, cancellation or
limitation could not reasonably be expected to have a CNS Material Adverse
Effect.

                  3.14.2 Set forth in SCHEDULE 3.14.2 is an accurate and current
listing of the ten (10) largest customers of CNS and the CNS Subsidiaries for
each of the two (2) most recent fiscal years. Except as set forth in SCHEDULE
3.14.2, CNS does not have any Knowledge indicating that any of such customers
intend to cease doing business with CNS or any CNS Subsidiary, or alter the
amount of the business that it is presently doing with the CNS or any CNS
Subsidiary, to the extent that such cessation or alteration would result in a
CNS Material Adverse Change.

                  3.14.3 As of the date of this Agreement, to the Knowledge of
CNS, SCHEDULE 3.14.3 contains a correct and current list of the ten (10) largest
suppliers of CNS and CNS Subsidiaries during the two (2) most recent fiscal
years. Except as indicated in SCHEDULE 3.14.3, CNS has no Knowledge of any
facts, indicating that any of these suppliers intend to cease doing business
with CNS or any CNS Subsidiary, or materially alter the amount of the business
that they are presently doing with CNS or any CNS Subsidiary, to the extent that
such cessation or alteration would result in a Material Adverse Change.

         3.15     LITIGATION.

         Except as set forth on SCHEDULE 3.15, there is no (a) action, suit,
claim, proceeding or investigation pending or, to the Knowledge of CNS,
threatened against or affecting CNS or any CNS Subsidiary (whether or not CNS or
any CNS Subsidiary is a party or prospective party thereto), at law or in
equity, or before or by any Governmental Authority, (b) pending or, to the
Knowledge of CNS, threatened arbitration proceeding relating to CNS or any CNS
Subsidiary or (c) governmental inquiry pending or, to the Knowledge of CNS,
threatened against or involving CNS or any CNS Subsidiary, and there is no basis
for any of the foregoing. Except as set forth on SCHEDULE 3.15, neither CNS nor
any CNS Subsidiary has received any opinion or memorandum or legal advice from
legal counsel to the effect that it is exposed to any liability or disadvantage
which could reasonably be expected to result in a CNS Material Adverse Effect.
Except as set forth on SCHEDULE 3.15, there are no outstanding orders, writs,
judgments, injunctions or decrees of any Governmental Authority or arbitration
tribunal against, involving or affecting CNS or any CNS Subsidiary and to the
Knowledge of CNS there are no facts or circumstances which may result in
institution of any such action, suit, claim or legal, administrative or
arbitration proceeding. Neither CNS nor any CNS Subsidiary is in

                                      -14-
<Page>

default with respect to any order, writ, injunction or decree known to or served
upon it from any court or of any Governmental Authority. Except as set forth on
SCHEDULE 3.15, there is no action, suit or proceeding by CNS or any CNS
Subsidiary pending or, to the Knowledge of CNS, threatened against others.
Except as set forth on SCHEDULE 3.15, none of CNS, any CNS Subsidiary or any
director or employee of CNS or any CNS Subsidiary or any physician employed by
or under contract with CNS or any CNS Subsidiary has been disqualified,
debarred, restricted or otherwise sanctioned (or gave future assurances to avoid
the imposition of sanctions) by the Food and Drug Administration in connection
with studies with human or animal subjects designed to develop evidence of the
safety and effectiveness of investigational human drugs, biological products, or
medical devices. Except as set forth on SCHEDULE 3.15, none of the following has
occurred with respect to any CNS or any CNS Subsidiary:

                   (a)      Neither CNS nor any CNS Subsidiary nor, to the
                         Knowledge of CNS, any director or executive officer
                         thereof, has been convicted in a criminal proceeding or
                         has been named or is a subject of a criminal,
                         governmental or other regulatory investigation or
                         proceeding (excluding minor traffic violations);

                   (b)      Neither CNS nor any CNS Subsidiary nor, to the
                         Knowledge of CNS, any director or executive officer
                         thereof, has been found by a court of competent
                         jurisdiction in a civil action or by any Governmental
                         Authority or other regulatory body to have violated any
                         Law.

         3.16     COMPLIANCE WITH LAW.

         Except as set forth in SCHEDULE 3.16, CNS and each CNS Subsidiary have
complied in all material respects with and is not in default under, all Laws
applicable to it, its operations, properties, assets, products and services,
except for such defaults or failures to comply as could not reasonably be
expected to result in a CNS Material Adverse Change. Neither CNS nor any CNS
Subsidiary has received any notices of violation with respect to any Law.
Without limiting the foregoing, CNS and each CNS Subsidiary is in compliance
with all Laws relating to its purchase, sale, handling, disposition and
transportation of biological specimens and its use and disclosure of patient
medical information. CNS and each CNS Subsidiary have entered into agreements
with each of their respective clinical investigators whereby the investigators
are required to maintain and keep informed patient consents in writing in
accordance with applicable protocols for clinical studies conducted at CNS sites
and all applicable Laws. Except as set forth on SCHEDULE 3.16, the structure and
operations of the CNS Business are in compliance with applicable Laws, including
state Laws relating to the corporate practice of medicine, fee-splitting, fraud
and abuse, and any Laws relating to the prohibition on referrals to entities
with which a healthcare provider or supplier has a financial relationship. There
is no existing Law, and neither CNS nor the CNS Stockholders are aware of any
proposed Law, which would prohibit or materially restrict CNS, any CNS
Subsidiary or the Surviving Corporation from, or otherwise materially adversely
affect CNS, any CNS Subsidiary and the Surviving Corporation in, conducting the
CNS Business. Except as set forth on SCHEDULE 3.16, CNS and each CNS Subsidiary
has obtained, or as of the Closing will have obtained, all requisite approvals
and consents

                                      -15-
<Page>

of, and made all requisite filings with all Governmental Authorities and other
third parties that are necessary to be obtained or made to (a) permit the
conduct of the CNS Business, (b) permit the valid execution, delivery and
performance by CNS of this Agreement and the Transactions, including without
limitation, the Merger, and (c) prevent any CNS Permit or agreement relating to
the CNS Business from terminating prior to its scheduled termination as a result
of the consummation of the Transactions. Neither CNS nor any CNS Subsidiary has
engaged in any activities which are prohibited under the federal Controlled
Substances Act, 21 U.S.C. ss.801 et seq., or the regulations promulgated
pursuant to such statute or any related state or local Laws concerning the
dispensing and sale of controlled substances and CNS and its Subsidiaries have
complied with all other requirements of the Food and Drug Administration
applicable to the CNS Business. Neither CNS nor any CNS Subsidiary receives, nor
has for the past ten (10) years received, funds from any program of any
Governmental Entity.

         3.17     LABOR AND EMPLOYEE RELATIONS.

         Neither CNS nor any CNS Subsidiary is a party to or bound by any
collective bargaining agreement with any labor organization, group or
association covering any of its employees, and CNS has no Knowledge of any
attempt to organize any of their employees by any person, unit or group seeking
to act as their bargaining agent. There are no pending or, to the Knowledge of
CNS, threatened charges (by employees or their representatives or any
Governmental Authority) of unfair labor practices or of employment
discrimination or of any other wrongful action with respect to any aspect of
employment of any employee of CNS or any CNS Subsidiary.

         3.18     CERTAIN EMPLOYEES.

                  3.18.1 Set forth on SCHEDULE 3.18.1 is a list of names of all
of the physicians, employees and consultants employed by or under contract with
CNS or any CNS Subsidiary in connection with the CNS Business, together with the
title or job classification of each such person and his or her current
compensation. SCHEDULE 3.18.1 sets forth each such physician, employee or
consultant whose employment agreement, contract or understanding, whether oral
or written, with CNS or any CNS Subsidiary is not terminable on thirty (30) days
or less notice by CNS or any CNS Subsidiary without cost or other liability to
CNS or any CNS Subsidiary. SCHEDULE 3.18.1 sets forth each such physician,
employee or consultant who is not a party to a written non-competition,
non-disclosure and/or non-solicitation agreement or understanding with CNS or
any CNS Subsidiary. No person listed on SCHEDULE 3.18.1 has indicated that he or
she intends to terminate his or her duties or status. To CNS's Knowledge, each
person listed on SCHEDULE 3.18.1 who is required to be licensed by applicable
state law in order to perform his or her duties is so licensed. Set forth on
SCHEDULE 3.18.1 is the amount, if any, of any severance liability in excess of
$50,000 of CNS or any CNS Subsidiary with respect to each person listed on
SCHEDULE 3.18.1.

                  3.18.2 Set forth in SCHEDULE 3.18.2 is a list of all
consulting, business or contractual agreements and relationships or other CNS
Contracts with referring physicians, physicians networks, hospitals or similar
Persons (the "CNS SOURCES") relating to the CNS Business. Neither CNS nor any
CNS Subsidiary is a party to any agreement with CNS Sources which involves any
activities which are prohibited under

                                      -16-
<Page>

federal statutes 42 U.S.C. Section 1320a-7a and 7b, or the regulations
promulgated pursuant to such statutes, or which are prohibited by rules of
professional conduct or which otherwise could constitute fraud, including the
following: (a) making or causing to be made a false statement or representation
of a material fact in any application for any benefit or payment; (b) making or
causing to be made any false statement or representation of a material fact for
use in determining rights to any benefit or payment; (c) failing to disclose
knowledge by a claimant of the occurrence of any event affecting the initial or
continued right to any benefit or payment on its behalf or on behalf of another,
with intent to secure such benefit or payment fraudulently; or (d) soliciting,
paying or receiving any remuneration (including any kickback, bribe, or rebate),
directly or indirectly, overtly or covertly, in cash or in kind or offering to
pay such remuneration (i) in return for referring, or inducing to refer, an
individual to a Person for the furnishing or arranging for the furnishing of any
item or service for which payment may be made in whole or in part by federal
programs, or (ii) in return for purchasing, leasing or ordering or arranging for
or recommending purchasing, leasing, or ordering any good, facility, service, or
item for which payment may be made in whole or in part by federal programs.

                  3.18.3 Except as set forth on SCHEDULE 3.18.3, no CNS Source
having a "FINANCIAL RELATIONSHIP" with CNS or any CNS Subsidiary, as that term
is defined in 42 U.S.C. Section 1395nn, directly or indirectly refers patients
or services to CNS or any CNS Subsidiary, other than referrals which comply with
(or are exempt from) the requirements of 42 U.S.C. Section 1395nn and the
regulations promulgated pursuant thereto.

         3.19     EMPLOYEE BENEFITS.

                  3.19.1 Set forth on SCHEDULE 3.19.1 is an accurate and
complete list of all "PLANS" within the meaning of the Employee Retirement
Income Security Act of 1974, as amended, 29 U.S.C. Section 1001 et seq.
("ERISA") including, without limitation, all pension plans within the meaning of
ERISA Section 3(2)(A) ("CNS PENSION PLANS"), deferred compensation, stock
purchase, stock option, incentive, bonus, vacation, severance, disability,
hospitalization, medical insurance, life insurance, fringe benefit, and other
employee benefit plans within the meaning of ERISA Section 3(1) ("CNS WELFARE
PLANS"), and all other obligations, customary practices, or programs and
arrangements, whether formal or informal, oral or written, and whether or not
legally enforceable which CNS, any CNS Subsidiary or any entity that, together
with CNS and/or any CNS Subsidiary would be treated as a single employer under
Code Section 414 or ERISA Section 4001(b) (a "CNS ERISA AFFILIATE") sponsors,
maintains, participates in, contributes to or is obligated to contribute to or
under which past or present employees, directors, contractors, service
providers, agents and representatives of CNS, any CNS Subsidiary, or CNS ERISA
Affiliate(s) may have any liability (collectively, the "CNS PLANS"). Through the
Closing Date, all such CNS Plans shall be maintained by CNS or any CNS
Subsidiary in full force and effect. Neither CNS, any CNS Subsidiary nor any CNS
ERISA Affiliate contributes, has contributed to or has ever been required to
contribute to, any plan subject to Title IV of ERISA or to any multiemployer
plan, as defined in section 3(37) or section 4001(a)(3) of ERISA and no
withdrawal liability has been or may be assessed under Title IV of ERISA against
CNS, any CNS Subsidiary or CNS ERISA Affiliate(s) based on circumstances
existing on or prior to the Closing Date.

                                      -17-
<Page>

                  3.19.2 Each CNS Plan has been established and administered in
accordance with its terms and in full compliance with the applicable provisions
of the Code, ERISA and other applicable laws, rules and regulations, and all
obligations of CNS, any CNS Subsidiary and CNS ERISA Affiliate(s) with respect
to each CNS Plan have been satisfied except with respect to contributions not
required to be made as of the date hereof or with respect to benefit claims in
the ordinary course not determined or not required to be paid as of the date
hereof. Each CNS Plan which is intended to be qualified within the meaning of
section 401(a) of the Code is so designated on SCHEDULE 3.19.2 and is so
qualified within and has received a favorable determination letter from the IRS
with respect to its qualification, is entitled to rely on an opinion letter from
the IRS with respect to a prototype plan sponsor, or has remaining a period of
time under applicable Treasury regulations or IRS pronouncements in which to
apply for such a determination letter and make any amendments necessary to
obtain a favorable determination and no event has occurred which would cause the
loss of such qualification. Each CNS Plan which is intended to meet the
requirements for tax-favored treatment under Subchapter D of Chapter 1 of
Subtitle A of the Code meets such requirements in all material aspects.

                  3.19.3 With respect to each CNS Plan, no actions, suits or
claims (other than claims for benefits in the ordinary course), government
administrative proceedings or investigations are pending or threatened, and no
facts or circumstances exist which could give rise to any such actions, suits or
claims. No "REPORTABLE EVENT" (as defined in ERISA Section 404 and its
regulations) has occurred. Neither CNS, any CNS Subsidiary, any CNS Stockholder
or any CNS ERISA Affiliate has engaged in a prohibited transaction, as defined
under section 4975 of the Code or section 406 of ERISA, with respect to any
Plan, and, to the Knowledge of CNS, no fiduciary with respect to any CNS Plan
has breached any fiduciary duty to such Plan under Part 4 of Title I of ERISA or
other applicable law. No event has occurred and no condition exists that has
subjected or would subject CNS, any CNS Subsidiary or CNS ERISA Affiliate(s) to
any tax, fine or penalty imposed by the Code, ERISA or other applicable law. All
required contributions have been timely made by CNS, any CNS Subsidiary or any
CNS ERISA Affiliate, as appropriate, to each of the CNS Plans and there is no
funding deficiency with respect to any of the CNS Plans. Each CNS Plan may be
amended or terminated in accordance with its terms without obligation or
liability, other than those obligations and liabilities for which specific
assets have been set aside or reserved for on the CNS Balance Sheet as of the
CNS Balance Sheet Date included in the CNS Financial Statements and those
obligations and liabilities reflected by the terms of the CNS Plan documents.
There are no unfunded obligations under any CNS Plan providing benefits to
employees of CNS, any CNS Subsidiary or CNS ERISA Affiliate(s) during employment
or after termination of their employment. The consummation of the Transactions
will not result in the payment, vesting or acceleration of any benefit, except
as required under Code Section 411(d)(3).

                  3.19.4 Except as set forth on SCHEDULE 3.19.4, (a) neither the
CNS Plans nor CNS (or any CNS Subsidiary) is obligated to pay separation,
severance, termination or similar benefits or to vest any person in whole or in
part solely as a result of any transaction contemplated by this Agreement or
solely as a result of a "change of control" (as such term is defined in those
individuals' employment or option agreements or in

                                      -18-
<Page>

Section 280G of the Code); (b) all required discretionary (in accordance with
historical practices) payments, premiums, contributions, reimbursements, or
accruals for all periods ending prior to or as of the Effective Time shall have
been made or properly accrued on the CNS Balance Sheet Date; and (c) none of the
CNS Plans has any unfunded liabilities that are not reflected on the CNS Balance
Sheet.

                  3.19.5 None of the CNS Plans ever maintained by CNS or any CNS
ERISA Affiliate has ever provided health care or any other non-pension benefits
to any employees after their employment was terminated (other than as required
by part 6 of subtitle B of Title I of ERISA) or has ever promised to provide
such post-termination benefits.

                  3.19.6 With respect to each CNS Plan maintained by CNS
preceding the Closing Date, complete and correct copies of the following
documents (if applicable to such CNS Plan) have previously been delivered to
ICSL: (a) all documents embodying or governing such CNS Plan and any funding
medium for the CNS Plan (including, without limitation, trust agreements) as
they may have been amended to the date hereof; (b) the most recent IRS
determination or approval letter with respect to such CNS Plan under Code
Section 401(a) or 501(c)(9), and any applications for determination or approval
subsequently filed with the IRS; (c) all filed IRS Forms 5500, with all
applicable schedules and accountants' opinions attached thereto; (d) all
actuarial valuation reports completed with respect to such Plan; (e) the summary
plan description for such CNS Plan (or other descriptions of such CNS Plan
provided to employees) and all modifications thereto; (f) any insurance policy
(including any fiduciary liability insurance policy or fidelity bond) related to
such CNS Plan; (g) any registration statement or other filing made pursuant to
any federal or state securities Law; and (h) all correspondence to and from any
state or federal agency with respect to such CNS Plan.

                  3.19.7 Each CNS Plan required to be listed on SCHEDULE 3.19.1
may be amended, terminated, or otherwise modified by CNS to the greatest extent
permitted by applicable Law, including the elimination of any and all future
benefit accruals under any CNS Plan and no employee communications or provision
of any CNS Plan document has failed to effectively reserve the right of CNS or
the CNS ERISA Affiliate to so amend, terminate or otherwise modify such CNS
Plan.

                  3.19.8 Each CNS Plan ever maintained by CNS (including each
non-qualified deferred compensation arrangement) has been maintained in
compliance with all applicable requirements of federal and state securities Laws
including (without limitation, if applicable) the requirements that the offering
of interests in such Plan be registered under the Securities Act of 1933, as
amended, and/or state "Blue Sky" laws.

         3.20     INSURANCE.

         CNS and each CNS Subsidiary is, and will be through and following the
Closing Date, adequately insured with responsible insurers in respect of their
properties, assets and business against risks normally insured against by
companies the business of which is similar to the CNS Business under similar
circumstances. SCHEDULE 3.20 sets forth an accurate and complete list of the
insurance coverage carried by CNS and any CNS Subsidiary with respect to the CNS
Business, which insurance will remain in full force and effect with respect to
all events occurring prior to the Closing, true and completed

                                      -19-
<Page>

copies of which have been provided to ICSL and CSL. CNS and any CNS Subsidiary
(a) have not failed to give any notice or present any claim under any such
policy or binder in due and timely fashion, (b) have not received notice of
cancellation or non-renewal of any such policy or binder and (c) have not
received notice of and are not otherwise aware of any insurance premiums which
will be materially increased in the future. There are no outstanding claims
under any such policy which have gone unpaid for more than forty-five days, or
as to which the coverage has been questioned, denied or disputed by the
underwriters of such policies or bonds. All premiums due and payable under all
such policies and bonds have been paid and CNS and each CNS Subsidiary is
otherwise in compliance with the terms of such policies and bonds. SCHEDULE 3.20
lists all claims made against CNS and each CNS Subsidiary's insurance coverage
during the 12 month period immediately preceding the date hereof. All insurance
coverage listed on SCHEDULE 3.20 is on an occurrence basis. Other than
reasonable deductible amounts customary in the industry, neither CNS nor any CNS
Subsidiary is self-insured nor is any one of them a party to any risk sharing or
similar agreement except as specifically noted on SCHEDULE 3.20.

         3.21     TRANSACTIONS WITH AFFILIATES.

         Except as set forth in SCHEDULE 3.21 hereto and only with respect to
transactions giving rise to current or contingent liabilities of CNS or any CNS
Subsidiary, no current holder of 5% or more of any class of capital stock of CNS
or any CNS Subsidiary at the time such transaction was entered into, or any
director, officer or employee of CNS or any CNS Subsidiary, or member of the
family of any such person, or any corporation, partnership, trust or other
entity in which any such person, or any member of the family of any such person,
has an interest or is an officer, director, trustee, partner or holder of any
equity interest, is a party to any transaction with CNS or any CNS Subsidiary,
including any contract, agreement or other arrangement providing for the
employment of, furnishing of services by, rental of real or personal property
from, or otherwise requiring payments or involving other obligations to or from
CNS or any CNS Subsidiary.

         3.22     TAXES.

         CNS and each CNS Subsidiary have filed all Tax returns and reports
required to be filed, including, without limitation, returns and estimated
returns, complete and accurate copies of which have been provided to ICSL, and
have paid in full all taxes shown due thereon and all estimated Tax when due
(together with all interest, penalties, assessments and deficiencies assessed in
connection therewith due through the date hereof, whether or not shown on any
Tax return). Neither CNS nor any CNS Subsidiary is required to pay any other Tax
except as shown in such Tax returns, reports and information filings. All such
returns, reports and information filings required to be filed, including any
amendments to date, have been prepared in good faith and without negligence or
misrepresentation and were correct and complete in all material respects. CNS
and each CNS Subsidiary has either paid or, in accordance with GAAP applied
consistently with prior periods, adequately provided for, by reserves or other
proper accounting treatment shown in the CNS Financial Statements, its liability
for all Taxes of every kind, for the current Tax year and for all prior years.
CNS has no Knowledge of any proposed or threatened assessment or reassessment of
any Taxes. In addition, at the date hereof, CNS and each CNS Subsidiary have
deducted and remitted all withholding

                                      -20-
<Page>

tax or source deductions when due to the appropriate Governmental Authority as
required by Law or CNS and each CNS Subsidiary have adequately provided for such
deductions by reserves or other proper accounting treatment, in accordance with
GAAP applied consistently with prior periods, in their books and records of
account. Neither CNS nor any CNS Subsidiary (a) has executed any waiver to
extend, or otherwise taken or failed to take any action that would have the
effect of extending, the applicable statute of limitations with respect to its
Tax liabilities, (b) is a "CONSENTING CORPORATION" within the meaning of Section
341(f) of the Code, (c) has been a member of any consolidated group (other than
with CNS and each CNS Subsidiary) for Tax purposes or (d) does not have, or will
fail to have, all records and information necessary for the timely and accurate
filing of any Tax returns due after the date hereof, including any returns due
after the Closing Date which relate to the period prior to the Closing Date.
Neither CNS nor any CNS Subsidiary is a party to any tax allocation or tax or
tax sharing agreement or member of an affiliated group of corporations other
than agreements or groups between CNS and its Subsidiaries. Neither CNS nor any
CNS Subsidiary has any liability for the Taxes of any other Person under
Treasury Regulations ss. 1.1502-6 (or similar provisions of any state, local, or
foreign law). Neither CNS, any CNS Subsidiary, nor, to the Knowledge of CNS, any
of its Affiliates has taken or agreed to take any action or failed to take any
action which action or failure would prevent the Merger from constituting a
reorganization within the meaning of section 368(a) of the Code.

         3.23     BROKERS.

         Except as set forth on SCHEDULE 3.23, no agent, person or firm acting
on behalf of CNS and any Subsidiary or under their authority is or will be
entitled to a financial advisory fee, brokerage commission, finder's fee or like
payment in connection with the transactions contemplated hereby.

         3.24     ENVIRONMENTAL LAWS.

                  3.24.1 CNS and each CNS Subsidiary have operated and continue
to operate the CNS Business in compliance in all material respects with all Laws
relating to (a) pollution or protection of the environment, natural resources or
human health from any Hazardous Substances (as hereinafter defined) or (b)
nuisance, trespass or "TOXIC TORT," including, without limitation, Laws relating
to emissions, discharges, releases or threatened releases of any Hazardous
Substance (including asbestos) or otherwise relating to the manufacture,
processing, importation, distribution, use, generation, treatment, storage,
disposal, transportation or handling of any such Hazardous Substance
(collectively, "ENVIRONMENTAL LAWS") where the failure to comply would result in
a CNS Material Adverse Change.

                  3.24.2 To the Knowledge of CNS, no CNS Owned Premises, CNS
Leased Premises or any real property contiguous thereto, is or has been
designated by any state, local or federal agency or body as a hazardous waste
disposal site or a site or location requiring investigation concerning, or
management, clean-up or removal of, any Hazardous Substance.

                  3.24.3 There is no civil, criminal or investigative action,
suit, litigation, hearing, communication (written or oral), demand, claim,
citation, notice or notice of violation, warning, consent decree, judgment or
order by any Person or Governmental

                                      -21-
<Page>

Authority alleging, claiming, concerning or finding liability or potential
liability arising out of, based on or resulting from, in whole or in part, (a)
the actual or alleged presence, threatened release, release, emission, disposal,
storage, treatment, transportation, generation, manufacture or use of any
Hazardous Substance at or from any location or (b) circumstances forming the
basis of any violation, or alleged violation, of any Environmental Laws
(collectively, "ENVIRONMENTAL CLAIMS"), pending or threatened against CNS or any
CNS Subsidiary or against any Person whose liability for any Environmental Claim
CNS or any CNS Subsidiary has or may have retained or assumed either
contractually or by operation of Law. There are no present, or, to the Knowledge
of CNS, past actions, activities, circumstances, conditions, events, incidents
or practices, including, without limitation, the release, threatened release,
emission, discharge, disposal, storage, treatment, transportation, generation,
manufacture or use of any Hazardous Substance that could form the basis of any
Environmental Claim against CNS or any CNS Subsidiary or, to the Knowledge of
CNS, against any Person whose liability for any Environmental Claim CNS or any
CNS Subsidiary has or may have retained or assumed either contractually or by
operation of Law.

                  3.24.4 All Waste (as hereinafter defined) generated in
connection with the CNS Business, operations, Assets and properties of CNS and
each CNS Subsidiary has been (i) treated, stored or disposed of by or at
facilities duly licensed pursuant to applicable Environmental Laws and (ii)
transported to such facilities by transporters duly licensed pursuant to
applicable Environmental Laws. CNS has maintained true and complete records
relating to the generation, transportation, treatment, storage and disposal of
Waste generated in connection with the business, operations, assets and
properties of CNS and any CNS Subsidiary.

                  3.24.5 CNS has delivered to ICSL and CSL all environmental
inspection reports ("CNS ENVIRONMENTAL REPORTS") prepared by any person or
entity concerning compliance with applicable Environmental Laws of the CNS
Business, operations, assets or properties or the use, manufacture, importation,
processing, storage, treatment, transportation, release or disposal therefrom,
therein or thereon of any Hazardous Substance. All such Environmental Reports
are listed on SCHEDULE 3.24.

         3.25     ACCOUNTS RECEIVABLE.

         All of the accounts receivable of CNS and any CNS Subsidiary shown or
reflected on the CNS Balance Sheet in the CNS Financial Statements and any
accounts receivable that have accrued subsequent to the CNS Balance Sheet Date
represent bona fide transactions and arose in the Ordinary Course of Business
and are carried at values determined in accordance with GAAP consistently
applied. Except as set forth on SCHEDULE 3.25, CNS has no accounts or loans
receivable from any of its directors, officers or employees.

         3.26     SECURITIES AND EXCHANGE COMMISSION FILINGS.

         CNS Financial Statements and other information relating to CNS
furnished in writing by CNS to ICSL for inclusion in the Proxy Statement or
Information Statement, as the case may be, at the time of the mailing of the
Proxy Statement or Information Statement to ICSL's stockholders will not contain
any untrue statement of a material fact or omit to state a material fact
concerning CNS or any CNS Subsidiary or omit to state a

                                      -22-
<Page>

material fact required or necessary to be stated therein in order to make the
statements contained therein concerning CNS or any CNS Subsidiary, in light of
the circumstances under which they are made, not misleading.

         3.27     DISCLOSURE.

         All documents and schedules delivered or to be delivered by or on
behalf of CNS and any CNS Subsidiary in connection with this Agreement and the
Transactions are true, complete and correct in all material respects. Neither
this Agreement, nor any Schedule or Exhibit to this Agreement contains any
untrue statement of a material fact or omits a material fact necessary to make
the statements contained herein or therein, in light of the circumstances in
which made, not misleading.

         3.28     APPRAISAL RIGHTS.

         No CNS Stockholder has the right to exercise or demand any appraisal or
dissenter's rights with respect to the Merger or the Transactions.

         ARTICLE 4 - REPRESENTATIONS AND WARRANTIES OF CSL AND ICSL

         CSL and ICSL jointly and severally represent and warrant to CNS,
Acquisition Sub and the CNS Stockholders as set forth in this Article 4. All
representations and warranties made in this Article 4 are made subject to the
exceptions that are noted in the CSL Disclosure Schedule. Schedules contained in
the CSL Disclosure Schedule are numbered to correspond with the Sections of this
Article 4 and are referenced accordingly. The information provided in one
section of the CSL Disclosure Schedule shall suffice, without repetition or
cross-reference, as a disclosure of such information in any other relevant
section of the CSL Disclosure Schedule, if the disclosure in respect of such one
section of the CSL Disclosure Schedule is sufficient on its face without further
inquiry reasonably to inform CNS of the information required to be disclosed in
respect of such other sections of the CSL Disclosure Schedule to avoid a
misrepresentation under the relevant counterpart sections of the Agreement.

         4.1      ORGANIZATION AND QUALIFICATION.

         Each of CSL and ICSL is a corporation duly organized, validly existing
and in good standing under the laws of the State of Delaware. Each of CSL and
ICSL is qualified to do business as a foreign corporation in each jurisdiction
where it is required to be so qualified, except where the failure to be so
qualified could not reasonably be expected to result in a CSL Material Adverse
Change, and each such jurisdiction and the status of its qualification is set
forth on SCHEDULE 4.1 hereto. Each of CSL and ICSL has previously furnished to
CNS true and complete copies of its Certificate of Incorporation and By-laws, as
amended to date.

         4.2      THE SUBSIDIARIES OF CSL.

         Each Subsidiary of CSL (a "CSL SUBSIDIARY") is listed on SCHEDULE 4.2.
Each CSL Subsidiary is a corporation duly organized, validly existing and in
good standing under the laws of the State of its incorporation and is qualified
to do business as a foreign corporation in each jurisdiction where it is
required to be so qualified, except where the failure to be so qualified could
not reasonably be expected to result in a CSL Material Adverse Change. All
issued and outstanding shares of capital stock of each CSL

                                      -23-
<Page>

Subsidiary are duly authorized, validly issued, fully paid and nonassessable and
CSL is the sole owner of all such issued and outstanding capital stock. There
are no preemptive rights, rights of first refusal or similar rights existing
with respect to the shares of capital stock of any CSL Subsidiary, and no such
rights arise or become exercisable by virtue of or in connection with the
Transactions contemplated hereby. There are no outstanding or authorized rights,
options, warrants, convertible securities, subscription rights, conversion
rights, exchange rights or other agreements or commitments of any kind that
require any CSL Subsidiary to issue, sell or otherwise cause to become
outstanding any of its capital stock or other securities. There are no
outstanding or authorized stock appreciation, phantom stock, profit
participation or similar rights with respect to any CSL Subsidiary. There are no
stockholder's agreements, voting trusts, proxies or other agreements or
understandings with respect to the voting or ownership of the capital stock of
any CSL Subsidiary. CSL does not control directly or indirectly or have any
direct or indirect equity participation in any corporation, partnership, joint
venture, trust or other business association other than the Subsidiaries.

         4.3      CAPITALIZATION.

                  4.3.1 The authorized capital stock of CSL consists of
1,000,000 shares of CSL Common Stock of which 100 shares are issued and
outstanding, all of which are owned by ICSL. All of the issued and outstanding
shares of the capital stock of CSL have been validly issued and are fully paid
and nonassessable, were issued in compliance with all applicable state and
federal securities laws and were not issued in violation of any preemptive
rights or rights of first refusal. No preemptive rights, rights of first refusal
or similar rights exist with respect to the shares of capital stock of CSL, and
no such rights arise or become exercisable by virtue of or in connection with
the Transactions. There are no outstanding or authorized rights, options,
warrants, convertible securities, subscription rights, conversion rights,
exchange rights or other agreements or commitments of any kind that could
require CSL to issue or sell any shares of its capital stock (or securities
convertible into or exchangeable for shares of its capital stock). CSL has no
obligation to register any shares of its capital stock under the Securities Act.
CSL is not obligated directly, indirectly or contingently to purchase or redeem
any shares of its capital stock.

                  4.3.2  The authorized capital stock of ICSL consists of
40,000,000 shares of ICSL Common Stock of which 11,998,972 shares are issued and
outstanding. All of the issued and outstanding shares of the capital stock of
ICSL have been validly issued and are fully paid and nonassessable. Except as
set forth on SCHEDULE 4.3.2, there are no outstanding options, warrants, rights
or other agreements or commitments obligating ICSL to issue or sell shares of
its capital stock or any securities or obligations convertible into or
exchangeable for any shares of its capital stock that will be converted into
options, warrants, rights or other agreements or commitments obliging CNS or
Newco to issue any shares of its capital stock. SCHEDULE 4.3.2 contains a true
and correct summary of the exercise or conversion price, vesting schedule and
amount of underlying securities, with respect to all ICSL Options for which ICSL
Replacement Options are to be issued.

                                      -24-
<Page>

         4.4      CORPORATE POWER AND AUTHORITY.

         Each of CSL, each CSL Subsidiary and ICSL has full corporate power and
authority to carry on the CSL Business or ICSL business, as the case may be, and
any other activities now being conducted and to own, operate and lease their
properties in the places where such CSL Business or ICSL business, as the case
may be, or such other activities are now conducted and such properties are now
owned, leased or operated. This Agreement and the Transactions, including
without limitation, the Merger, have been duly approved by the Board of
Directors of each of CSL and ICSL as the stockholder of CSL. Except for the
approval of the stockholders of ICSL, which shall be sought promptly following
the execution and delivery of this Agreement, each of CSL and ICSL has all
requisite corporate power and authority to enter into this Agreement and to
consummate the Transactions, including the Merger, and this Agreement and the
Ancillary Agreements to be executed and delivered by CSL and ICSL in connection
herewith constitute the legal, valid and binding obligations of CSL and ICSL
enforceable against each of them in accordance with their respective terms.

         4.5      NO VIOLATION.

         Neither the execution and delivery of this Agreement and the other
documents and instruments contemplated hereby and the consummation of the
Transactions, including the Merger, nor the performance of this Agreement and
such other documents and instruments in compliance with the terms and conditions
hereof and thereof, expect as set forth in SCHEDULE 4.5, will (a) violate,
conflict with or result in any breach of the certificate of incorporation,
by-laws or any other charter document of CSL, each CSL Subsidiary or ICSL, (b)
require any consent, approval, authorization or permit of, or filing with or
notification to, any Governmental Authority (other than filing the Certificate
of Merger with the Secretary of State of the State of Delaware), (c) violate,
conflict with or result in a breach, default or termination or give rise to any
right of termination, cancellation or acceleration of the maturity of any
payment date of any obligation of CSL or each CSL Subsidiary or increase or
otherwise affect the obligations of CSL or any CSL Subsidiary under any Law or
Permit (each as defined herein) or any of the terms, conditions or provisions of
any mortgage, indenture, note, license, agreement or other instrument or
obligation related to CSL or any CSL Subsidiary or to CSL's, or any CSL
Subsidiary's or ICSL's ability to consummate the Transactions, including the
Merger, or result in the creation of any Claim upon or against the properties of
CSL or any CSL Subsidiary, except (i) for such defaults (or rights of
termination, cancellation or acceleration) as to which requisite waivers or
consents, in form and substance satisfactory to CNS, have been or will be
obtained in writing and provided to CNS at or prior to the Closing, or (ii)
where such violations, conflicts or defaults would not, individually or in the
aggregate, result in a CSL Material Adverse Change.

         4.6      FINANCIAL STATEMENTS.

         ICSL has previously furnished to CNS the following financial statements
of CSL: (a) a financial report of CSL consisting of statements of income,
statements of cash flows and balance sheet for the fiscal year ended January 31,
2001, which form the basis for the audited financial statements of ICSL for such
period ("AUDITED CSL FINANCIALS") and (b) unaudited financial report of CSL
consisting of statements of income and statements

                                      -25-
<Page>

of cash flow for the six months ended July 31, 2001 and a pro forma stand alone
balance sheet as of June 30, 2001, prepared internally by CSL (the "UNAUDITED
CSL FINANCIALS" and together with the Audited CSL Financials, the "CSL FINANCIAL
STATEMENTS"). The pro forma stand alone balance sheet of CSL dated June 30, 2001
and included among the CSL Financial Statements is referred to herein as the
"CSL BALANCE SHEET." All CSL Financial Statements were prepared from the books
and records of ICSL, which books and records are complete and correct. The CSL
Financial Statements fairly present the financial position of CSL and the CSL
Subsidiaries as of the dates thereof and the results of CSL's and CSL
Subsidiaries' operations for the periods presented therein, as the case may be,
all in conformity with GAAP, consistently applied, except that the CSL Financial
Statements (other than the CSL Balance Sheet) do not include adjustments
required to present CSL and the CSL Subsidiaries on a standalone basis, which
adjustments are reflected on and described in the notes to the CSL Balance
Sheet, and do not have notes in accordance with GAAP, and, in the case of the
Unaudited CSL Financials, subject to normal year-end adjustments in accordance
with GAAP. There has been no change in CSL's accounting policies except as
described in the notes to the CSL Financial Statements.

         4.7      BOOKS AND RECORDS.

         The minute books and other records of corporate actions of CSL and each
CSL Subsidiary are correct and complete in all material respects. All corporate
action requiring approval of the Board of Directors or the stockholders of
either CSL or any CSL Subsidiary has been so approved and confirmed, as required
by the certificate of incorporation, by-laws, regulations or other
organizational documents of each and by the DGCL or other applicable law, and
such approval and confirmation has been so noted in the minute books. All
accounts, books, ledgers and official and other records of the CSL and each CSL
Subsidiary have been fully, properly and accurately kept and are complete, and
there are no material inaccuracies or discrepancies contained therein. The stock
ledgers of CSL and each CSL Subsidiary contain accurate and complete records of
all issuances, transfers and cancellations of shares of the capital stock of CSL
and each CSL Subsidiary. As of the Closing Date, all of the books and records
referenced in this Section 4.7 will be in the possession of CSL.

         4.8      ABSENCE OF UNDISCLOSED LIABILITIES.

         Except as set forth or reserved against in the CSL Balance Sheet as of
June 30, 2001 (the "CSL BALANCE SHEET DATE") included in the CSL Financial
Statements and except as set forth on SCHEDULE 4.8 and except which,
individually or in the aggregate, would not result in a CSL Material Adverse
Change, CSL (a) did not have as of the CSL Balance Sheet Date any Liability of
any nature, including, without limitation, Liabilities that may become known or
arise after the date hereof and which relate to transactions entered into or any
state of facts existing on or before the CSL Balance Sheet Date, and (b) has not
incurred since the CSL Balance Sheet Date any Liability except in the Ordinary
Course of Business (none of which relates to breaches of contract, breaches of
warranty, tort, infringement or violation of law or which arose out of any
action, suit, claim, governmental investigation or arbitration proceeding).

                                      -26-
<Page>

         4.9      CONDUCT OF BUSINESS SINCE THE CSL BALANCE SHEET DATE.

         Since the CSL Balance Sheet Date, except as set forth on SCHEDULE 4.9,
there has been no CSL Material Adverse Change (as hereinafter defined) with
respect to CSL, and no such CSL Material Adverse Change is threatened,
contemplated, or anticipated. Since the CSL Balance Sheet Date, except as set
forth on SCHEDULE 4.9, neither CSL nor any CSL Subsidiary has not taken or
agreed to take any action that would obligate ICSL, CSL or any CSL Subsidiary to
have:

                  4.9.1  taken any action or entered into or agreed to enter
into any transaction, agreement or commitment other than in the Ordinary Course
of Business;

                  4.9.2  entered into or agreed to enter into any transaction,
agreement or commitment, or suffered the occurrence of any event or events (a)
that has interfered or is reasonably likely to interfere with the normal and
usual operations of the business of CSL or any CSL Subsidiary (b) that, singly
or in the aggregate, has resulted or is reasonably likely to result in a CSL
Material Adverse Change;

                  4.9.3  mortgaged, pledged, or otherwise encumbered, or, other
than in the Ordinary Course of Business, sold, transferred or otherwise disposed
of, any of the properties or assets of CSL or any CSL Subsidiary, including any
cancelled, released, hypothecated or assigned indebtedness owed to CSL or any
CSL Subsidiary, or any Claims held by CSL or any CSL Subsidiary;

                  4.9.4  made any investment of a capital nature or entered into
a commitment for such investment either by purchase of stock or securities,
contributions to capital, property transfer or otherwise, or by the purchase of
any property or assets of any other Person;

                  4.9.5  declared, set aside, or paid any dividend or other
distribution (whether in cash, stock, or property, or any combination thereof)
in respect of the capital stock of CSL, or redeemed or otherwise acquired,
directly or indirectly, any shares of capital stock of CSL;

                  4.9.6  paid any long-term liability, otherwise than in
accordance with its terms;

                  4.9.7  paid any bonus compensation to any officer, director,
stockholder or employee of CSL or any CSL Subsidiary or otherwise increased the
compensation paid or payable to any of the foregoing;

                  4.9.8  sold, assigned or transferred any CSL Proprietary
Assets or other in tangible assets;

                  4.9.9  entered into any material agreement, contract, lease,
indenture or commitment (whether written or oral) or any amendment, waiver or
modification to any existing agreement, contract, lease, indenture or commitment
(whether written or oral);

                  4.9.10 contracted with or committed to any third party (a) to
sell any capital stock of CSL, (b) to sell any assets of CSL or any CSL
Subsidiary other than in the Ordinary Course of Business, (c) to effect any
merger, consolidation or other reorganization of CSL or any CSL Subsidiary, or
(d) to enter into any agreement with respect thereto;

                                      -27-
<Page>

                  4.9.11 suffered any material casualty or extraordinary losses
(whether or not covered by insurance);

                  4.9.12 made or adopted any change in its accounting practice
or policies; or

                  4.9.13   agreed to do or authorized any of the foregoing.

         4.10     TANGIBLE PROPERTIES.

         SCHEDULE 4.10 contains a true and complete list of all fixed assets,
fixtures, computer hardware and software, automobiles, and other tangible
personal property owned or leased by CSL or any CSL Subsidiary with a book value
in excess of $10,000 (the "CSL TANGIBLE PERSONAL PROPERTY"). Except as listed on
SCHEDULE 4.10 with respect to leased CSL Tangible Personal Property, CSL and
each CSL Subsidiary has good and marketable title free and clear of all Claims
to the CSL Tangible Personal Property. With respect to any CSL Tangible Personal
Property leased by CSL or any CSL Subsidiary, all leases, conditional sale
contracts, franchises or licenses pursuant to which CSL or any CSL Subsidiary
may hold or use (or permit others to hold or use) such CSL Tangible Personal
Property are valid and in full force and effect, and there is not under any of
such instruments and existing default or event of default or event which with
notice or lapse of time or both would constitute such a default, except for any
such defaults or notices that individually or in the aggregate could not
reasonably be expected to result in a CSL Material Adverse Change; and CSL's or
any CSL Subsidiary's possession and use of such property has not been disturbed
and no claim has been asserted against CSL or any CSL Subsidiary adverse to
their rights in such leasehold interests, except for any such claims that
individually or in the aggregate could not reasonably be expected to result in a
CSL Material Adverse Change. All CSL Tangible Personal Property is adequate and
usable for the purposes for which it is currently used and each item of CSL
Tangible Personal Property, whether owned or leased, is in good operating
condition, reasonable wear and tear excepted, and has been properly maintained
and repaired, except as would not, individually or in the aggregate, result in a
CSL Material Adverse Change. The CSL Tangible Personal Property comprises all
the equipment necessary for the continuing operation of the Business in the
manner in which is has been operated to date.

         4.11     PREMISES.

         The real property and the leases described on SCHEDULE 4.11 represent
all the real property owned (the "CSL OWNED PREMISES") or leased or subleased
(the "CSL LEASED PREMISES") and the real property leases and subleases (the "CSL
LEASES") entered into or assumed by CSL or any CSL Subsidiary, and, with respect
to the Leased Properties, SCHEDULE 4.11 sets forth the date of the lease and
each amendment thereto and the aggregate annual rental payments and other fees
payable under such lease. Except as set forth on SCHEDULE 4.11, each of the CSL
Leases is in full force and effect, and there is not under any of the CSL Leases
any existing default or event of default, except for any such defaults or
notices that singly or in the aggregate could not reasonably by expected to
result in a CSL Material Adverse Change. CSL and each CSL Subsidiary has good
and marketable title to each of the CSL Owned Premises and except as set forth
on SCHEDULE 4.11, each CSL Lease conveys good and marketable leasehold title to
the CSL Leased

                                      -28-
<Page>

Premises purported to be conveyed thereunder, is enforceable by CSL or any CSL
Subsidiary which is the lessee thereunder, provides exclusive possession of the
CSL Leased Premises leased thereunder, and, subject to the receipt of
non-disturbance agreements with respect to such CSL Leases, following the
Transactions will continue to be enforceable in accordance with its terms.
Except as set forth on SCHEDULE 4.11, CSL or each CSL Subsidiary has the right
to use its respective CSL Leased Premises in accordance with the terms of each
respective CSL Lease free and clear of all Claims. Each of the CSL Leased
Premises currently used in the CSL Business ("CSL OCCUPIED LEASED PREMISES") is
adequately maintained, fully equipped with all necessary utilities and is in
reasonably satisfactory condition and repair, consistent with the uses to which
it is presently being put or intended to be put. To CSL's Knowledge, there is no
violation of any material covenant, restriction or other agreement or
understanding, oral or written, affecting or relating to title or use of any CSL
Leased Premises. Neither CSL nor any CSL Subsidiary has received notice of any
pending or threatened condemnation or similar proceedings or any assessments
affecting any of the CSL Leased Premises, nor to CSL's Knowledge is any such
condemnation or assessment contemplated by any Governmental Authority. CSL has
delivered to CNS true and correct copies of all CSL Leases, as amended to date.

         4.12     LICENSES AND PERMITS.

         SCHEDULE 4.12 lists all material licenses, permits, pending
applications, consents, approvals and authorizations of or from any Governmental
Authority (other those issued (i) pursuant to CLIA, (ii) with respect to the
handling and disposal of Hazardous Substances and (iii) by the United States
Drug Enforcement Administration or any state agency with respect to the storage,
use and dispensing of "controlled substances" (as defined by applicable federal
and state Law)) by CSL and each CSL Subsidiary or used in or otherwise necessary
for the conduct of the CSL Business (collectively, the "CSL Permits") together
with any conditions imposed thereon. CSL and each CSL Subsidiary has complied
with all conditions and requirements imposed by the CSL Permits and neither CSL
nor any CSL Subsidiary has received any notice of, or has any reason to believe,
that any Governmental Authority intends to cancel, terminate or suspend any of
the CSL Permits of that valid grounds for such cancellation, termination or
suspension exist. Except as set forth on SCHEDULE 4.12, and, except as would
not, individually or in the aggregate, result in a CSL Material Adverse Change,
no other licenses, permits, consents, approvals or authorizations of or from any
Governmental Authority other than the CSL Permits are necessary to operate the
Business. ICSL, CSL, any CSL Subsidiary own or have the right to use the CSL
Permits in accordance with the terms thereof without any conflict or alleged
conflict or infringement with the rights of others and subject to no Claim. Each
CSL Permit is and immediately after the Merger will be valid and in full force
and effect and no CSL Permit will be subject to termination or be terminated or
adversely affected by the Merger.

         4.13     CSL PROPRIETARY ASSETS.

                  4.13.1 SCHEDULE 4.13.1 identifies all material Proprietary
Assets (as hereinafter defined) owned or licensed to, or otherwise used by, CSL
or any CSL Subsidiary in the conduct of the CSL Business (collectively, the "CSL
PROPRIETARY ASSETS"). SCHEDULE 4.13.1 lists each patent, trademark and service
mark owned by or

                                      -29-
<Page>

licensed to, or otherwise used by, CSL or any CSL Subsidiary and states with
respect to each such patent, trademark or service mark, whether it is registered
with the U.S. Patent and Trademark Office or any state or foreign Governmental
Agency. Except as set forth in SCHEDULE 4.13.1, neither CSL nor any CSL
Subsidiary is obligated to make any payment to any person or entity for the use
of any CSL Proprietary Asset. Except as set forth in SCHEDULE 4.13.1, neither
CSL nor any CSL Subsidiary has developed jointly with any other Person any CSL
Proprietary Asset with respect to which such other Person has any rights.

                  4.13.2 CSL and each CSL Subsidiary has taken reasonably
prudent steps to protect and maintain the confidentiality and secrecy of all CSL
Proprietary Assets (except CSL Proprietary Assets whose value would be
unimpaired by public disclosure) and otherwise to maintain and protect the value
of all CSL Proprietary Assets.

                  4.13.3 To the Knowledge of CSL, none of the CSL Proprietary
Assets infringes or conflicts with any Proprietary Asset owned or used by any
other Person. Neither CSL nor any CSL Subsidiary has received any notice or
other communication (in writing or otherwise) of any actual, alleged, possible
or potential infringement, misappropriation or unlawful use of, any CSL
Proprietary Asset owned or used by any other Person. To CSL's Knowledge, neither
CSL nor any CSL Subsidiary is infringing, misappropriating, or making any
unlawful use of, nor has at any time infringed, misappropriated or made any
unlawful use of, any Proprietary Asset owned or used by any other Person. To the
Knowledge of CSL, no other Person is infringing, misappropriating or making any
unlawful use of, and no Proprietary Asset owned or used by any other person or
entity infringes or conflicts with, any CSL Proprietary Asset.

                  4.13.4 CSL Proprietary Assets constitute all the Proprietary
Assets necessary to enable CSL and the CSL Subsidiaries to conduct the CSL
Business in the manner in which the CSL Business has been and is being
conducted. Except as set forth in SCHEDULE 4.13.4: (a) neither CSL nor any CSL
Subsidiary has licensed any CSL Proprietary Asset to any Person, and (b) neither
CSL nor any CSL Subsidiary has entered into any contract, agreement, covenant
not to compete, or other arrangement limiting its ability to exploit fully any
of its CSL Proprietary Assets or to transact business in any market or
geographical area or with any Person.

         4.14     OUTSTANDING COMMITMENTS.

                  4.14.1 SCHEDULE 4.14.1 sets forth a list of all contracts,
agreements, leases, subleases, commitments, licenses and franchises, whether
written or oral, to which CSL or any CSL Subsidiary is a party or which relate
to the CSL Business and under which CSL has any continuing obligations, each of
which (a) relates to the purchase, sale, lease, pledge or license of property or
services the cost or value of which is $50,000 or greater; or (b) pursuant to
which CSL or any CSL Subsidiary is obligated to, or reasonably expects to,
receive or pay, or has received or paid in any 12 month period, in cash,
services, securities or other property, $50,000 or more (collectively, the "CSL
CONTRACTS"). Except as set forth on SCHEDULE 4.14.1, CSL has delivered or made
available to CNS true, correct and complete copies of all written CSL Contracts
and SCHEDULE 4.14.1 contains an accurate and complete description of all CSL
Contracts which are not in writing. All of the CSL Contracts are in full force
and effect. CSL and

                                      -30-
<Page>

each CSL Subsidiary which is a party to the CSL Contracts has performed all the
obligations required to be performed by them to date, and, to CSL's Knowledge,
there is not under any of the CSL Contracts any existing default or event of
default or event which with notice or lapse of time or both would constitute
such a default, except where failure to perform or such default or event of
default could not reasonably be expected to have a CSL Material Adverse Effect.
Neither CSL nor any CSL Subsidiary has (a) any present expectation or intention
of not fully performing all its obligations under each of the CSL Contracts to
which it is a party or (b) any Knowledge of any breach or anticipated breach by
any other party to any of the CSL Contracts, except where such breach or
anticipated breach could not reasonably be expected to have a CSL Material
Adverse Effect. None of the CSL Contracts has been terminated or notice of
termination given with respect thereto, and neither CSL nor any CSL Subsidiary
has Knowledge of any intention or right of any party to any Contract to default
another party to any CSL Contract, except where such termination or default
could not reasonably be expected to have a CSL Material Adverse Effect. There
exists no actual or, to the Knowledge of CSL, threatened termination,
cancellation or limitation of the business relationship of CSL or any CSL
Subsidiary with any party to any CSL Contract, except where such termination,
cancellation or limitation could not reasonably be expected to have a CSL
Material Adverse Effect.

                  4.14.2 Set forth in SCHEDULE 4.14.2 is an accurate and current
listing of the ten (10) largest customers of CSL and the CSL Subsidiaries for
each of the two (2) most recent fiscal years. Except as set forth in SCHEDULE
4.14.2, CSL does not have any Knowledge indicating that any of such customers
intend to cease doing business with CSL or any CSL Subsidiary, or alter the
amount of the business that it is presently doing with the CSL or any CSL
Subsidiary, to the extent that such cessation or alteration would result in a
CSL Material Adverse Change.

                  4.14.3 As of the date of this Agreement, to the Knowledge of
CSL, SCHEDULE 4.14.3 contains a correct and current list of the ten (10) largest
suppliers of CSL and the CSL Subsidiaries during the two (2) most recent fiscal
years. Except as indicated in SCHEDULE 4.14.3, CSL has no Knowledge of any
facts, indicating that any of these suppliers intend to cease doing business
with CSL or any CSL Subsidiary, or materially alter the amount of the business
that they are presently doing with CSL or any CSL Subsidiary, to the extent that
such cessation or alteration would result in a CSL Material Adverse Change.

         4.15     LITIGATION.

         Except as set forth on SCHEDULE 4.15, there is no (a) action, suit,
claim, proceeding or investigation pending or, to the Knowledge of CSL,
threatened against or affecting CSL or any CSL Subsidiary (whether or not CSL or
any CSL Subsidiary is a party or prospective party thereto), at law or in
equity, or before or by any Governmental Authority, (b) pending or, to the
Knowledge of CSL, threatened arbitration proceeding relating to CSL or any CSL
Subsidiary or (c) governmental inquiry pending or, to the Knowledge of CSL,
threatened against or involving CSL or any CSL Subsidiary, and there is no basis
for any of the foregoing. Except as set forth on SCHEDULE 4.15, neither CSL not
any CSL Subsidiary has received any opinion or memorandum or legal advice from
legal counsel to the effect that it is exposed, from a legal standpoint, to any
liability

                                      -31-
<Page>

or disadvantage which may have a CSL Material Adverse Effect. Except as set
forth on SCHEDULE 4.15, there are no outstanding orders, writs, judgments,
injunctions or decrees of any Governmental Authority or arbitration tribunal
against, involving or affecting CSL or any CSL Subsidiary and to the Knowledge
of CSL there are no facts or circumstances which may result in institution of
any such action, suit, claim or legal, administrative or arbitration proceeding.
Neither CSL nor any CSL Subsidiary nor ICSL is in default with respect to any
order, writ, injunction or decree known to or served upon it from any court or
of any Governmental Authority. Except as set forth on SCHEDULE 4.15, there is no
action, suit or proceeding by CSL or any CSL Subsidiary pending or to the
Knowledge of CSL or ICSL, threatened against others. Except as set forth on
SCHEDULE 4.15, none of CSL, any CSL Subsidiary or any director or employee of
CSL or any CSL Subsidiary or any physician employed by or under contract with
CSL or any CSL Subsidiary has been disqualified, debarred, restricted or
otherwise sanctioned (or gave future assurances to avoid the imposition of
sanctions) by the Food and Drug Administration in connection with studies with
human or animal subjects designed to develop evidence of the safety and
effectiveness of investigational human drugs, biological products, or medical
devices. Except as set forth on SCHEDULE 4.15, none of the following has
occurred with respect to CSL or any CSL Subsidiary:

                  (a)   Neither CSL nor any CSL Subsidiary nor, to the Knowledge
                        of CSL, any director or executive officer thereof, has
                        been convicted in a criminal proceeding or has been
                        named or is a subject of a criminal, governmental or
                        other regulatory investigation or proceeding (excluding
                        minor traffic violations); or

                  (b)   Neither CSL nor any CSL Subsidiary nor, to the Knowledge
                        of ICSL or CSL, any director or executive officer
                        thereof, has been found by a court of competent
                        jurisdiction in a civil action or by any Governmental
                        Authority or other regulatory body to have violated any
                        Law.

         4.16     COMPLIANCE WITH LAW.

         Except as set forth in SCHEDULE 4.16, CSL and each CSL Subsidiary has
complied in all material respects with and is not in default under, all Laws
applicable to it, its operations, properties, assets, products and services,
except for such defaults or failures to comply as could not reasonably be
expected to result in a CSL Material Adverse Change. Neither CSL nor any CSL
Subsidiary has received any notices of violation with respect to any Law.
Without limiting the foregoing, CSL and each CSL Subsidiary is in compliance
with all Laws relating to its purchase, sale, handling, disposition and
transportation of biological specimens and its use and disclosure of patient
medical information. CSL and each CSL Subsidiary has entered into agreements
with each of its clinical investigators whereby the investigators are required
to maintain and keep informed patient consents in writing in accordance with
applicable protocols for clinical studies conducted at the CSL sites and all
applicable Laws. Except as set forth on SCHEDULE 4.16, the structure and
operations of the CSL Business are in compliance with applicable Laws, including
state Laws relating to the corporate practice of medicine, fee-splitting, fraud
and abuse, and any Laws relating to the prohibition on referrals to entities
with which a healthcare provider or supplier has a financial relationship. There
is no

                                      -32-
<Page>

existing Law, and CSL has no Knowledge of any proposed Law, which would prohibit
or materially restrict the Surviving Corporation from, or otherwise materially
adversely affect the Surviving Corporation in, conducting the CSL Business.
Except as set forth on SCHEDULE 4.16, CSL and any CSL Subsidiary has obtained,
or as of the Closing will have obtained, all requisite approvals and consents
of, and made all requisite filings with all Governmental Authorities and other
third parties that are necessary to be obtained or made to (a) permit the
conduct of the CSL or any Subsidiary's Business, (b) permit the valid execution,
delivery and performance by ICSL and CSL or any Subsidiary of this Agreement and
the Transactions, including, without limitation, the Merger, and (c) prevent any
CSL Permit or agreement relating to the CSL Business from terminating prior to
its scheduled termination as a result of the consummation of the Transactions.
Neither CSL nor any CSL Subsidiary has engaged in any activities which are
prohibited under the federal Controlled Substances Act, 21 U.S.C. ss.801 et
seq., or the regulations promulgated pursuant to such statute or any related
state or local Laws concerning the dispensing and sale of controlled substances
and ICSL, CSL and any CSL Subsidiary have complied with all other requirements
of the Food and Drug Administration applicable to the CSL Business. Neither CSL
nor any CSL Subsidiary receives, nor has for the past ten (10) years received,
funds from any program of any Governmental Entity.

         4.17     LABOR AND EMPLOYEE RELATIONS.

         Neither CSL nor any CSL Subsidiary is a party to or bound by any
collective bargaining agreement with any labor organization, group or
association covering any of its employees, and CSL has no Knowledge of any
attempt to organize any of their employees by any person, unit or group seeking
to act as their bargaining agent. Except as set forth on SCHEDULE 4.17, there
are no pending or, to the Knowledge of CSL, threatened charges (by employees or
their representatives or any Governmental Authority) of unfair labor practices
or of employment discrimination or of any other wrongful action with respect to
any aspect of employment of any employee of CSL or any CSL Subsidiary.

         4.18     CERTAIN EMPLOYEES.

                  4.18.1 Set forth on SCHEDULE 4.18.1 is a list of names of all
of the physicians, employees and consultants employed by or under contract with
CSL or any CSL Subsidiary, together with the title or job classification of each
such person and his or her current compensation. Except as set forth on SCHEDULE
4.18.1, none of such persons has (a) an employment agreement, contract or
understanding, whether oral or written, with CSL or any CSL Subsidiary which is
not terminable on thirty (30) days or less notice by CSL or any CSL Subsidiary
without cost or other liability to CSL or any CSL Subsidiary or (b) a
non-competition, non-disclosure and/or non-solicitation agreement or
understanding with CSL or any CSL Subsidiary, whether written or oral, and all
such employment and other agreements are set forth in SCHEDULE 4.18.1 hereto. No
person listed on SCHEDULE 4.18.1 has indicated that he or she intends to
terminate his or her duties or status. To CSL's Knowledge, each person listed on
SCHEDULE 4.18.1 who is required to be licensed by applicable state law in order
to perform his or her duties is so licensed. Set forth on SCHEDULE 4.18.1 is the
amount, if any, of any severance liability in excess of $50,000 of CSL or any
CSL Subsidiary with respect to each person listed on SCHEDULE 4.18.1.

                                      -33-
<Page>

                  4.18.2 Set forth in SCHEDULE 4.18.2 is a list of all
consulting, business or contractual agreements and relationships or other CSL
Contracts with referring physicians, physicians networks, hospitals or similar
Persons (the "CSL SOURCES"). Neither CSL nor any CSL Subsidiary is a party to
any agreement with CSL Sources which involves any activities which are
prohibited under federal statutes 42 U.S.C. Section 1320a-7a and 7b, or the
regulations promulgated pursuant to such statutes, or which are prohibited by
rules of professional conduct or which otherwise could constitute fraud,
including the following: (a) making or causing to be made a false statement or
representation of a material fact in any application for any benefit or payment;
(b) making or causing to be made any false statement or representation of a
material fact for use in determining rights to any benefit or payment; (c)
failing to disclose knowledge by a claimant of the occurrence of any event
affecting the initial or continued right to any benefit or payment on its behalf
or on behalf of another, with intent to secure such benefit or payment
fraudulently; or (d) soliciting, paying or receiving any remuneration (including
any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in
cash or in kind or offering to pay such remuneration (i) in return for
referring, or inducing to refer, an individual to a Person for the furnishing or
arranging for the furnishing of any item or service for which payment may be
made in whole or in part by federal programs, or (ii) in return for purchasing,
leasing or ordering or arranging for or recommending purchasing, leasing, or
ordering any good, facility, service, or item for which payment may be made in
whole or in part by federal programs.

                  4.18.3 Except as set forth on SCHEDULE 4.18.3, no CSL Source
having a "FINANCIAL RELATIONSHIP" with CSL or any CSL Subsidiary, as that term
is defined in 42 U.S.C. Section 1395nn, directly or indirectly refers patients
or services to CSL or any CSL Subsidiary, other than referrals which comply with
(or are exempt from) the requirements of 42 U.S.C. Section 1395nn and the
regulations promulgated pursuant thereto.

         4.19     EMPLOYEE BENEFITS.

                  4.19.1 Set forth on SCHEDULE 4.19.1 is an accurate and
complete list of all "PLANS" within the meaning of ERISA including, without
limitation, all pension plans within the meaning of ERISA Section 3(2)(A) ("CSL
PENSION PLANS"), deferred compensation, stock purchase, stock option, incentive,
bonus, vacation, severance, disability, hospitalization, medical insurance, life
insurance, fringe benefit, and other employee benefit plans within the meaning
of ERISA Section 3(1) ("CSL WELFARE PLANS"), and all other obligations,
customary practices, or programs and arrangements, whether formal or informal,
oral or written, and whether or not legally enforceable which CSL, any CSL
Subsidiary or any entity that, together with ICSL and CSL or any CSL Subsidiary
would be treated as a single employer under Code Section 414 or ERISA Section
4001(b) (an "CSL ERISA AFFILIATE") sponsors, maintains, participates in,
contributes to or is obligated to contribute to or under which past or present
employees, directors, contractors, service providers, agents and representatives
of CSL, any CSL Subsidiary or CSL ERISA Affiliate(s) may have any liability
(collectively, the "CSL PLANS"). Through the Closing Date, all such CSL Plans
shall be maintained by CSL in full force and effect. Neither ICSL, CSL, any CSL
Subsidiary, nor any CSL ERISA Affiliate contributes, has contributed to or has
ever been required to contribute to, any plan subject to Title IV of ERISA or to
any multiemployer plan, as defined in section 3(37)

                                      -34-
<Page>

or section 4001(a)(3) of ERISA and no withdrawal liability has been or may be
assessed under Title IV of ERISA against ICSL, CSL, or CSL ERISA Affiliate(s)
based on circumstances existing on or prior to the Closing Date.

                  4.19.2 Each CSL Plan has been established and administered in
accordance with its terms and in full compliance with the applicable provisions
of the Code, ERISA and other applicable laws, rules and regulations, and all
obligations of ICSL, CSL, each CSL Subsidiary and CSL ERISA Affiliate(s) with
respect to each CSL Plan have been satisfied except with respect to
contributions not required to be made as of the date hereof or with respect to
benefit claims in the ordinary course not determined or not required to be paid
as of the date hereof. Each CSL Plan which is intended to be qualified within
the meaning of section 401(a) of the Code is so designated on SCHEDULE 4.19.2
and is so qualified within and has received a favorable determination letter
from the IRS with respect to its qualification, is entitled to rely on any
opinion letter from the IRS with respect to a prototype plan sponsor, or has
remaining a period of time under applicable Treasury regulations or IRS
pronouncements in which to apply for such a determination letter and make any
amendments necessary to obtain a favorable determination and no event has
occurred which would cause the loss of such qualification. Each CSL Plan which
is intended to meet the requirements for tax-favored treatment under Subchapter
D of Chapter 1 of Subtitle A of the Code meets such requirements in all material
aspects.

                  4.19.3 With respect to each CSL Plan, no actions, suits or
claims (other than claims for benefits in the ordinary course), government
administrative proceeding or investigations are pending or threatened, and no
facts or circumstances exist which could give rise to any such actions, suits or
claims. No "REPORTABLE EVENT" (as defined in ERISA Section 404 and its
regulations) has occurred. Neither ICSL, CSL, any CSL Subsidiary nor any CSL
ERISA Affiliate has engaged in a prohibited transaction, as defined under
section 4975 of the Code or section 406 of ERISA, with respect to any Plan, and,
to the Knowledge of ICSL, CSL, any CSL Subsidiary, no fiduciary with respect to
any Plan has breached any fiduciary duty to such CSL Plan under Part 4 of Title
I of ERISA or other applicable law. No event has occurred and no condition
exists that has subjected or would subject ICSL, CSL, any CSL Subsidiary, or any
CSL ERISA Affiliate(s) to any tax, fine or penalty imposed by the Code, ERISA or
other applicable law. All required contributions have been timely made by ICSL,
CSL, any CSL Subsidiary, or any CSL ERISA Affiliate, as appropriate, to each of
the CSL Plans and there is no funding deficiency with respect to any of the CSL
Plans. Each CSL Plan may be amended or terminated in accordance with its terms
without obligation or liability, other than those obligations and liabilities
for which specific assets have been set aside or reserved for on the ICSL
Balance Sheet as of the ICSL Balance Sheet Date included in the ICSL Financial
Statements and those obligations and liabilities reflected by the terms of the
Plan documents. There are no unfunded obligations under any CSL Plan providing
benefits to employees of CSL, any CSL Subsidiary, or CSL ERISA Affiliate(s)
during employment or after termination of their employment. The consummation of
the Transactions will not result in the payment, vesting or acceleration of any
benefit, except as required under Code Section 411(d)(3).

                  4.19.4 Except as set forth on SCHEDULE 4.19.4, (a) neither the
CSL Plans
                                      -35-
<Page>

nor CSL (or any CSL Subsidiary) is obligated to pay separation, severance,
termination or similar benefits or to vest any person in whole or in part solely
as a result of any transaction contemplated by this Agreement or solely as a
result of a "change of control" (as such term is defined in those individuals'
employment or option agreements or in Section 280G of the Code); (b) all
required discretionary (in accordance with historical practices) payments,
premiums, contributions, reimbursements, or accruals for all periods ending
prior to or as of the Effective Time shall have been made or properly accrued on
the CSL Balance Sheet Date; and (c) none of the CSL Plans has any unfunded
liabilities that are not reflected on the CSL Balance Sheet.

                  4.19.5 None of the CSL Plans ever maintained by CSL or any CSL
ERISA Affiliate has ever provided health care or any other non-pension benefits
to any employees after their employment was terminated (other than as required
by part 6 of subtitle B of Title I of ERISA) or has ever promised to provide
such post-termination benefits.

                  4.19.6 With respect to each CSL Plan maintained by CSL
preceding the Closing Date, complete and correct copies of the following
documents (if applicable to such CSL Plan) have previously been delivered to
CNS: (a) all documents embodying or governing such CSL Plan and any funding
medium for the CSL Plan (including, without limitation, trust agreements) as
they may have been amended to the date hereof; (b) the most recent IRS
determination or approval letter with respect to such CSL Plan under Code
Section 401(a) or 501(c)(9), and any applications for determination or approval
subsequently filed with the IRS; (c) all filed IRS Forms 5500, with all
applicable schedules and accountants' opinions attached thereto; (d) all
actuarial valuation reports completed with respect to such Plan; (e) the summary
plan description for such CSL Plan (or other descriptions of such CSL Plan
provided to employees) and all modifications thereto; (f) any insurance policy
(including any fiduciary liability insurance policy or fidelity bond) related to
such CSL Plan; (g) any registration statement or other filing made pursuant to
any federal or state securities Law; and (h) all correspondence to and from any
state or federal agency with respect to such CSL Plan.

                  4.19.7 Each CSL Plan required to be listed on SCHEDULE 4.19.1
may be amended, terminated, or otherwise modified by CSL to the greatest extent
permitted by applicable Law, including the elimination of any and all future
benefit accruals under any CSL Plan and no employee communications or provision
of any CSL Plan document has failed to effectively reserve the right of CSL or
the CSL ERISA Affiliate to so amend, terminate or otherwise modify such CSL
Plan.

                  4.19.8 Each CSL Plan ever maintained by CSL (including each
non-qualified deferred compensation arrangement) has been maintained in
compliance with all applicable requirements of federal and state securities Laws
including (without limitation, if applicable) the requirements that the offering
of interests in such Plan be registered under the Securities Act of 1933, as
amended, and/or state "Blue Sky" laws.

         4.20     INSURANCE.

         CSL and each CSL Subsidiary is, and will be through the Closing Date,
adequately insured with responsible insurers in respect of their properties,
assets and business with respect to the CSL Business against risks normally
insured against by

                                      -36-
<Page>

companies in similar lines of business under similar circumstances. SCHEDULE
4.20 correctly describes (by type, carrier, policy number, limits, premium and
expiration date) the insurance coverage carried by ICSL, CSL or any CSL
Subsidiary with respect to the CSL Business, which insurance will remain in full
force and effect with respect to all events occurring prior to the Closing.
Neither ICSL nor CSL nor any CSL Subsidiary (a) has failed to give any notice or
present any claim under any such policy or binder in due and timely fashion, (b)
has received notice of cancellation or non-renewal of any such policy or binder
or (c) has received notice of or is otherwise aware of any insurance premiums
which will be materially increased in the future. There are no outstanding
claims under any such policy which have gone unpaid for more than forty-five
days, or as to which coverage has been questioned, denied or disputed by the
underwriters of such policies or bonds. All premiums due and payable under all
such policies and bonds have been paid and CSL and each CSL Subsidiary is
otherwise in compliance with the terms of such policies and bonds. SCHEDULE 4.20
lists all claims made against CSL and each CSL Subsidiary's insurance coverage
during the 12 month period immediately preceding the date hereof. Except as set
forth on SCHEDULE 4.20, all insurance coverage listed on SCHEDULE 4.20 is on an
occurrence basis. Other than reasonable deductible amounts customary in the
industry, neither CSL nor any CSL Subsidiary is self-insured nor is any one of
them a party to any risk sharing or similar agreement except as specifically
noted on SCHEDULE 4.20.

         4.21     TRANSACTIONS WITH AFFILIATES.

         Except as set forth in SCHEDULE 4.21 hereto and only with respect to
transactions giving rise to current or contingent liabilities of ICSL, CSL or
any CSL Subsidiary, no current holder of 5% or more of any class of capital
stock of ICSL, CSL or any CSL Subsidiary at the time such transaction was
entered into, or any director, officer or employee of ICSL, CSL or any CSL
Subsidiary, or member of the family of any such person, or any corporation,
partnership, trust or other entity in which any such person, or any member of
the family of any such person, has an interest or is an officer, director,
trustee, partner or holder of any equity interest, is a party to any transaction
with ICSL, CSL or any CSL Subsidiary, including any contract, agreement or other
arrangement providing for the employment of, furnishing of services by, rental
of real or personal property from, or otherwise requiring payments or involving
other obligations to or from ICSL, CSL or any CSL Subsidiary.

         4.22     TAXES.

         ICSL, CSL and each CSL Subsidiary have filed (on a consolidated basis)
all Tax returns and reports required to be filed, including, without limitation,
returns and estimated returns, complete and accurate copies of which have been
provided to CNS, and have paid in full all taxes shown due thereon and all
estimated Tax when due (together with all interest, penalties, assessments and
deficiencies assessed in connection therewith due through the date hereof,
whether or not shown on any Tax return). Except as set forth on SCHEDULE 4.22,
neither CSL nor any CSL Subsidiary is required to pay any other Tax except as
shown in such Tax returns, reports and information filings. All such returns,
reports and information filings required to be filed, including any amendments
to date, have been prepared in good faith and without negligence or
misrepresentation and were correct and complete in all material respects. CSL
and each CSL Subsidiary has

                                      -37-
<Page>

either paid or, in accordance with GAAP applied consistently with prior periods,
adequately provided for, by reserves or other proper accounting treatment shown
in CSL Financial Statements, its liability for all Tax of every kind, for the
current Tax year and for all prior years. CSL has no Knowledge of any proposed
or threatened assessment or reassessment of any Taxes. In addition, at the date
hereof, CSL and each CSL Subsidiary has deducted and remitted all withholding
tax or source deductions when due to the appropriate Governmental Authority as
required by Law or CSL and each CSL Subsidiary has adequately provided for such
deductions by reserves or other proper accounting treatment, in accordance with
GAAP applied consistently with prior periods, in their books and records of
account. Neither CSL nor any CSL Subsidiary (a) has executed any waiver to
extend, or otherwise taken or failed to take any action that would have the
effect of extending, the applicable statute of limitations with respect to its
Tax liabilities, (b) is not a "CONSENTING CORPORATION" within the meaning of
Section 341(f) of the Code, (c) has not been a member of any consolidated group
(other than with ICSL) for Tax purposes or (d) does not have, or will not fail
to have, all records and information necessary for the timely and accurate
filing of any Tax returns due after the date hereof, including any returns due
after the Closing Date which relate to the period prior to the Closing Date.
Neither CSL nor any CSL Subsidiary is a party to any tax allocation or tax or
tax sharing agreement or member of an affiliated group of corporations other
than agreements or groups between ICSL and its Subsidiaries. Neither CSL, nor
any CSL Subsidiary nor ICSL (to the Knowledge of CSL, any CSL Subsidiary or
ICSL) has any liability for the Taxes of any other Person under Treasury
Regulations Section 1.1502-6 (or similar provisions of any state, local, or
foreign law). Neither CSL, nor any CSL Subsidiary, nor ICSL, nor (to the
Knowledge of CSL, any CSL Subsidiary or ICSL) any of its Affiliates has taken or
agreed to take any action or failed to take any action which action or failure
would prevent the Merger from constituting a reorganization within the meaning
of section 368(a) of the Code.

         4.23     BROKERS.

         Except as set forth on SCHEDULE 4.23, no agent, person or firm acting
on behalf of ICSL, CSL and each CSL Subsidiary or under their authority is or
will be entitled to a financial advisory fee, brokerage commission, finder's fee
or like payment in connection with the transactions contemplated hereby.

         4.24     ENVIRONMENTAL LAWS.

                  4.24.1 ICSL, CSL and each CSL Subsidiary has operated and
continue to operate the CSL Business in compliance in all material respects with
all Environmental Laws where the failure to comply would result in a CSL
Material Adverse Change.

                  4.24.2 To the Knowledge of CSL, no CSL Owned Premises, CSL
Leased Premises or any real property contiguous thereto, is or has been
designated by any state, local or federal agency or body as a hazardous waste
disposal site or a site or location requiring investigation concerning, or
management, clean-up or removal of, any Hazardous Substance.

                  4.24.3 There are no Environmental Claims pending or threatened
against CSL or any CSL Subsidiary or against any Person whose liability for any
Environmental Claim CSL or any CSL Subsidiary has or may have retained or
assumed either

                                      -38-
<Page>

contractually or by operation of Law. There are no present, or to the Knowledge
of CSL, past actions, activities, circumstances, conditions, events, incidents
or practices, including, without limitation, the release, threatened release,
emission, discharge, disposal, storage, treatment, transportation, generation,
manufacture or use of any Hazardous Substance that could form the basis of any
Environmental Claim against CSL or, to the Knowledge of CSL, against any Person
whose liability for any Environmental Claim CSL or any CSL Subsidiary has or may
have retained or assumed either contractually or by operation of Law.

                  4.24.4 All Waste generated in connection with the CSL
Business, operations, Assets and properties of CSL and each CSL Subsidiary has
been (a) treated, stored or disposed of by or at facilities duly licensed
pursuant to applicable Environmental Laws and (b) transported to such facilities
by transporters duly licensed pursuant to applicable Environmental Laws. CSL has
maintained true and complete records relating to the generation, transportation,
treatment, storage and disposal of Waste generated in connection with the
business, operations, assets and properties of CSL and the CSL Subsidiaries.

                  4.24.5 CSL has delivered to CNS all environmental inspection
reports ("CSL ENVIRONMENTAL REPORTS") prepared by any person or entity
concerning compliance with applicable Environmental Laws of the CSL Business,
operations, assets or properties or the use, manufacture, importation,
processing, storage, treatment, transportation, release or disposal therefrom,
therein or thereon of any Hazardous Substance. All such CSL Environmental
Reports are listed on SCHEDULE 4.24.

         4.25     ACCOUNTS RECEIVABLE.

         All of the accounts receivable of CSL and each CSL Subsidiary with
respect to the CSL Business shown or reflected on the CSL Balance Sheet in the
CSL Financial Statements and any accounts receivable that have accrued
subsequent to the CSL Balance Sheet Date represent bona fide transactions and
arose in the Ordinary Course of Business and are carried at values determined in
accordance with GAAP consistently applied. Except as set forth on SCHEDULE 4.25,
neither CSL not any CSL Subsidiary has any accounts or loans receivable from any
of its directors, officers or employees.

         4.26     SECURITIES AND EXCHANGE COMMISSION FILINGS.

         The information included in the Proxy Statement or Information
Statement, as the case may be, (other than CNS Financial Statements and other
information relating to CNS furnished to ICSL by CNS expressly for inclusion
therein) at the time of the mailing of the Proxy Statement or Information
Statement to ICSL's stockholders will not contain any untrue statement of a
material fact or omit to state a material fact required or necessary to be
stated therein in order to make the statements contained therein in light of the
circumstances under which they are made, not misleading.

         4.27     DISCLOSURE.

         All documents and schedules delivered or to be delivered by or on
behalf of ICSL and CSL in connection with this Agreement and the Transactions
are true, complete and correct in all material respects. Neither this Agreement,
nor any Schedule or Exhibit to this Agreement contains any untrue statement of a
material fact or omits a material fact

                                      -39-
<Page>

necessary to make the statements contained herein or therein, in light of the
circumstances in which made, not misleading.

         4.28     SEC FILINGS.

         Since January 31, 1999, ICSL has filed all reports and statements,
together with any amendments required to be made with respect thereto, that it
was required to file with the SEC (except the Form 10-Q for the fiscal quarter
ended April 30, 2001, the Form 10-Q for the fiscal quarter ended July 31, 2001,
and except where failure to file is not reasonably likely to cause a Material
Adverse Change). As of their respective dates, each of such reports and
documents, including the financial statements, schedules and exhibits thereto,
complied in all material respects with the Securities Act, the Exchange Act and
the rules and regulations promulgated thereunder (each as in effect on the date
of such filing). As of its respective date, each such report and document did
not contain any untrue statement of material fact or omit to state a material
fact required to be stated therein or necessary to make the statements made
therein, in light of the circumstances under which they were made, not
misleading, provided, however, that to the extent that the foregoing relates to
facts or omissions regarding Persons other than ICSL and its Affiliates, such
representation and warranty is made to ICSL's knowledge.

                          ARTICLE 5 - COVENANTS OF CNS

         CNS and Acquisition Sub covenant and agree with CSL and ICSL as
follows:

         5.1      EMPLOYEE MATTERS.

         CNS will cause the Surviving Corporation to offer to employees of CSL
and each CSL Subsidiary who continue employment with the Surviving Corporation
("TRANSFERRED EMPLOYEES") (i) the CSL Plans offered to the Transferred Employees
immediately prior to the Closing Date on substantially the same terms as are
currently offered by CSL to Transferred Employees or (ii) benefits of the same
type and under the same terms and conditions as are offered from time to time to
CNS employees generally, provided that for the purpose of determining
participation, vesting and benefit accrual, CNS will, or will cause the
Surviving Corporation to, give credit under such benefit plan to Transferred
Employees for all service with the Surviving Corporation and with CSL and/or
ICSL prior to the Effective Time. CNS shall also cause the Surviving Corporation
to assume and honor in accordance with their terms all employment, severance,
consulting and other compensation agreements between CSL and those officers,
employees or consultants of CSL who shall become officers, employees or
consultants of the Surviving Corporation from and after the Effective Time, and
all provisions for vested benefits or other vested amounts earned or accrued
through the Effective Time under any CSL Plan. CNS will, or will cause the
Surviving Corporation to, make offers of employment to those of ICSL's employees
as shall be mutually agreed by CNS and ICSL.

         5.2      CNS SECURED CONVERTIBLE DEBT.

         CNS shall obtain firm commitments from the Newco Investors for the
purchase from CNS, concurrently with the closing of the Merger, of not less than
$1.25 Million in original principal amount of Convertible Notes, to be issued
and sold by CNS substantially in accordance with the term sheet attached hereto
as EXHIBIT 5.2 (the "NOTE

                                      -40-
<Page>

PURCHASE TERM SHEET") pursuant to documentation that is mutually acceptable to,
ICSL and CNS (the "NOTE PURCHASE AGREEMENT").

         5.3      CNS OPTIONS AND ICSL REPLACEMENT OPTIONS.

                  5.3.1 As soon as practicable after the execution and delivery
of this Agreement, the Board of Directors of CNS (or, if appropriate, any
committee administering CNS Options) shall adopt or cause to be adopted, such
resolutions, and shall take or cause to be taken, such other actions as are
required to adjust the terms of the outstanding CNS Options to provide that each
CNS Option outstanding immediately prior to the Effective Time (whether or not
vested) and granted to an officer or employee of CNS holding a position with a
title that is junior to senior vice president, at the Effective Time, shall not
accelerate and immediately vest as a result of the Merger or other transactions
contemplated by this Agreement. CNS shall use its best efforts to enter into
option amendment agreements with all officers holding a position of senior vice
president or senior, to provide that such options granted to those officers
shall not accelerate and immediately vest as a result of the Merger of other
transactions contemplated by this Agreement.

                  5.3.2 As soon as practicable after the execution and delivery
of this Agreement, the Board of Directors of CNS shall take the actions set
forth in Section 1.5.4. CNS shall take all corporate action necessary to reserve
for issuance sufficient shares of New Common Stock for delivery upon exercise of
ICSL Replacement Options granted by CNS in accordance with the provisions of
this Agreement.

                  5.3.3 In the event that any of the ICSL Replacement Options
issued in exchange for the ICSL Options listed on SCHEDULE 5.3.3 terminate in
the period from and including the Effective Time until the Trigger Date (as
defined in the Investor Rights Agreement) (by reason of termination of
employment or service, death or disability of the option holder or otherwise
under the terms of the option plan or agreement governing such ICSL Replacement
Options), the shares of New Common Stock reserved for issuance upon exercise of
such ICSL Replacement Options shall be issued by Newco to ICSL within thirty
(30) days of termination of such ICSL Option(s).

         5.4      CNS STOCKHOLDER APPROVAL.

         CNS shall take all actions to obtain any stockholder approval required
by Law to be obtained to consummate the Transactions, including the calling,
giving notice of, convening and holding a Special Meeting of the CNS
Stockholders. CNS shall, through its Board of Directors, recommend to its
stockholders that they approve the Amended Certificate.

         5.5      TERMINATION OF STOCKHOLDER AND VOTING AGREEMENTS.

         CNS and the CNS stockholders shall take all actions to terminate all
stockholder, voting, registration rights and other similar agreements, if any
(collectively, the "CNS SHAREHOLDERS AGREEMENTS") other than that certain (i)
Shareholders Agreement dated as of March 26, 1999 between CNS and certain CNS
Stockholders, as amended, and (ii) Investor Rights Agreement dated as of March
26, 1999 between CNS and certain CNS stockholders, as amended.

                                      -41-
<Page>

         5.6      ADOPTION OF AMENDMENT TO CNS STOCK OPTION PLAN.

         There shall be adopted by the Board of Directors and stockholders of
CNS an amendment to the CNS Stock Option Plan (the "CNS OPTION PLAN") increasing
the number of shares of Newco Common Stock authorized for issuance under the CNS
Option Plan such that the number of shares so authorized is equal to the sum of
(i) the number of shares reserved for issuance upon exercise of outstanding CNS
Options, (ii) the number of shares to be issuable upon exercise of ICSL
Replacement Options and (iii) a number of shares equal to at least 10% of the
New Common Stock Equivalents outstanding immediately after the Effective Time
for use in granting new options to Newco employees and executive officers. The
Board of Directors of CNS shall take and shall cause to be taken all action
necessary to reserve for issuance such shares of New Common Stock pursuant to
the CNS Option Plan.

         5.7      PAYMENT OF CNS PREFERRED STOCK DIVIDEND.

         CNS shall take any and all action necessary to issue, immediately prior
to the filing of the Amended Certificate with the Secretary of State of the
State of Delaware, to the holders of CNS Preferred Stock, in full satisfaction
of the CNS Preferred Stock Dividend, that number of shares of CNS Common Stock
equal to the quotient of the CNS Preferred Stock Dividend divided by the CNS Per
Share Value, provided that the number of shares of CNS Common Stock issued to
each holder of CNS Preferred Stock shall be rounded up or down to the nearest
whole number.

         5.8      TERMINATION OF PSILOS AGREEMENT.

         CNS shall take any and all actions necessary to terminate the Psilos
Agreement, effective immediately after the Effective Time; PROVIDED, HOWEVER,
that CNS shall remain liable for the Psilos Fee.

                      ARTICLE 6 - COVENANTS OF CSL AND ICSL

         CSL and ICSL covenant and agree with CNS, Acquisition Sub and the CNS
Stockholders as follows:

         6.1      ICSL ACTIONS.

         As soon as practicable after the execution and delivery of this
Agreement, ICSL shall take all actions, including the filing with the SEC, to
prepare either (i) a Proxy Statement pursuant to Regulation 14A under the
Exchange Act (a "PROXY STATEMENT"), or (ii) in the event that ICSL obtains the
requisite approval from its stockholders without the necessity of a Special
Meeting of ICSL stockholders, an Information Statement pursuant to Regulation
14C under the Exchange Act (the "INFORMATION STATEMENT"), and shall use its
reasonable best efforts to cause the Proxy Statement or Information Statement,
as the case may be, to be "cleared" by the SEC, and to be mailed to all holders
of ICSL Common Stock. ICSL shall deliver copies of the proposed form of Proxy
Statement or Information Statement, as the case may be, to CNS within a
reasonable time prior to the filing thereof with the SEC for review and comment
by CNS and its counsel. ICSL shall take all steps necessary to amend or
supplement the Proxy Statement or Information Statement and to cause such
amended Proxy Statement or Information Statement to be filed with the SEC and
disseminated to ICSL's stockholders as required by applicable federal securities
Laws. If ICSL is required to solicit the approval of

                                      -42-
<Page>

ICSL's stockholders, ICSL shall, as soon as practicable, duly call, give notice
of, convene and hold a Special Meeting of ICSL stockholders for the purpose of
seeking approval to consummate the Merger. ICSL shall, through its Board of
Directors, recommend to its stockholders that they approve the Merger.

         6.2      ICSL REPLACEMENT OPTIONS.

         As soon as practicable after the execution and delivery of this
Agreement, the Board of Directors of ICSL shall adopt or cause to be adopted,
such resolutions, and shall take or cause to be taken, such other actions as are
required to cancel the outstanding ICSL Options in consideration of the grant by
Newco of ICSL Replacement Options at the Effective Time in accordance with
Section 1.5.4 hereto.

                          ARTICLE 7 - MUTUAL COVENANTS

         7.1      BEST EFFORTS COOPERATION.

         Until the Closing or earlier termination of this Agreement, each of
ICSL, CSL, CNS, Acquisition Sub and the CNS Stockholders, respectively, shall
use its best efforts in good faith to perform and fulfill, or cause to be
performed and fulfilled, all conditions and obligations to be fulfilled, or
performed by it hereunder, to the end that the transactions contemplated hereby
will be fully and timely consummated.

         7.2      ACCESS.

         Until the Closing, each party shall give the other parties, and their
attorneys, accountants and other authorized representatives complete access,
upon reasonable notice and at reasonable times, to each party's offices,
suppliers, employees, business and financial records, contracts, business plans,
budgets and projections, agreements and commitments and other documents and
information. In order that each party may have full opportunity to make such
examination and investigation as they may desire of the other parties, each
party hereto and their respective representatives during such period will
furnish the other parties with all such information as such representatives may
reasonably request and cause the respective officers, employees, consultants,
agents, accountants and attorneys of each to cooperate fully with the
representatives of each other party in connection with such review and
examination and to make full disclosure to each party of all material facts
affecting the financial condition and the operations, properties and prospects
of each of the parties hereto; provided, however, that each such party will,
unless the Closing occurs, hold the documents and information concerning the
other parties hereto confidential in accordance with Section 7.15 hereof.

         7.3      INSURANCE.

         Until the Closing, each of CNS and CSL shall maintain with financially
sound and reputable insurers, insurance against such casualties and
contingencies and of such types and in such amounts as is customary for
companies similarly situated.

         7.4      COMPLIANCE WITH LAWS.

         Until the Closing, each of CNS and CSL shall conduct its operations in
compliance with all applicable Laws.

                                      -43-
<Page>

         7.5      KEEPING OF BOOKS AND RECORDS.

         Until the Closing, each of CNS and CSL shall keep adequate records and
books of account, in which complete entries will be made in accordance with GAAP
consistently applied, reflecting all financial transactions and in which all
proper reserves for depreciation, depletion, obsolescence, amortization, taxes,
bad debts and other purposes in connection with its operations shall be made.

         7.6      CONDUCT OF BUSINESS.

         Prior to the Effective Time, unless, in the case of CSL, CNS shall have
consented in writing thereto, and in the case of CNS, ICSL or CSL shall have
consented in writing thereto, CNS and CSL:

                  7.6.1  shall, and shall cause each of its respective
Subsidiaries to, conduct its operations in the Ordinary Course of Business in
substantially the same manner as heretofore conducted;

                  7.6.2  shall use its best efforts, and shall cause each of its
respective Subsidiaries to use its best efforts, to preserve intact its business
organization and goodwill, keep available the services of its officers and
employees, and maintain satisfactory relationships with those persons having
business relationships with it;

                  7.6.3  except as otherwise contemplated hereby, shall not, and
shall not permit any of its respective Subsidiaries to, amend its Certificate of
Incorporation or By-laws;

                  7.6.4  shall promptly notify the other party of any material
emergency or other material change in its or any of its Subsidiary's condition
(financial or otherwise), business, properties, assets, liabilities, prospects
or the Ordinary Course of Business of it or any Subsidiary or in the operation
of its or any of its Subsidiary's properties and of any litigation or
governmental complaints, investigations or hearings (or communications
indicating that the same may be contemplated);

                  7.6.5  shall not, and shall not permit any of its respective
Subsidiaries to, (a) except pursuant to the exercise of options, warrants,
conversion rights and other contractual rights existing on the date hereof and
listed on SCHEDULE 3.3.1 or SCHEDULE 4.3, respectively, issue any shares of its
capital stock, effect any stock split or otherwise change its capitalization as
it exists on the date hereof, (b) grant, confer or award any option, warrant,
conversion right or other right to acquire any shares of its capital stock not
existing on the date hereof and listed on SCHEDULE 3.3.1 or SCHEDULE 4.3,
respectively, (c) except as otherwise provided for in this Agreement or as
required under the governing document, accelerate the vesting or exercisability
of any option, warrant, conversion right or other right to acquire any shares of
its capital stock, (d) increase, or permit any of its Subsidiaries to increase,
any compensation or enter into or amend any employment agreement with any of its
present or future officers, directors or employees except for the payment of
cash bonuses to officers, directors or employees pursuant to and consistent with
existing plans or programs described on SCHEDULES 3.18.1 and 3.19.1 or SCHEDULES
4.18.1 and 4.19.1, (e) adopt any employee benefit plan (including any stock
option, stock benefit or stock purchase plan) or amend any existing employee
benefit plan in any respect or (f) sell, lease or otherwise dispose of any of
its assets which are material,

                                      -44-
<Page>

individually or in the aggregate, except in the Ordinary Course of Business;
PROVIDED HOWEVER, that ICSL may sell or otherwise dispose of its network
management division;

                  7.6.6  shall not, and shall not permit any of its respective
Subsidiaries to, (a) incur or obligate itself to incur any capital expenditure
in excess of $50,000, incur any long-term indebtedness in addition to that
outstanding on the date hereof or any other indebtedness or liability other than
pursuant to existing credit agreements or in the Ordinary Course of Business;
(b) make any loans, advances or capital contributions to, or investments in, any
other person, other than travel or other advances to employees consistent with
past practice; or (c) assume, guarantee, endorse or otherwise become liable or
responsible (whether directly, contingently, or otherwise) for the obligations
of any other Person, except to endorse checks for collection or deposit in the
Ordinary Course of Business;

                  7.6.7  declare or pay any dividend or distribution on any
shares of its capital stock; or

                  7.6.8  agree, or permit any of its respective Subsidiaries to
agree, in writing or otherwise to take any of the foregoing actions or any
action that would make any representation or warranty in this Agreement untrue
or incorrect as of the date hereof or as of the Effective Time, as if made as of
such time.

         7.7      LITIGATION.

         Until the Closing, CNS will promptly notify ICSL, and ICSL and CSL will
promptly notify CNS, of any lawsuits, claims, proceedings or investigations
which are threatened or commenced against or by CNS and any CNS Subsidiary or
their Affiliates, or against any employee, consultant or director of CNS or any
CNS Subsidiary, on the one hand, or ICSL, CSL and any CSL Subsidiary or their
Affiliates, or against any employee, consultant or director of ICSL, CSL, or any
CSL Subsidiary on the other hand.

         7.8      CONTINUED EFFECTIVENESS OF REPRESENTATIONS AND WARRANTIES.

         From the date hereof up to and including the Closing Date (a) each of
(i) CNS and any CNS Subsidiary and (ii) ICSL, CSL and any CSL Subsidiary will
conduct its operations in a manner such that the representations and warranties
contained herein shall continue to be true and correct on and as of the Closing
Date as if made on and as of the Closing Date, except for changes and events
arising as a consequence of the Transactions, or actions in the Ordinary Course
of Business after the date hereof which would not have an adverse effect on the
properties, assets, operations or condition (financial or otherwise) or
prospects of the CNS Business or CSL Business; and (b) (i) CNS will advise ICSL
and CSL promptly in writing of any condition or circumstance occurring from the
date hereof up to and including the Closing Date which could cause any
representations or warranties of CNS to become untrue and (ii) ICSL or CSL, as
the case may be, will advise CNS promptly in writing of any condition or
circumstance occurring from the date hereof up to and including the Closing Date
which could cause any representations or warranties of ICSL or CSL to become
untrue.

         7.9      NO NEGOTIATIONS.

         During the term of this Agreement, CNS, Acquisition Sub, ICSL or CSL
and each officer, director, employee, consultant, advisor, agent or investment
banker of CNS,

                                      -45-
<Page>

Acquisition Sub, ICSL or CSL, respectively, shall not, directly or indirectly,
initiate, solicit or continue discussions with, engage in negotiations with, or
provide any information to any corporation, partnership, person or other entity
or group involving the possible sale, directly or indirectly, transfer or joint
venture of any part of the business or the stock or assets of CNS or CSL,
respectively, to any person or entity (collectively, an "ALTERNATIVE
TRANSACTION") other than as contemplated herein. Each of ICSL, CSL, CNS and
Acquisition Sub shall cease immediately all discussions and negotiations that
may have occurred prior to the date of this Agreement regarding any Alternative
Transaction. Each of ICSL, CSL, CNS and Acquisition Sub shall notify the other
parties hereto immediately of any such Alternative Transaction or any inquiry,
proposal or offer relating thereto. The parties expressly acknowledge and agree
that this Section 7.9 shall not apply to any transaction whereby ICSL shall sell
its network management division.

         7.10     FURTHER ASSURANCES.

         Each of CNS, Acquisition Sub, ICSL and CSL will use its commercially
reasonable efforts to have all present officers and directors of CNS,
Acquisition Sub, ICSL and CSL execute whatever minutes of meetings or other
instruments and take whatever action as may be necessary or desirable to effect,
perfect or confirm of record or otherwise, in the Surviving Corporation, full
right, title and interest in and to the business, properties and assets now
conducted or owned by each of CNS, Acquisition Sub, ICSL and CSL, free and clear
of all restrictions, liens, encumbrances, rights, title and interests in others,
or to collect, realize upon, gain possession of, or otherwise acquire full
right, title and interest in and to such business, properties and assets, or to
carry out the intent and purposes of the transactions contemplated hereby.

         7.11     REPLACEMENT FACILITY.

         Following the execution of this Agreement, each of ICSL, CSL, CNS and
Acquisition Sub shall use their commercially reasonable efforts to obtain the
Replacement Facility.

         7.12     GENERAL COVENANTS.

         Following the execution of this Agreement, CSL, ICSL, CNS and
Acquisition Sub agree:

                  7.12.1 If any event should occur, either within or without the
Knowledge or control of any party, which would prevent fulfillment of the
conditions to the obligations of any party hereto to consummate the transactions
contemplated by this Agreement, to use its or their reasonable efforts to cure
the same as expeditiously as possible;

                  7.12.2 To cooperate fully with each other in preparing,
filing, prosecuting, and taking any other actions which are or may be reasonable
and necessary to obtain the consent of any Governmental Authority or any third
party to accomplish the transactions contemplated by this Agreement;

                  7.12.3 To deliver such other instruments of title,
certificates, consents, endorsements, assignments, assumptions and other
documents or instruments, in form reasonably acceptable to the party requesting
the same and its counsel, as may be reasonably necessary to carry out and/or to
comply with the terms of this Agreement and the transactions contemplated
herein;

                                      -46-
<Page>

                  7.12.4 To confer on a regular basis with the other, report on
material operational matters and promptly advise the other orally and in writing
of any change or event resulting in, or which, insofar as can reasonably be
foreseen could result in, a Material Adverse Change to such party or which would
cause or constitute a material breach of any of the representations, warranties
or covenants of such party contained herein;

                  7.12.5 To file all reports required to be filed by each of
them or their Affiliates with the SEC between the date hereof and the Closing
Date and to deliver to the other (or its counsel) copies of all such reports
promptly after the same are filed; and

                  7.12.6 To promptly provide the other (or its counsel) with
copies of all other filings made by such party with any Governmental Authority
in connection with this Agreement or the transactions contemplated hereby.

         7.13     PROXY STATEMENT/INFORMATION STATEMENT.

         Following the execution of this Agreement, ICSL, CSL, CNS and
Acquisition Sub agree:

                  7.13.1 ICSL, CSL, CNS and Acquisition Sub shall take any
action reasonably required to be taken under the Securities Act, the Exchange
Act and the DGCL in connection with the consummation of the Transactions;

                  7.13.2 CNS and Acquisition Sub shall, to the extent reasonably
necessary (a) cooperate in the preparation and filing of the Proxy Statement,
Information Statement, or other filing required to be made with the SEC under
the Securities Act or the Exchange Act in connection with the Transactions,
including the Merger and (b) provide all material reasonably requested by ICSL
(including all financial statements of CNS, financial information and other
information) for inclusion in the Proxy Statement, Information Statement or
other required SEC Filing;

                  7.13.3 If at any time CNS becomes aware of any event or
circumstance that should be set forth in a supplement to the Proxy Statement or
Information Statement (as the case may be), CNS shall promptly inform ICSL;

                  7.13.4 Each of ICSL and CNS shall promptly correct any
information provided by it for use in the Proxy Statement or Information
Statement if and to the extent that such information shall have become false or
misleading in any material respect; and

                  7.13.5 ICSL and CNS shall promptly furnish to each other all
information, and take such other actions as may reasonably be requested in
connection with any action by either of them in furtherance of the provisions of
this Section 7.13.

         7.14     PUBLIC ANNOUNCEMENTS.

         ICSL, CSL, CNS and Acquisition Sub will consult with each other before
issuing, and provide each other the opportunity to review and comment upon, any
press release or other public statements with respect to the Transactions,
including the Merger, and shall not issue any such press release or make any
such public statement prior to such

                                      -47-
<Page>

consultation, except as may be required by applicable Law or court process.
Unless in the opinion of CNS's counsel such disclosure is required by law,
neither CNS nor any CNS Subsidiary shall issue any public announcement regarding
this Agreement or the Transactions without the prior written consent of ICSL,
and in any event, CNS shall provide a copy of any such public disclosure to ICSL
prior to its dissemination. Unless, in the opinion of the ICSL's counsel such
disclosure is required by Law, neither ICSL nor CSL shall issue any public
announcement regarding this Agreement or the Transactions without the prior
written consent of CNS.

         7.15     CONFIDENTIALITY.

         As used herein, "CONFIDENTIAL INFORMATION" means any information or
data that a party has acquired from another party that is confidential or not
otherwise available to the public, whether oral or written, including without
limitation any analyses, computations, studies or other documents prepared from
such information or data by or for the directors, officers, employees, agents or
representatives of such party (collectively, the "REPRESENTATIVES"), but
excluding information or data which (a) became available to the public other
than as a result of such party's violation of this Agreement, (b) became
available to such party from a source other than the other party if that source
was not bound by a confidentiality agreement with such other party and such
source lawfully obtained such information or data, or (c) is required to be
disclosed by applicable law, provided that promptly after being compelled to
disclose any such information or data, the party being so compelled shall
provide notice thereof to the other party so that such other party may seek a
protective order or other appropriate remedy. Each party covenants and agrees
that it and its Representatives shall keep confidential and shall not disclose
any Confidential Information, except to its Representatives and lenders who need
to know such information and agree to keep it confidential. Each party shall be
responsible for any breach of this provision by its Representatives. In the
event that the Closing does not occur, each party will promptly return to the
other all copies of such other party's Confidential Information. The obligations
of this Section 7.15 shall survive the Closing or earlier termination of this
Agreement.

         7.16     CNS VOTING AGREEMENT.

         Certain stockholders of CNS shall have executed and delivered a Voting
Agreement substantially in the form attached hereto as EXHIBIT 7.16 (the "CNS
VOTING AGREEMENT").

         7.17     CSL VOTING AGREEMENT.

         Certain stockholders of ICSL shall have executed and delivered a Voting
Agreement substantially in the form attached hereto as EXHIBIT 7.17 (the "CSL
VOTING AGREEMENT").

         7.18     ESCROW AGREEMENT.

         ICSL, CNS and Hinckley, Allen & Snyder LLP, as Escrow Agent, shall have
executed and delivered an Escrow Agreement substantially in the form attached
hereto as EXHIBIT 7.18 (the "ESCROW AGREEMENT").

                                      -48-
<Page>

             ARTICLE 8 - CONDITIONS TO ICSL'S AND CSL'S OBLIGATIONS

         The obligation of CSL and ICSL to consummate the transactions
contemplated hereby is subject to the satisfaction, on or before the Closing
Date, of the following conditions each of which may be waived by ICSL in its
sole discretion:

         8.1      REPRESENTATIONS AND WARRANTIES TRUE.

         All of the representations and warranties of CNS, Acquisition Sub
contained in this Agreement or in any Exhibits or Schedules or other documents
attached hereto or referred to herein or delivered pursuant hereto or in
connection with the transactions contemplated hereby shall be true and correct
all material respects (except to the extent already qualified by materiality
(including a Material Adverse Change qualification), in which case those
representations and warranties shall be true and correct in all respect, on and
as of the date hereof and on and as of the Closing Date, as if made on and as of
the Closing Date (other than representations and warranties that address matters
only as of a certain date, which shall be true and correct in all material
respects). On the Closing Date, CNS and Acquisition Sub shall have executed and
delivered to ICSL and CSL a certificate, in form and substance satisfactory to
ICSL and CSL and its counsel, to such effect.

         8.2      PERFORMANCE.

         CNS and Acquisition Sub shall have performed and complied with all
covenants and agreements contained herein required to be performed or complied
with by them prior to or at the Closing Date. CNS shall have executed and
delivered to ICSL and CSL a certificate, in form and substance satisfactory to
ICSL and its counsel, to such effect and to the further effect that all of the
conditions set forth in this Article 8 have been satisfied.

         8.3      OFFICERS AND DIRECTORS.

         CNS and its Board of Directors and stockholders shall have taken such
action as is necessary to elect those persons as shall be mutually agreed prior
to the Effective Time as members of the Board of Directors and as officer(s) of
Newco, each to serve in accordance with the provisions of the Shareholders
Agreement and the By-laws of Newco until his successor is duly elected and
qualified.

         8.4      CONSENTS.

         CNS and Acquisition Sub shall have obtained all requisite approvals and
consents of, and made all requisite filings with, all Governmental Authorities
and third parties which are necessary to be obtained or made to (a) permit the
valid execution, delivery and performance by CNS of this Agreement and the
Transactions, and (b) prevent any Permit or agreement relating to the CNS
Business from terminating prior to its scheduled termination as a result of the
consummation of the Transactions. In addition, CNS and the Acquisition Sub shall
have received or obtained all Permits from any Governmental Authority or any
third party consents necessary as a result of the Transactions, and any appeal
period with respect to the same shall have expired without an objection thereto
having been filed.

                                      -49-
<Page>

         8.5      FINANCIAL DUE DILIGENCE.

         ICSL shall have completed to its reasonable satisfaction a review of
CNS's books and records and the accountant's work papers prepared in connection
with the CNS Financial Statements.

         8.6      NO ACTIONS, SUITS OR PROCEEDINGS.

         As of the Closing Date, no action, suit, investigation or proceeding
brought by any Governmental Authority shall be pending or, to the Knowledge of
the parties to this Agreement, threatened, before any Governmental Authority (a)
to restrain, prohibit, restrict or delay, or to obtain damages or a discovery
order in respect of this Agreement or the consummation of the of the
Transactions, (b) which has resulted or may result in a Material Adverse Change
with respect to CNS or any CNS Subsidiary or (c) which has or may adversely
affect the operation of the CNS Business or has or may result in the imposition
of liability on CNS or any CNS Subsidiary. No order, decree or judgment of any
Governmental Authority shall have been issued and remain in effect at the
Closing restraining, prohibiting, restricting or delaying the consummation of
the Transactions. No insolvency proceeding of any character including, without
limitation, bankruptcy, receivership, reorganization, dissolution or arrangement
with creditors, voluntary or involuntary, affecting CNS or any CNS Subsidiary
shall be pending, and neither CNS nor any CNS Subsidiary shall have taken any
action in contemplation of, or which would constitute the basis for, the
institution of any such proceedings.

         8.7      OPINION OF COUNSEL.

         ICSL and CSL shall have received from Proskauer Rose LLP, an opinion
dated as of the Closing Date in form reasonably acceptable to ICSL and CSL, as
to the matters set forth in EXHIBIT 8.7 hereto.

         8.8      ACCOUNTANTS.

         CSL shall have received from CNS's independent public accountants, a
certificate or letter, dated the Closing Date, to the effect that such
accountants will, to the extent such consent is required, consent to the
inclusion or incorporation of its report on the audited financial statements of
CNS for the years ended December 31, 1998, 1999 and 2000 in any SEC Filing
required in connection with this Agreement, the Merger, the Transactions and
ICSL's ownership of the New Common Stock, subject to such accountants normal due
diligence procedures for such a consent. The cost of obtaining any such
certificate shall be borne solely by ICSL.

         8.9      APPROVAL OF ICSL AND ITS COUNSEL.

         All actions, proceedings, consents, instruments and documents required
to be delivered by, or at the behest or direction of, CNS hereunder or incident
to its performance hereunder, and all other related matters, shall be reasonably
satisfactory as to form and substance to ICSL and its counsel.

         8.10     CLOSING DOCUMENTS.

         CNS shall have delivered all of the resolutions, certificates,
documents and instruments required by this Agreement, including without
limitation:

                                      -50-
<Page>

                  8.10.1 Resolutions of the Boards of Directors and stockholders
of CNS, certified by the Secretary of CNS, and other evidence satisfactory to
ICSL that the requisite consent of the Board of Directors and the CNS
Stockholders has been obtained.

                  8.10.2 Certificates of Good Standing with respect to CNS and
any CNS Subsidiary issued by the Secretary of State of its state of
incorporation and of any state where it is qualified to do business as a foreign
corporation;

                  8.10.3 Copies of the charter documents and By-laws of CNS and
any CNS Subsidiary as in effect on the date hereof, certified by the Secretary
of State of its state of incorporation and by the Secretary of CNS;

                  8.10.4 Copies of the Amended Certificate certified by the
Secretary of the State of Delaware and the By-laws as amended as set forth in
Section 1.3 hereof, certified by the Secretary of CNS;

                  8.10.5 Resignations of all officers and directors of CNS and
any CNS Subsidiary effective as of the Effective Time; and

                  8.10.6 Certificate of the Chief Financial Officer of CNS,
certifying as to (a) CNS Cash-on-Hand, and (b) CNS Debt, each as of the Closing
Date.

         8.11     MINIMUM CASH-ON-HAND.

         On the Closing Date, CNS and the CNS Subsidiaries shall have combined
Cash-on-Hand that together with the New Investment shall equal not less than
$4.0 million.

         8.12     CONVERTIBLE DEBT.

         CNS shall have entered into the Note Purchase Agreement for the
purchase from CNS (the "NEW INVESTMENT") of Convertible Notes in an original
principal amount that together with the Cash-on-Hand as of the Closing Date
shall equal not less than $4.0 million, and all conditions precedent to the
consummation of the transactions contemplated thereby, other than the Merger,
shall have been satisfied.

         8.13     INTENTIONALLY BLANK.

         8.14     CNS PREFERRED STOCK DIVIDEND.

         The CNS Preferred Stockholders shall have received the CNS Preferred
Stock Dividend in shares of CNS Common Stock prior to the Effective Time.

         8.15     FILING OF AMENDED CERTIFICATE.

         CNS shall have caused to be filed the Amended Certificate in the form
attached hereto as EXHIBIT 8.15 with the Secretary of the State of Delaware and
the Amended Certificate shall have become effective.

    ARTICLE 9 - CONDITIONS TO CNS'S AND ACQUISITION SUB'S OBLIGATION TO CLOSE

         The obligation of CNS and Acquisition Sub to consummate the
transactions contemplated hereby is subject to the satisfaction, on or before
the Closing Date, of the following conditions, each of which may be waived by
CNS in its sole discretion:

                                      -51-
<Page>

         9.1      REPRESENTATIONS AND WARRANTIES TRUE.

         All of the representations and warranties of ICSL and CSL contained in
this Agreement or in any Exhibits or Schedules or other documents attached
hereto or referred to herein or delivered pursuant hereto or in connection with
the transactions contemplated hereby shall be true and correct in all material
respects (except to the extent already qualified by materiality (including a
Material Adverse Change qualification)) in which case those representations and
warranties shall be true and correct in all respects on and as of the date
hereof and on and as of the Closing Date, as if made on and as of the Closing
Date (other than representations and warranties that address matters only as of
a certain date, which shall be true and correct in all material respects). On
the Closing Date, ICSL and CSL shall have executed and delivered to CNS a
certificate, in form and substance satisfactory to CNS and its counsel, to such
effect.

         9.2      PERFORMANCE.

         ICSL and CSL shall have performed and complied with all covenants and
agreements contained herein required to be performed or complied with by them
prior to or at the Closing Date. ICSL and CSL shall have executed and delivered
to CNS a certificate in form and substance satisfactory to CNS and its counsel
to such effect and to the further effect that all of the conditions set forth in
this Article 9 have been satisfied.

         9.3      CONSENTS.

         ICSL and CSL shall have obtained all requisite approvals and consents
of, and made all requisite filings with, all Governmental Authorities and third
parties which are necessary to be obtained or made to (a) permit the valid
execution, delivery and performance by ICSL and CSL of this Agreement and the
Transactions, and (b) prevent any Permit or agreement relating to the CSL
Business from terminating prior to its scheduled termination as a result of the
consummation of the Transactions. In addition, ICSL and CSL shall have received
or obtained all Permits from any Governmental Authority or any third party
consents necessary as a result of the Transactions, and any appeal period with
respect to the same shall have expired without an objection thereto having been
filed.

         9.4      FINANCIAL DUE DILIGENCE.

         CNS shall have completed to its reasonable satisfaction a review of
CSL's books and records and the accountant's work papers prepared in connection
with the CSL Financial Statements.

         9.5      NO ACTIONS, SUITS OR PROCEEDINGS.

         As of the Closing Date, no action, suit, investigation or proceeding
brought by any Governmental Authority shall be pending or, to the Knowledge of
the parties to this Agreement, threatened, before any Governmental Authority (a)
to restrain, prohibit, restrict or delay, or to obtain damages or a discovery
order in respect of this Agreement or the consummation of the Transaction, (b)
which has resulted or may result in a Material Adverse Change with respect to
ICSL, CSL or any CSL Subsidiary (c) which may adversely effect the operation of
the business of ICSL, CSL or any CSL Subsidiary or has or may result in the
imposition of liability on ICSL, CSL or any CSL Subsidiary. No order, decree or
judgment of any Governmental Authority shall have been issued and

                                      -52-
<Page>

remain in effect at the Closing restraining, prohibiting, restricting or
delaying the consummation of the Transactions. No insolvency proceeding of any
character including without limitation, bankruptcy, receivership,
reorganization, dissolution or arrangement with creditors, voluntary or
involuntary, affecting ICSL, CSL or any CSL Subsidiary shall be pending, and
neither ICSL, CSL, any CSL Subsidiary shall have taken any action in
contemplation of, or which would constitute the basis for, the institution of
any such proceedings.

         9.6      OPINION OF COUNSEL.

         CNS shall have received from Hinckley, Allen & Snyder LLP, an opinion
dated as of the Closing Date in form reasonably acceptable to CNS, as to the
matters set forth in EXHIBIT 9.6 hereto.

         9.7      APPROVAL OF CNS AND ITS COUNSEL.

         All actions, proceedings, consents, instruments and documents required
to be delivered by, or at the behest or direction of, ICSL and CSL hereunder or
incident to their performance hereunder, and all other related matters, shall be
reasonably satisfactory as to form and substance to CNS and its counsel.

         9.8      CLOSING DOCUMENTS.

         ICSL and CSL shall have delivered all of the resolutions, certificates,
documents and instruments required by this Agreement, including without
limitation:

                  9.8.1  Resolutions of the Boards of Directors and stockholders
of ICSL and CSL, certified by the Secretary of ICSL and CSL, and other evidence
satisfactory to CNS that the requisite consent of the Board of Directors and
stockholders of each of ICSL and CSL has been obtained;

                  9.8.2  Certificates of Good Standing with respect to ICSL and
CSL and any CSL Subsidiaries issued by the Secretary of State of its state of
incorporation and of any state where it is qualified to do business as a foreign
corporation;

                  9.8.3  Copies of the charter documents and By-laws of ICSL and
CSL and any CSL Subsidiaries certified, as in effect on the date hereof, by the
Secretary of State of its state of incorporation and by the Secretary of each of
ICSL and CSL;

                  9.8.4  Resignations of all officers and directors of CSL
effective as of the Effective Time; and

                  9.8.5  Certificate of the Chief Financial Officer of CSL,
certifying as to (a) CSL Cash-on-Hand, and (b) CSL Debt, each as of the Closing
Date.

         9.9      CONSENT OF CERTIFIED PUBLIC ACCOUNTANTS.

         CNS shall have received from ICSL's independent public accountants, a
certificate or letter, dated the Closing Date, to the effect that such
accountants will, to the extent such consent is required, consent to the
inclusion or incorporation of its report on the audited financial statements of
ICSL for the years ended January 31, 1999, 2000 and 2001 in any SEC Filing
required in connection with this Agreement, the Merger, the Transactions and
ICSL's ownership of the New Common Stock, subject to such accountants normal due
diligence procedures for such a consent. The cost of obtaining any such
certificate shall be borne solely by ICSL.

                                      -53-
<Page>

         9.10     TARGUM NOTE.

         The Targum Note shall have been executed and delivered by the parties
thereto and shall remain in full force and effect; and neither ICSL nor CSL
shall have any other liability (fixed or contingent) or obligations to Targum
other than as expressly set forth in the Targum Note or in connection with his
continuing employment.

                         ARTICLE 10 - MUTUAL CONDITIONS

         The respective obligations of each party to effect the Merger shall be
subject to the satisfaction at or prior to the Effective Time of the following
conditions:

         10.1     NO INJUNCTIONS OR RESTRAINTS; ILLEGALITY.

         No order, injunction or decree issued by any court or agency of
competent jurisdiction or other legal restraint or prohibition preventing the
consummation of the Transactions shall be in effect. No statute, rule,
regulation, order, injunction or decree shall have been enacted, entered,
promulgated or enforced by any Governmental Authority, which prohibits,
restricts or makes illegal the consummation of the Transactions.

         10.2     SHAREHOLDERS AGREEMENT.

         Each of ICSL, the holders of CNS Stock and Convertible Notes and CNS
shall have executed and delivered the Amended and Restated Shareholders
Agreement in the form attached hereto as EXHIBIT 10.2 (the "SHAREHOLDERS
AGREEMENT").

         10.3     LEGENDS.

         Certificates representing New Stock to be issued hereunder shall bear
the following legend:

         THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT") AND MAY NOT BE SOLD,
TRANSFERRED OR OTHERWISE DISPOSED OF BY THE HOLDER EXCEPT PURSUANT TO AN
EFFECTIVE REGISTRATION STATEMENT FILED UNDER THE ACT, AND IN COMPLIANCE WITH
APPLICABLE SECURITIES LAWS OF ANY STATE WITH RESPECT THERETO, OR IN ACCORDANCE
WITH AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE
ISSUER THAT AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE.

         10.4     TAX TREATMENT.

         ICSL, CSL, CNS, Acquisition Sub shall use their respective best efforts
to cause the Merger to qualify as a reorganization under the provisions of
Section 368(a) of the Code. All parties hereto agree to file the Merger
Agreement with their respective federal income tax returns for the year in which
the Merger is effective, and to comply with the reporting requirements of
Treasury Regulation Section 1.368-3.

                                      -54-
<Page>

         10.5     FAIRNESS OPINION.

         ICSL shall have received the written opinion of Shields & Company, Inc.
addressed to the Board of Directors of ICSL prior to the Closing to the effect
that, as of the date of such opinion, the CSL Merger Consideration is fair from
a financial point of view to ICSL and its stockholders, and as of the Closing
Date, such opinion shall not have been withdrawn.

         10.6     STOCKHOLDER APPROVAL.

         If required by Law, ICSL shall have complied with Regulation 14A or 14C
under the Exchange Act and shall have obtained the approval of the holders of
the requisite number of shares of ICSL Common Stock.

         10.7     INVESTOR RIGHTS AGREEMENT.

         CNS and ICSL and certain CNS stockholders and noteholders shall have
entered into an Amended and Restated Investor Rights Agreement, in the form
attached hereto as EXHIBIT 10.7 (the "INVESTOR RIGHTS AGREEMENT").

         10.8     MODIFICATION OF CSL DEBT.

         ICSL and CSL shall have (a) entered into a definitive agreement for the
replacement of the AbleCo Facility or (b) entered into a definitive amendment to
the AbleCo Facility, in either case, on terms reasonably satisfactory to CSL and
CNS (the "REPLACEMENT FACILITY").

         10.9     EMPLOYMENT AGREEMENT.

         Newco and Gary S. Gillheeney shall have executed and delivered an
employment agreement on terms and conditions mutually satisfactory to each party
(the "GILLHEENEY EMPLOYMENT AGREEMENT").

                              ARTICLE 11 - SURVIVAL

         Notwithstanding any investigation made by any party to this Agreement,
all covenants, agreements, representations and warranties (a) in Article 3 made
by any of CNS and any CNS Subsidiary and (b) in Article 4 made by any of ICSL,
CSL and any CSL Subsidiary, shall survive the Closing or the termination of this
Agreement until the date that is one year after the Closing Date; PROVIDED,
HOWEVER, that the representations and warranties in Sections 3.22 and 4.22 (with
respect to Taxes), shall survive until the expiration of the applicable statute
of limitations, and Section 3.3 (with respect to the issuance of shares of New
Common Stock to ICSL), shall survive indefinitely and Section 7.1B (with respect
to the provision of financial information to ICSL) shall survive until ICSL is
no longer a stockholder of Newco (the last day of the survival period specified
for each covenant, agreement, representation and warranty specified in clauses
(a) and (b) above is referred to herein as the "SURVIVAL DATE"). Except as
otherwise set forth in this Article 11, no representation, warranty, covenant or
agreement of the parties set forth in this Agreement or any of the rights and
remedies of the other party for any one or more breach thereof shall survive
subsequent to the date that is one year after the Closing Date.

                                      -55-
<Page>

                          ARTICLE 12 - INDEMNIFICATION

         12.1     DEFINITIONS.

         As used in this Agreement, the following terms shall have the following
meanings:

                  12.1.1 "CNS INDEMNIFIED PERSONS" shall mean CNS, Acquisition
Sub and the Surviving Corporation and their respective Affiliates, successors
and assigns, and their respective officers and directors.

                  12.1.2 "CNS LOSSES" shall mean any and all losses, claims,
shortages, damages, liabilities, expenses (including reasonable actual
attorneys' and accountants' fees), assessments, tax deficiencies and taxes
(including interest or penalties thereon) sustained, suffered or incurred by any
CNS Indemnified Person arising from or in connection with any such matter which
is the subject of indemnification under Section 12.2(a) hereof, offset by any
net tax benefit to the CNS Indemnified Person so affected.

                  12.1.3 "ESCROWED SHARES" shall mean the number of shares of
New Common Stock equal to the quotient of $4,000,000 divided by the CNS Per
Share Value, rounded up or down to the nearest whole number.

                  12.1.4 "EVENT OF CNS INDEMNIFICATION" shall mean and include
the following:

                         (a)  the inaccuracy or breach of any representation or
warranty of ICSL contained herein, or in the CSL Disclosure Schedule, any
Exhibit hereto or any certificate delivered in connection herewith at or before
the Effective Time; or

                         (b)  breach of any agreement or covenant of ICSL
contained in this Agreement (including the CSL Disclosure Schedule and the
Exhibits attached hereto); or

                         (c)  the assertion of any claim, demand, liability or
obligation against ICSL, CSL, CNS Acquisition Sub or the Surviving Corporation
arising from or in connection with (i) any action or inaction of ICSL in
connection with the action of the stockholders of ICSL required to approve the
transactions contemplated by this Agreement, or (ii) any assertion by any
stockholder of ICSL of any impropriety with respect to any actions or
transactions of or involving ICSL prior to or at the Effective Time (including,
without limitation, the actions and transactions contemplated by this
Agreement); or

                         (d)  the assertion of any claim, demand, liability or
obligation against any CNS Indemnified Person, arising from or in connection
with any of the items set forth on SCHEDULE 12.1.4 attached hereto.

                  12.1.5 "EVENT OF INDEMNIFICATION" shall mean any Event of CNS
Indemnification or Event of ICSL Indemnification, as the case may be.

                  12.1.6 "EVENT OF ICSL INDEMNIFICATION" shall mean and include
the following:

                         (a)  the inaccuracy or breach of any representation or
warranty of CNS or Acquisition Sub in the CNS Disclosure Schedule and any
Exhibit hereto or any certificate delivered in connection herewith at or before
the Effective Time; or

                                      -56-
<Page>

                         (b)  the breach of any agreement or covenant of CNS or
the Acquisition Sub contained in this Agreement (including the CNS Disclosure
Letter and the Exhibits attached hereto).

                         (c)  the assertion of any claim, demand, liability or
obligation against ICSL, CSL, CNS, Acquisition Sub or the Surviving Corporation
arising from or in connection with (i) any action or inaction of CNS and
Acquisition Sub in connection with the action of the stockholders of CNS or
Acquisition Sub required to approve the transactions contemplated by this
Agreement, or (ii) any assertion by any stockholder of CNS or Acquisition Sub of
any impropriety with respect to any actions or transactions of or involving CNS
or Acquisition Sub prior to or at the Effective Time (including, without
limitation, the actions and transactions contemplated by this Agreement).

                  12.1.7  "INDEMNIFIED PERSONS" shall mean the CNS Indemnified
Persons or the ICSL Indemnified Persons, as the case may be.

                  12.1.8  "INDEMNIFYING PERSONS" shall mean CNS or ICSL, as the
case may be.

                  12.1.9  "LOSSES" shall mean the CNS Losses or the ICSL Losses,
as the case may be.

                  12.1.10 "MARKET VALUE" shall be measured in any case as of the
date of payment with respect to any claim for indemnification made under Section
12.4 hereof and shall mean (i) the CNS Per Share Value or (ii) if CNS
consummates any transaction after the Closing Date pursuant to which CNS issues
securities valued at no less than $10,000,000 (10% of which shall have been
issued to a Person or Persons not Affiliates of ICSL, CNS or the Surviving
Corporation) the value per CNS Common Stock Equivalent paid or implied in
connection with any such transaction or (iii) if the shares of New Common Stock
are traded on any national or regional stock exchange or the Nasdaq Stock
Market, the average of the daily closing prices for a share of such New Common
Stock on the 20 consecutive trading days immediately before the date of
determination of such Market Value.

                  12.1.11 "ICSL INDEMNIFIED PERSONS" shall mean ICSL and its
respective Affiliates, successors and assigns (but excluding CNS and the
Surviving Corporation).

                  12.1.12 "ICSL LOSSES" shall mean any and all losses, claims,
shortages, damages, liabilities, expenses (including reasonable actual
attorneys' and accountants' fees), assessments, tax deficiencies and taxes
(including interest or penalties thereon sustained, suffered or incurred by
Newco, any CNS Subsidiary or any ICSL Indemnified Person arising from or in
connection with any matter which is the subject of indemnification under Section
12.2.2 hereof, offset by any net tax benefit to the ICSL Indemnified Persons so
affected.

         12.2     INDEMNIFICATION GENERALLY; ETC.

                  12.2.1 ICSL shall indemnify the CNS Indemnified Persons for,
and hold each of them harmless from and against, any and all CNS Losses arising
from or in connection with any Event of CNS Indemnification, up to that amount
constituting the

                                      -57-
<Page>

Escrow Fund (which shall initially be the Escrowed Shares), which
indemnification pursuant to this Section 12.2.1 shall be effected solely in
accordance with the terms and provisions of the Escrow Agreement and shall be
subject to the qualifications and limitations set forth therein. In connection
therewith, ICSL shall have no liability to the CNS Indemnified Persons in
respect of CNS Losses arising from or in connection with any Event of CNS
Indemnification over and above the amounts from time to time representing the
Escrow Fund and the CNS Indemnified Persons, and each of them, shall look for
indemnification in respect of any such claim under this Section 12.2.1 solely to
the Escrow Fund in accordance with the terms and provisions of the Escrow
Agreement; PROVIDED, HOWEVER, that ICSL may, it its sole discretion, elect to
substitute United States Dollars in lieu of shares of New Common Stock for the
payment of any indemnification obligation arising hereunder, and the Escrow
Agent shall, upon such payment in United States Dollars to the CNS Indemnified
Persons, deliver to ICSL from the Escrowed Shares, such number of shares of New
Common Stock as otherwise would have been deliverable to the CNS Indemnified
Person entitled to such indemnification.

                  12.2.2 CNS hereby agrees to indemnify the ICSL Indemnified
Persons for, and hold each of them harmless from and against, any and all ICSL
Losses arising from or in connection with any Event of ICSL Indemnification,
which indemnification pursuant to this Section 12.2.2 shall be effected solely
in accordance with Section 12.3 hereof by the issuance of additional shares of
New Common Stock to ICSL; PROVIDED, HOWEVER, that CNS may, in its sole
discretion, elect to substitute United States Dollars in lieu of shares of New
Common Stock for the payment of any indemnification obligation arising
hereunder.

         12.3     LIMITATIONS ON INDEMNIFICATION.

         Notwithstanding anything herein to the contrary:

                  12.3.1 (a) the CNS Indemnified Persons shall not have the
right to be indemnified pursuant to Section 12.2.1 hereof unless and until the
CNS Indemnified Persons have incurred on a cumulative basis since the Effective
Date aggregate CNS Losses in an amount not less than $100,000; and

                         (b) any claim by a CNS Indemnified Person for
indemnification pursuant to Section 12.2.1 shall be settled in shares of New
Common Stock comprising the Escrow Fund, each share of which shall be valued at
the Market Value, pursuant to the Escrow Agreement or cash in lieu thereof as
contemplated by Section 12.2; and

                         (c) ICSL shall have no liability to the CNS Indemnified
Persons in respect of CNS Losses arising from or in connection with any events
of CNS Indemnification over and above $4,000,000; and

                  12.3.2 (a) the ICSL Indemnified Persons shall not have the
right to be indemnified pursuant to Section 12.2.2 hereof unless and until the
ICSL Indemnified Persons have incurred on a cumulative basis since the Effective
Date aggregate ICSL Losses in an amount not less than $100,000; and

                         (b) any claim with respect to an Event of ICSL
Indemnification shall be settled solely in New Common Stock, each share of which
shall be valued at the Market Value or cash in lieu thereof as contemplated by
Section 12.2; and

                                      -58-
<Page>

                         (c) CNS shall have no liability to the ICSL Indemnified
Persons in respect of ICSL Losses arising from or in connection with
any Events of ICSL Indemnification over and above $2,000,000.

         12.4     LIMITATIONS ON INDEMNIFICATION.

         No claim shall be made for indemnification under Section 12.2 hereof
unless the Indemnified Persons or any one of them, at any time prior to the
applicable Survival Date, shall deliver to the Indemnifying Persons (a) written
notice of the existence of any such claim, specifying in reasonable detail the
nature and basis of such claim and the amount thereof, to the extent known or
(b) written notice pursuant to Section 12.5 of any Third Party Claim, the
existence of which might give rise to such a claim. Upon the giving of such
written notice as aforesaid, the Indemnified Persons, or any of them, shall have
the right to commence legal proceedings subsequent to the Survival Date for the
enforcement of their rights under Section 12.2 hereof.

         12.5     NOTICE AND DEFENSE OF THIRD PARTY CLAIMS.

         The obligations and liabilities of an Indemnifying Person with respect
to Losses resulting from the assertion of liability by third parties (each, a
"THIRD PARTY CLAIM") shall be subject to the following terms and conditions:

                  12.5.1 The Indemnified Persons shall promptly (and, in any
event, within five Business Days) give written notice to the Indemnifying
Persons of any Third Party Claim which might give rise to any Loss by the
Indemnified Persons, stating the nature and basis of such Third Party Claim, and
the amount thereof to the extent known. Such notice shall be accompanied by
copies of all relevant documentation with respect to such Third Party Claim,
including, without limitation, any summons, complaint or other pleading which
may have been served, any written demand or any other document or instrument.

                  12.5.2 If the Indemnifying Persons shall acknowledge in a
writing delivered to the Indemnified Persons that the Indemnifying Persons shall
be obligated under the terms of their indemnification obligations hereunder in
connection with such Third Party Claim, then the Indemnifying Persons shall have
the right to assume the defense of any Third Party Claim at their own expense
and by their own counsel, which counsel shall be reasonably satisfactory to the
Indemnified Persons; PROVIDED, HOWEVER, that the Indemnifying Persons shall not
have the right to assume the defense of any Third Party Claim, notwithstanding
the giving of such written acknowledgment, if (a) the Indemnified Persons shall
have been advised by counsel that there are one or more legal or equitable
defenses available to them which are different from or in addition to those
available to the Indemnifying Persons, and, in the reasonable opinion of the
Indemnified Persons, counsel for the Indemnifying Persons could not adequately
represent the interests of the Indemnified Persons because such interests could
be in conflict with those of the Indemnifying Persons or (b) such action or
proceeding involves, or could have a material effect on, any material matter
beyond the scope of the indemnification obligation of the Indemnifying Persons.

                                      -59-
<Page>

                  12.5.3 If the Indemnifying Persons shall assume the defense of
a Third Party Claim (under circumstances in which the proviso to the first
sentence of Section 12.5.2 is not applicable), the Indemnifying Persons shall
not be responsible for any legal or other defense costs subsequently incurred by
the Indemnified Persons in connection with the defense thereof. If the
Indemnifying Persons do not exercise their right to assume the defense of a
Third Party Claim by giving the written acknowledgment referred to in Section
12.5.2, or are otherwise restricted from so assuming by the proviso to the first
sentence of Section 12.5.2, the Indemnifying Persons shall nevertheless be
entitled to participate in such defense with their own counsel and at their own
expense; and in any such case, the Indemnified Persons shall assume the defense
of the Third Party Claim, which counsel shall be reasonably satisfactory to the
Indemnifying Persons, and shall act reasonably and in accordance with their good
faith business judgment and shall not effect any settlement without the consent
of the Indemnifying Persons, which consent shall not unreasonably be withheld or
delayed. The Indemnifying Persons and the Indemnified Persons shall make
available to each other and their counsel and accountants all books and records
and information relating to any Third Party Claim, keep each other fully
apprised as to the details and progress of all proceedings relating thereto and
render to each other such assistance as may be reasonably required to ensure the
proper and adequate defense of any and all Third Party Claims.

                  12.5.4 If the Indemnifying Persons exercise their right to
assume the defense of a Third Party Claim, they shall not make any settlement of
any claims without the written consent of the Indemnified Persons, which consent
shall not to unreasonably withheld; PROVIDED, HOWEVER, that in the event the
Indemnifying Persons shall propose the settlement of any claim which is capable
of settlement by the payment of money and shall demonstrate to the reasonable
satisfaction of the Indemnified Persons the ability to pay such amount, and the
Indemnified Persons shall not consent thereto within 20 days after the receipt
of written notice thereof, any Losses incurred by the Indemnified Persons in
excess of such proposed settlement shall be at the sole expense of the
Indemnified Persons.

         12.6     REMEDIES EXCLUSIVE.

         The remedies provided for in this Section 12 shall be the exclusive
remedies of the Indemnified Persons in connection with any claim, demand, loss,
liability or obligation arising under this Agreement or in connection with the
transactions contemplated hereby; PROVIDED, HOWEVER, that nothing in this
Section 12.6 shall be construed to limit in any way the rights and benefits of,
or the remedies available to, any party to this Agreement, if any, under or in
respect of the Investor Rights Agreement, the Shareholders Agreement or the
Gillheeney Employment Agreement.

                            ARTICLE 13 - TERMINATION

         13.1     TERMINATION.

                  13.1.1 This Agreement may be terminated and the Merger may be
abandoned at any time prior to the Closing:

                  (a)    By mutual written consent duly authorized by the Board
of Directors of ICSL, CSL and CNS;

                                      -60-
<Page>

                  (b)    By ICSL and CSL or CNS if any Governmental Authority of
competent jurisdiction shall have issued an order, decree or ruling, or taken
any other action, permanently restraining, enjoining or otherwise prohibiting
the transactions contemplated by this Agreement, provided that no termination
shall be permitted under this paragraph unless the party seeking such
termination shall have used its reasonable best efforts to oppose such issuance
or taking;

                  (c)    By ICSL or CNS, on or after December 31, 2001 (the
"TERMINATION DATE"), PROVIDED, that if the Proxy Statement or Information
Statement has been filed with the SEC in preliminary form and such preliminary
Proxy Statement or Information Statement is under review by the SEC for a period
that exceeds 10 days, the Termination Date shall be extended by the number of
days in excess of such 10 day period; PROVIDED, FURTHER, that the Termination
Date may be extended by mutual agreement of the parties; or

                  (d)    By ICSL and CSL, upon a vote at a duly held
stockholders meeting to obtain ICSL stockholder approval, such approval is not
obtained.

                  13.1.2 This Agreement may be terminated by CNS:

                  (a)    if ICSL or CSL commits any material breach of its
representations, warranties, agreements or covenants set forth herein and such
breach has not been cured within ten (10) days after notice is given to
terminate this Agreement as a result of such breach; or

                  (b)    if ICSL refuses to consummate the Merger for any reason
other than the failure of a condition to Closing set forth in Article 8 or
Article 10.

                  13.1.3   This Agreement may be terminated by ICSL:

                  (a)    if CNS commits any material breach of its
representations, warranties, agreements or covenants set forth herein and such
breach has not been cured within ten (10) days after notice is given to
terminate this Agreement as a result of such breach; or

                  (b)    if CNS refuses to  consummate  the Merger for any
reason other than the failure of a condition to Closing set forth in Article 9
or Article 10.

                  13.1.4 Upon the occurrence of any of the events specified in
this Section 13.1 (other than Section 13.1.1 hereof), written notice of such
event shall forthwith be given to the other parties to this Agreement, whereupon
this Agreement shall terminate and the Merger shall be abandoned. The right to
terminate this Agreement pursuant to this Section 13.1 shall not be available to
any party whose failure to fulfill any of its obligations contained in this
Agreement has been the cause of, or resulted in, the failure of the Merger to
have occurred on or prior to such date.

         13.2     EFFECT OF TERMINATION.

         In the event of the termination of this Agreement and abandonment of
the Merger pursuant to Section 13.1:

                  13.2.1 This Agreement, except for the provisions of Section
7.6 and Articles 11, 12, 13 and 14, shall forthwith become void and be of no
effect, without any liability on the part of any party or its Affiliates,
directors, officers or stockholders;

                                      -61-
<Page>

provided that nothing in this Section 13.2.1 shall relieve any party to this
Agreement of liability for breach of this Agreement.

                  13.2.2 In the event that this Agreement is terminated prior to
the Termination Date (a) pursuant to Section 13.1.1(d) and ICSL consummates a
transaction whereby it sells all or substantially all of the assets or capital
stock of CSL to a third party or merges with a third party at any time prior to
March 31, 2002 or (b) pursuant to Section 13.1.2(b), ICSL shall pay on demand to
CNS One Million Dollars ($1,000,000) by wire transfer of immediately available
funds as full and complete liquidated damages, representing the parties best
efforts estimate of the actual financial costs associated with the termination
of this Agreement, it being understood that the actual costs associated with
such termination will be difficult to ascertain.

                  13.2.3 In the event that this Agreement is terminated prior to
the Termination Date (a) as a result of the failure of the stockholders of CNS
to approve the Amended Charter and CNS consummates a transaction whereby it
sells all or substantially all of its assets or capital stock to a third party
or merges with a third party at any time prior to March 31, 2002 or (b) pursuant
to Section 13.1.3(b), CNS shall pay on demand to ICSL One Million Dollars
($1,000,000) by wire transfer of immediately available funds as full and
complete liquidated damages representing the parties best efforts estimate of
the actual financial costs associated with the termination of this Agreement, it
being understood that the actual costs associated with such termination will be
difficult to ascertain.

                   13.2.4 Notwithstanding the provisions of Section 13.2.2
above, in the event that the Agreement is terminated as a result of a breach of
Section 7.9 hereof, the breaching party shall pay on demand to the non-breaching
party Two Hundred Fifty Thousand Dollars ($250,000) as liquidated damages.

                           ARTICLE 14 - MISCELLANEOUS

               14.1        CERTAIN DEFINITIONS.

               As used in this Agreement, the following terms shall have the
respective meanings set forth below:

         "ABLECO FACILITY" means that certain Financing Agreement dated
September 19, 2000 with AbleCo Finance, LLC.

         "ACQUISITION SUB" has the meaning provided in the preamble to this
Agreement.

         "ACQUISITION SUB STOCK" means the common stock, par value $.01 per
share, of Acquisition Sub.

         "AFFILIATE" has the meaning set forth in Rule 12b-2 of the regulations
promulgated under the Exchange Act.

         "AGREEMENT" means this Agreement and Plan of Merger.

         "ALTERNATIVE TRANSACTION" has the meaning provided in Section 7.9.

         "AMENDED CERTIFICATE" has the meaning provided in the preamble to this
Agreement.

                                      -62-
<Page>

         "ANCILLARY AGREEMENTS" means the Investor Rights Agreement, the
Shareholders Agreement, CNS Voting Agreement, CSL Voting Agreement, Gillheeney
Employment Agreement and Escrow Agreement.

         "AUDITED CNS FINANCIALS" has the meaning provided in Section 3.6.

         "AUDITED CSL FINANCIALS" has the meaning provided in Section 4.6.

         "BUSINESS DAY" means any day other than Saturday, Sunday, any Federal
holiday or any other day on which the United States Postal Service does not
deliver mail.

         "CERTIFICATE OF MERGER" has the meaning provided in Section 1.1.

         "CLAIM" means liability, claim, assessment, security interest, lien,
restriction, encumbrance, or right, title or interest in others.

         "CLIA" means the Clinical Laboratory Improvement Amendments, Pub. L.
100-578, 102 Stat. 2903, 42 U.S.C.Section 263a, enacted in 1988, and the
regulations promulgated thereunder.

         "CLOSING" has the meaning provided in Section 2.1.

         "CLOSING DATE" means the date on which the Closing occurs.

         "CNS" has the meaning provided in the preamble to this Agreement.

         "CNS BALANCE SHEET" has the meaning provided in Section 3.6.

         "CNS BALANCE SHEET DATE" has the meaning provided in Section 3.8.

         "CNS BUSINESS" has the meaning provided in the preamble to this
Agreement.

         "CNS CASH-ON-HAND" means all cash and cash equivalents of CNS and CNS
Subsidiaries determined on a consolidated basis in accordance with GAAP less the
amount of the Psilos Fees as certified by the Chief Financial Officer of CNS.

         "CNS COMMON EQUITY VALUE" has the meaning provided in Section 1.5.1.

         "CNS COMMON STOCK" has the meaning provided in the preamble to this
Agreement.

         "CNS COMMON STOCK EQUIVALENTS" has the meaning provided in Section
1.5.1.

         "CNS CONTRACT" has the meaning provided in Section 3.14.1.

         "CNS DEBT" means any obligation (other than the Convertible Notes) of
CNS and CNS Subsidiaries (on a consolidated basis) for the repayment of borrowed
money (including, without limitation, fees, penalties and other obligations in
respect thereof), whether or not evidenced by bonds, debentures, notes or other
written instruments.

         "CNS DISCLOSURE SCHEDULE" means the Schedule referenced in Article 3
and attached hereto.

         "CNS ENVIRONMENTAL REPORT" has the meaning provided in Section 3.24.5.

         "CNS ERISA AFFILIATE" has the meaning provided in Section 3.19.1.

         "CNS FINANCIAL STATEMENTS" has the meaning provided in Section 3.6.

                                      -63-
<Page>

         "CNS INDEMNIFIED PERSONS" has the meaning provided in Section 12.1.

         "CNS KNOWLEDGE" means the Knowledge of CNS and all CNS Subsidiaries.

         "CNS LEASED PREMISES" has the meaning provided in Section 3.11.

         "CNS LEASES" has the meaning provided in Section 3.11.

         "CNS LOSSES" has the meaning provided in Section 12.1.2

         "CNS MATERIAL ADVERSE CHANGE" means a Material Adverse Change to CNS.

         "CNS MATERIAL ADVERSE EFFECT" means, any effect which results in a CNS
Material Adverse Change.

         "CNS NET ENTERPRISE VALUE" has the meaning provided in Section 1.5.1.

         "CNS OPTION PLAN" has the meaning provided in Section 5.6.

         "CNS OPTIONS" means all outstanding options and warrants to purchase
CNS Common Stock whether or not such options are currently vested.

         "CNS OWNED PREMISES" has the meaning provided in Section 3.11.

         "CNS PENSION PLANS" has the meaning provided in Section 3.19.1.

         "CNS PER SHARE VALUE" has the meaning provided in Section 1.5.1.

         "CNS PERMITS" has the meaning provided in Section 3.12.

         "CNS PLAN" has the meaning provided in Section 3.19.1.

         "CNS PREFERRED STOCK" has the meaning provided in the preamble to this
Agreement.

         "CNS PREFERRED STOCK DIVIDEND" has the meaning provided in Section
1.5.1.

         "CNS PROPRIETARY ASSETS" has the meaning provided in Section 3.13.1.

         "CNS SHAREHOLDERS AGREEMENTS" has the meaning provided in Section 5.5.

         "CNS SOURCE" has the meaning provided in Section 3.18.2.

         "CNS STOCK" means CNS Common Stock and CNS Preferred Stock.

         "CNS SUBSIDIARY" has the meaning provided in Section 3.2.

         "CNS TANGIBLE PERSONAL PROPERTY" has the meaning provided in Section
3.10.

         "CNS VOTING AGREEMENT" has the meaning provided in Section 7.16.

         "CNS WELFARE PLANS" has the meaning provided in Section 3.19.1.

         "CODE" means the Internal Revenue Code of 1986, as amended to date.

         "CONFIDENTIAL INFORMATION" has the meaning provided in Section 7.15.

         "CONVERTIBLE NOTES" has the meaning provided in the preamble to this
Agreement.

         "CONVERTIBLE PORTION OF THE TARGUM DEBT" means the lesser of the
outstanding principal balance of the Targum Note at the Effective Time or
$500,000, which amount is

                                      -64-
<Page>

payable, at the option of CSL, by the issuance to Steven D. Targum of fully paid
non-assessable shares of New Common Stock, but only to the extent that CSL
elects to pay such amount with shares of New Common Stock.

         "CSL" has the meaning provided in the preamble to this Agreement.

         "CSL BALANCE SHEET" has the meaning provided in Section 4.6.

         "CSL BALANCE SHEET DATE" has the meaning provided in Section 4.8.

         "CSL BUSINESS" has the meaning provided in the preamble to this
Agreement.

         "CSL CASH-ON-HAND" means all cash and cash equivalents of CSL and CSL
Subsidiaries determined on a consolidated basis in accordance with GAAP as
certified by the Chief Financial Officer of ICSL.

         "CSL CERTIFICATES" has the meaning provided in Section 1.6.1.

         "CSL COMMON STOCK" has the meaning provided in the preamble to this
Agreement.

         "CSL CONTRACTS" has the meaning provided in Section 4.14.1.

         "CSL DEBT" means any obligation of CSL and CSL Subsidiaries determined
on a consolidated basis in accordance with GAAP for the repayment of borrowed
money (including, without limitation, fees, penalties and other obligations in
respect thereof, but specifically excluding the Convertible Portion of the
Targum Debt if and to the extent that CSL directs that shares of New Common
Stock be delivered in satisfaction of such Convertible Portion of the Targum
Debt as contemplated by Section 1.6.4 at the Effective Time), whether or not
evidenced by bonds, debentures, notes or other written instruments including,
but not limited to, Liabilities under the AbleCo Facility, as certified by the
Chief Financial Officer of ICSL.

         "CSL DISCLOSURE SCHEDULE" means the schedule referenced in Article 4
and attached hereto.

         "CSL ENVIRONMENTAL REPORTS" has the meaning provided in Section 4.24.5.

         "CSL ERISA AFFILIATE" has the meaning provided in Section 4.19.1.

         "CSL FINANCIAL STATEMENTS" has the meaning provided in Section 4.6.

         "CSL KNOWLEDGE" means the Knowledge of CSL and all CSL Subsidiaries.

         "CSL LEASED PREMISES" has the meaning provided in Section 4.11.

         "CSL LEASES" has the meaning provided in Section 4.11.

         "CSL MATERIAL ADVERSE CHANGE" means a Material Adverse Change to CSL.

         "CSL MATERIAL ADVERSE EFFECT" means, any effect which results in a CSL
Material Adverse Change.

         "CSL MERGER CONSIDERATION" means the number of shares of New Common
Stock obtained by dividing CSL Net Enterprise Value by CNS Per Share Value.

         "CSL NET ENTERPRISE VALUE" has the meaning provided in Section 1.5.1.

                                      -65-
<Page>

         "CSL OCCUPIED LEASED PREMISES" has the meaning provided in Section 4.1.

         "CSL OWNED PREMISES" has the meaning provided in Section 4.11.

         "CSL PENSION PLAN" has the meaning provided in Section 4.19.1.

         "CSL PERMITS" has the meaning provided in Section 4.12.

         "CSL PLAN" has the meaning provided in Section 4.19.1.

         "CSL PROPRIETARY ASSET" has the meaning provided in Section 4.13.1.

         "CSL SOURCES" has the meaning provided in Section 4.18.2.

         "CSL SUBSIDIARY" has the meaning provided in Section 4.2.

         "CSL TANGIBLE PERSONAL PROPERTY" has the meaning provided in Section
4.10.

         "CSL VOTING AGREEMENT" has the meaning provided in Section 7.17.

         "CSL WELFARE PLAN" has the meaning provided in Section 4.19.1.

         "DGCL" means the Delaware General Corporation Law.

         "DISCLOSURE SCHEDULES" means the CNS Disclosure Schedule and the CSL
Disclosure Schedule.

         "DOCUMENTS" has the meaning provided in Section 14.3. "EFFECTIVE TIME"
         has the meaning provided in Section 1.1.

         "ENVIRONMENTAL CLAIM" has the meaning provided in Section 3.24.3.

         "ENVIRONMENTAL LAWS" means, collectively, the Clean Air Act, the Clean
Water Act, the Resource Conservation and Recovery Act of 1976, the Hazardous
Materials Transportation Act, the Comprehensive Environmental Response,
Compensation and Liability Act of 1980, the Emergency Planning and Community
Right-to-Know Act or any other federal, state or local environmental law.

         "ERISA" has the meaning provided in Section 3.19.1.

         "ESCROW AGENT" has the meaning provided in the Escrow Agreement.

         "ESCROW AGREEMENT" has the meaning provided in Section 7.18.

         "ESCROW FUND" shall mean, at any time, the number of shares of New
Common Stock then held by the Escrow Agent.

         "ESCROWED SHARES" has the meaning provided in Section 12.1.3

         "EVENT OF CNS INDEMNIFICATION" has the meaning provided in Section
12.1.4

         "EVENT OF ICSL INDEMNIFICATION" has the meaning provided in Section
12.1.6.

         "EVENT OF INDEMNIFICATION" has the meaning provided in Section 12.1.5.

         "EXCHANGE ACT" means the Securities Exchange Act of 1934, as amended,
including the rules and regulations promulgated thereunder.

         "GAAP" means generally accepted accounting principles in the United
States.

                                      -66-
<Page>

         "GILLHEENEY EMPLOYMENT AGREEMENT" has the meaning provided in Section
10.9.

         "GOVERNMENTAL AUTHORITY" means any federal, state or municipal court
and any other governmental or public department, commission, board, bureau,
agency, authority or instrumentality, domestic or foreign.

         "HAZARDOUS SUBSTANCE" means any chemical, pollutant, contaminant, waste
(including, without limitation, toxic, hazardous, infectious, sanitary, solid,
radioactive and petroleum waste collectively, "WASTE"), toxic substance,
hazardous substance, extremely hazardous substance, hazardous material,
radioactive material, asbestos, oil and petroleum product, as such terms, or any
similar terms, are or shall be used under any applicable laws relating to
pollution or protection of the environment, natural resources or human health.

         "ICSL" has the meaning provided in the preamble to this Agreement.

         "ICSL COMMON STOCK" means the common stock of ICSL, par value $.01 per
share.

         "ICSL COMMON STOCK EQUIVALENTS" means all ICSL Common Stock and any and
all shares of ICSL Common Stock issuable pursuant to any and all rights,
options, warrants, or convertible or exchangeable securities entitling the
holder thereof to subscribe for or purchase or otherwise acquire shares of ICSL
Common Stock or shares convertible into or exchangeable for ICSL Common Stock.

         "ICSL CONVERSION RATIO" means the quotient obtained by dividing the CSL
Merger Consideration by the total number of ICSL Common Stock Equivalents
outstanding immediately prior to the Closing.

         "ICSL INDEMNIFIED PERSON" has the meaning provided in Section 12.1.11

         "ICSL LOSSES" has the meaning provided in Section 12.1.12

         "ICSL OPTIONS" means those options to purchase ICSL Common Stock
granted to those certain directors, officers and employees of ICSL who, at the
Effective Time, will become directors, officers and employees of Newco, as more
fully set forth on SCHEDULE 4.3.2 hereto.

         "ICSL REPLACEMENT OPTIONS" means those options granted by CNS to
holders of ICSL Options pursuant to Section 1.5.4.

         "INDEMNIFIED PERSONS" has the meaning provided in Section 12.1.7

         "INDEMNIFYING PERSONS" has the meaning provided in Section 12.1.8

         "INFORMATION STATEMENT" has the meaning provided in Section 6.1.

         "INVESTOR RIGHTS AGREEMENT" has the meaning provided in Section 10.7.

         "IRS" means the Internal Revenue Service.

         "KNOWLEDGE" means as to CNS, ICSL or CSL, the actual knowledge of any
person who constitutes an "EXECUTIVE OFFICER" of CNS, a CNS Subsidiary, ICSL,
CSL or a CSL Subsidiary for purposes of the Securities Act (whether or not such
company is subject to the Securities Act) and any knowledge which such CNS, CNS
Subsidiary,

                                      -67-
<Page>

ICSL, CSL or CSL Subsidiary Executive Officer reasonably would have in the usual
and prudent discharge of his or her duties.

         "LAW" means all federal, state, local and foreign laws, regulations,
rules, ordinances, permits (including, without limitation, authorizations,
approvals, registrations and licenses), administrative and other orders,
judicial decisions or the like.

         "LIABILITY" means any liability (whether known or unknown, whether
asserted or unasserted, whether absolute or contingent, whether accrued or
unaccrued, whether liquidated or unliquidated, and whether due or to become
due), including any liability for Taxes.

         "LOSSES" has the meaning provided in Section 12.1.9.

         "MARKET VALUE" has the meaning provided in Section 12.1.10.

         "MATERIAL ADVERSE CHANGE" means with respect to CSL or CNS, as
appropriate, a material adverse change in the financial condition, results of
operation, assets, liabilities or business of such corporation and its
Subsidiaries, taken as a whole, or any change that would prevent or materially
delay consummation of the Transactions or otherwise prevent such corporation and
its Subsidiaries from performing their obligations under this Agreement and the
Ancillary Agreements.

         "MERGER" has the meaning provided in the preamble to this Agreement.

         "NEW COMMON STOCK" means the common stock of Newco, par value $0.001
per share, after giving effect to the Amended Certificate.

         "NEW COMMON STOCK EQUIVALENTS" means all New Common Stock and any and
all rights, options, warrants, or convertible or exchangeable securities
entitling the holder thereof to subscribe for or purchase or otherwise acquire
shares of New Common Stock or shares convertible into or exchangeable for New
Common Stock following the Effective Time and the issuance of the Convertible
Notes.

         "NEW INVESTMENT" shall have the meaning provided in Section 8.12 of
this Agreement.

         "NEW PREFERRED STOCK" means the Series A Preferred Stock of Newco, par
value $0.001 per share, after giving effect to the Amended Certificate.

         "NEW STOCK" means the New Common Stock and New Preferred Stock.

         "NEWCO" has the meaning provided in the preamble to this Agreement.

         "NEWCO INVESTORS" has the meaning provided in the preamble.

         "NOTE PURCHASE AGREEMENT" has the meaning provided in Section 5.2.

         "NOTE PURCHASE TERM SHEET" has the meaning provided in Section 5.2.

         "ORDINARY COURSE OF BUSINESS" means the ordinary course of business
consistent with past custom and practice (including with respect to quantity and
frequency).

         "PERSON" means an individual, a partnership, a corporation, a firm, an
association, a joint stock company, a trust, a joint venture, an unincorporated
organization, or a

                                      -68-
<Page>

governmental entity (or any department, agency, or political subdivision
thereof), or any other legally recognized entity.

         "PROPRIETARY ASSET" means any (a) patent, patent application, trademark
(whether registered or unregistered), trademark application, trade name,
fictitious business name, service mark (whether registered or unregistered),
service mark application, copyright (whether registered or unregistered),
copyright application, mask work, mask work application, trade secret, know-how,
confidential information, customer list, franchise, system, computer software,
computer program, invention, design, blueprint, engineering drawing, proprietary
product, technology, proprietary right or other intellectual property right or
intangible asset; or (b) license or right to use or exploit any of the
foregoing; PROVIDED, HOWEVER, that Proprietary Asset shall not include any
pharmaceutical products (including any drug) licensed to or used by CSL or CNS
or any of their respective Subsidiaries belonging to the sponsor of any clinical
study or clinical research conducted by CSL or CNS or any of their respective
Subsidiaries.

         "PROXY STATEMENT" has the meaning provided in Section 6.1.

         "PSILOS CONSULTING AGREEMENT" means that certain consulting agreement
by and between Psilos Group Managers, LLC, a Delaware limited liability company,
and CNS, dated March 26, 1999.

         "PSILOS FEE" means the consulting fee due to Psilos Group Managers LLC
in connection with the transactions contemplated hereby.

         "REPLACEMENT FACILITY" has the meaning provided in Section 10.8.

         "REPLACEMENT OPTION RESERVE" has the meaning provided in Section 1.5.1

         "REPRESENTATIVES" has the meaning provided in Section 7.15.

         "SEC" means the Securities and Exchange Commission.

         "SEC FILING" means any registration statement or other voluntary or
required filing pursuant to the Securities Act or the Exchange Act.

         "SECURITIES ACT" means the Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder.

         "SHAREHOLDERS AGREEMENT" has the meaning provided in Section 10.2.

         "SUBSIDIARY" means any corporation, partnership, limited liability
company, association or other entity of any nature whatsoever which CSL or CNS,
as the case may be, controls, either directly or indirectly.

         "SURVIVAL DATE" has the meaning provided in Article 11.

         "SURVIVING CORPORATION" has the meaning provided in Section 1.2.

         "TARGUM DEBT" means the unpaid principal balance as of the Effective
Time of that certain indebtedness owed by CSL to Steven D. Targum evidenced by
the Targum Note.

         "TARGUM NOTE" means that certain Amended and Restated Subordinated
Promissory Note dated as of September 12, 2001 in the original principal amount
of $2,000,000 payable by CSL to Steven D. Targum.

                                      -69-
<Page>

         "TAX" means any federal, state, local, or foreign income, gross
receipts, license, payroll, employment, excise, severance, stamp, occupation,
premium, windfall profits, environmental (including taxes under Code Sec. 59A),
customs duties, capital stock, franchise, profits, withholding, social security
(or similar), unemployment, disability, real property, personal property, sales,
use, transfer, registration, value added, alternative or add-on minimum,
estimated, or other tax of any kind whatsoever, including any interest, penalty,
or addition thereto, whether disputed or not.

         "TERMINATION DATE" has the meaning provided in Section 13.1.1(c).

         "TRANSACTIONS" has the meaning provided in the preamble to this
Agreement.

         "TRANSFERRED EMPLOYEES" has the meaning provided in Section 5.1.

         "UNAUDITED CNS FINANCIALS" has the meaning provided in Section 3.6.

         "UNAUDITED CSL FINANCIALS" has the meaning provided in Section 4.6.

         14.2     NOTICES.

         All notices, requests, consents and other communications hereunder
shall be in writing, shall be addressed to the receiving party's address set
forth below or to such other address as a party may designate by notice
hereunder, and shall be either (i) delivered by hand, (ii) made by telex,
telecopy or facsimile transmission with a confirmatory copy by regular mail,
(iii) sent by recognized overnight courier or (iv) sent by registered or
certified mail, return receipt requested, postage prepaid.

         If to ICSL or CSL:

                  Innovative Clinical Solutions, Ltd.
                  10 Dorrance Street, Suite 400
                  Providence, Rhode Island 02903
                  Attn:  Michael T. Heffernan, President and Chief Executive
                         Officer
                  Facsimile telephone number:  401-831-6758

         With a copy to:

                  Hinckley, Allen & Snyder LLP
                  1500 Fleet Center
                  Providence, RI  02903
                  Facsimile telephone number: (401) 277-9600
                  Attn:  James P. Redding, Esq.; and
                         Margaret D. Farrell, Esq.

         If to CNS:

         Comprehensive Neuroscience, Inc.
         21 Bloomingdale Road
         White Plains, New York 10605

                                      -70-
<Page>

         Facsimile telephone number: (914) 682-6960
         Attn:  John Docherty, M.D., Chief Executive Officer

         With a copy to:

                  Proskauer Rose LLP
                  1585 Broadway
                  New York, NY  10036-8299
                  Facsimile telephone number:  (212) 969-2900
                  Attn:  Julie M. Allen, Esq.

         All notices, requests, consents and other communications hereunder
shall be deemed to have been properly given (i) if by hand, at the time of the
delivery thereof to the receiving party at the address of such party set forth
above, (ii) if made by telex, telecopy or facsimile transmission, at the time
that receipt thereof has been acknowledged by electronic confirmation or
otherwise, (iii) if sent by overnight courier, on the next business day
following the day such notice is delivered to the courier service or (iv) if
sent by registered or certified mail, on the fifth business day following the
day such mailing is made.

         14.3     ENTIRE AGREEMENT.

         This Agreement together with the Exhibits and Schedules hereto and the
other documents executed and to be executed in connection herewith (together,
the "DOCUMENTS") embodies the entire agreement and understanding between the
parties hereto with respect to the subject matter hereof and supersedes all
prior oral or written agreements and understandings relating to the subject
matter hereof. No statement, representation, warranty, covenant or agreement of
any kind not expressly set forth in the Documents shall affect, or be used to
interpret, change or restrict, the express terms and provisions of this
Agreement.

         14.4     MODIFICATIONS AND AMENDMENTS.

         The terms and provisions of this Agreement may be modified or amended
only by written agreement executed by all parties hereto.

         14.5     WAIVERS AND CONSENTS.

         No failure or delay by a party hereto in exercising any right, power or
remedy under this Agreement, and no course of dealing between the parties
hereto, shall operate as a waiver of any such right, power or remedy of the
party. No single or partial exercise of any right, power or remedy under this
Agreement by a party hereto, nor any abandonment or discontinuance of steps to
enforce any such right, power or remedy, shall preclude such party from any
other or further exercise thereof or the exercise of any other right, power or
remedy hereunder. The election of any remedy by a party hereto shall not
constitute a waiver of the right of such party to pursue other available
remedies. No notice to or demand on a party not expressly required under this
Agreement shall entitle the party receiving such notice or demand to any other
or further notice or demand in similar or other circumstances or constitute a
waiver of the rights of the party giving such notice or demand to any other or
further action in any circumstances without such notice

                                      -71-
<Page>

or demand. The terms and provisions of this Agreement may be waived, or consent
for the departure therefrom granted, only by written document executed by the
party entitled to the benefits of such terms or provisions. No such waiver or
consent shall be deemed to be or shall constitute a waiver or consent with
respect to any other terms or provisions of this Agreement, whether or not
similar. Each such waiver or consent shall be effective only in the specific
instance and for the purpose for which it was given, and shall not constitute a
continuing waiver or consent.

         14.6     ASSIGNMENT.

         Neither this Agreement, nor any right hereunder, may be assigned by any
of the parties hereto without the prior written consent of the other parties.

         14.7     PARTIES IN INTEREST.

         This Agreement shall be binding upon and inure solely to the benefit of
each party hereto and their permitted assigns, and nothing in this Agreement,
express or implied, is intended to confer upon any other person any rights or
remedies of any nature whatsoever under or by reason of this Agreement. Nothing
in this Agreement shall be construed to create any rights or obligations except
among the parties hereto, and no person or entity shall be regarded as a
third-party beneficiary of this Agreement.

         14.8     GOVERNING LAW.

         This Agreement and the rights and obligations of the parties hereunder
shall be construed in accordance with and governed by the internal laws of the
State of Delaware, without giving effect to the conflict of law principles
thereof.

         14.9     JURISDICTION AND SERVICE OF PROCESS.

         Any legal action or proceeding with respect to this Agreement may be
brought in the courts of the State of Rhode Island or the State of Delaware, or
of the United States of America for the District of Rhode Island or the District
of Delaware. By execution and delivery of this Agreement, each of the parties
hereto accepts for itself and in respect of its property, generally and
unconditionally, the jurisdiction of the aforesaid courts. The parties hereby
irrevocably waive any objection or defense that they may now or hereafter have
to the assertion of personal jurisdiction by any such court in any such action
or to the laying of the venue of any such action in any such court, and hereby
waive, to the extent not prohibited by law, and agree not to assert, by way of
motion, as a defense, or otherwise, in any such proceeding, any claim that it is
not subject to the jurisdiction of the above-named courts for such proceedings.
Each of the parties hereto irrevocably consents to the service of process of any
of the aforementioned courts in any such action or proceeding by the mailing of
copies thereof by registered mail, postage prepaid, to the party at its address
set forth in Section 14.2 hereof and irrevocably waives any objection or defense
that it may now or hereafter have to the sufficiency of any such service of
process in any such action. Nothing in this Section 14.9 shall affect the rights
of the parties to commence any such action in any other forum or to serve
process in any such action in any other manner permitted by law.

                                      -72-
<Page>

         14.10    SEVERABILITY.

         In the event that any court of competent jurisdiction shall finally
determine that any provision, or any portion thereof, contained in this
Agreement shall be void or unenforceable in any respect, then such provision
shall be deemed limited to the extent that such court determines it enforceable,
and as so limited shall remain in full force and effect. In the event that such
court shall determine any such provision, or portion thereof wholly
unenforceable, the remaining provisions of this Agreement shall nevertheless
remain in full force and effect.

         14.11    INTERPRETATION.

         The parties hereto acknowledge and agree that: (i) each party and its
counsel reviewed and negotiated the terms and provisions of this Agreement and
have contributed to its revision; (ii) the rule of construction to the effect
that any ambiguities are resolved against the drafting party shall not be
employed in the interpretation of this Agreement; and (iii) the terms and
provisions of this Agreement shall be construed fairly as to all parties hereto
and not in favor of or against any party, regardless of which party was
generally responsible for the preparation of this Agreement.

         14.12    HEADINGS AND CAPTIONS.

         The headings and captions of the various subdivisions of this Agreement
are for convenience of reference only and shall in no way modify, or affect, or
be considered in construing or interpreting the meaning or construction of any
of the terms or provisions hereof.

         14.13    CHOICE OF REMEDIES AND ENFORCEMENT.

         The parties shall be entitled to pursue any and all remedies available
to them, in law or in equity, in the event of a breach of this Agreement. Each
of the parties hereto acknowledges and agrees that the rights acquired by each
party hereunder are unique and that irreparable damage would occur in the event
that any of the provisions of this Agreement to be performed by the other party
were not performed in accordance with their specific terms or were otherwise
breached. Accordingly, in addition to any other remedy to which the parties
hereto are entitled at law or in equity, each party hereto shall be entitled to
an injunction or injunctions to prevent breaches of this Agreement by the other
party and to enforce specifically the terms and provisions hereof in any federal
or state court to which the parties have agreed hereunder to submit to
jurisdiction.

         14.14    EXPENSES.

         Except as provided elsewhere herein, each of CNS and CSL shall pay its
own fees and expenses (including the fees of any attorneys, accountants,
appraisers or others engaged by such party) in connection with this Agreement
and the transactions contemplated hereby whether or not the transactions
contemplated hereby are consummated.

         14.15    COUNTERPARTS.

         This Agreement may be executed in one or more counterparts, and by
different parties hereto on separate counterparts, each of which shall be deemed
an original, but all of which together shall constitute one and the same
instrument.

                                      -73-
<Page>

         IN WITNESS WHEREOF, CSL, ICSL, CNS and Acquisition Sub have executed
this Agreement as of the day and year first above written.

                                              CLINICAL STUDIES, LTD.

                                            By: /s/ Michael T. Heffernan
                                                --------------------------------

                                            Name: Michael T. Heffernan
                                                  ------------------------------

                                            INNOVATIVE CLINICAL SOLUTIONS, LTD.

                                            By: /s/ Michael T. Heffernan
                                                --------------------------------

                                            Name: Michael T. Heffernan
                                                  ------------------------------

                                            COMPREHENSIVE NEUROSCIENCE, INC.

                                            By: /s/ John P. Docherty, M.D.
                                                --------------------------------

                                            Name: John P. Docherty, M.D.
                                                  ------------------------------

                                            CNS ACQUISITION, INC.

                                            By: /s/ John P. Docherty, M.D.
                                                --------------------------------

                                            Name: John P. Docherty, M.D.
                                                  ------------------------------

                [SIGNATURE PAGE TO AGREEMENT AND PLAN OF MERGER]

<Page>

                                   EXHIBIT 5.2
                            NOTE PURCHASE TERM SHEET

<Page>

                                  EXHIBIT 7.16
                              CNS VOTING AGREEMENT

<Page>

                                  EXHIBIT 7.17
                              CSL VOTING AGREEMENT

<Page>

                                  EXHIBIT 7.18
                                ESCROW AGREEMENT

<Page>

                                   EXHIBIT 8.7
                MATTERS UPON WHICH PROSKAUER ROSE LLP WILL OPINE

<Page>

                                  EXHIBIT 8.15
                             CNS AMENDED CERTIFICATE

<Page>

                                   EXHIBIT 9.6
           MATTERS UPON WHICH HINCKLEY, ALLEN & SNYDER LLP WILL OPINE

<Page>

                                  EXHIBIT 10.2
                             SHAREHOLDERS AGREEMENT

<Page>

                                  EXHIBIT 10.7
                            INVESTOR RIGHTS AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}]]